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Abstract
Human malignant glioma exhibits considerable clinical radioresistance. It has been 
postulated that the phenomenon of intrinsic cellular radioresistance might underlie 
treatment failure in these tumours.
The phenomena of cellular radioresistance has been investigated in this thesis, 
using as models both continuous human glioma-derived cell lines, and primary 
cultures.
The cellular radiosensitivity of five continuous glioma lines has been evaluated by 
clonogenic assay; this has been compared with results obtained in eight other 
human tumour cell lines, derived from a range of human tumour types of varying 
clinical radiocurability, including embryonic tumours and carcinomas. Parameters 
of cellular radiosensitivity were derived by fitting multitarget, and linear-quadratic 
models of radiation action to survival data; the model-free parameter of cellular 
radiosensitivity, the surviving fraction of clonogenic cells at the clinically relevant 
dose of 2Gy (SF2), was also measured.
Considerable heterogeneity of intrinsic cellular radiosensitivity was observed in the 
thirteen human tumour lines studied. All five continuous glioma lines displayed 
values of cellular radiosensitivity within the ranges previously observed in 
radioresistant human cell lines.By comparison, cell lines derived from three 
embryonic tumours exhibited marked cellular radiosensitivity. Considerable 
overlap in cellular radiosensitivity was noted between five carcinoma-derived 
lines, and the human glioma lines.Cellular radiosensitivity of 9 primary human 
glioma cultures was also assessed by soft agar cloning. The intrinsic cellular 
radiosensitivity of both primary cultures, and continuous cell lines derived from 
human malignant glioma were observed to fall within the range of values 
previously reported for radioresistant human tumours; it is therefore suggested 
that intrinsic cellular radioresistance might contribute to the profound clinical 
radioresistance observed in human glioma.
Cellular recovery from ionising radiation damage has been proposed as a 
determinant of intrinsic radiosensitivity. The ability of human tumour cell lines of 
differing intrinsic radiosensitivity to recover from sublethal radiation damage (SLD) 
was investigated by clonogenic cell survival following split dose irradiation. Five 
glioma lines exhibited an ability to recover from sublethal radiation damage, which 
increased with radiation dose, as predicted by the linear-quadratic model of 
radiation action. SLD recovery was assessed in three radiosensitive human cell 
lines, derived from a teratoma, SUSA, a neuroblastoma ,IMR32, and an ovarian 
carcinoma A2780. All three lines exhibited cellular recovery, but the extent of
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recovery at iso-effective radiation dose levels producing 90% cell kill were lower 
than observed in the glioma lines.Values for recovery half-times obtained in the 
glioma cell lines did not differ significantly from those obtained in the three 
radiosensitive cell lines. Proficient recovery from sublethal damage may therefore 
contribute to the cellular radioresistance observed in human glioma cell lines.
The molecular basis of the differences in radiosensitivity observed in human 
tumours remains unclear. A body of evidence supports the notion that DNA 
double strand breaks (dsb) are a class of radiation-induced lesions which can 
lead to both chromosomal aberrations, and cell death. An in vitro assay has been 
established to assess the ability of nuclear protein extracts derived from human 
cells to rejoin dsb. The model dsb substrate was plC20H, a 2.7Kb recombinant 
plasmid DNA molecule bearing two bacterial genes encoding ampicillin resistance 
and p-galactosidase activity; dsb of defined end-structure were produced by 
restriction endonuclease digestion to yield both cohesive and noncohesive termini 
for rejoining reactions. Rejoining activity was assessed both qualitatively, and 
quantitatively. Conformation of the plasmid substrate molecule was evaluated 
following rejoining reactions by electron microscopy, and Southern blotting. 
Accurate dsb rejoining enabled the plasmid molecule to confer both ampicillin 
resistance and p-galactosidase activity on JM83 E.coli transformants. A protein 
concentration -dependent increase in rejoining of cohesive dsb (EcoR I) was 
detected in nuclear extracts from 4 human tumour lines studied; no significant 
rejoining activity for a noncohesive terminus (Nru I) was observed in any 
extracts.No significant difference has been detected in maximal rejoining or rejoin 
fidelity of cohesive dsb mediated by extracts derived from 2 radiosensitive and 
2 radioresistant human tumour cell lines. Such an in vitro system provides a 
powerful tool for the further analysis of the molecular mechanisms involved in the 
recognition, and repair of ionising radiation-induced DNA lesions.
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Chapter 1
Human malignant glioma as a model for the study of clinical
radioresistance.
"These are tumours which usually recur soon after surgical removal, even after 
extensive removal of the involved area of the brain en bloc. The lesion has 
infiltrating propensities, and from its behavior it is natural that it should have been 
looked upon as a 'gliosarcoma', and has been so designated in former days. 
When first exposed, the tumour may sometimes have the misleading appearance 
of enucleability, but when enucleation is attempted, a growth is found at the depth 
to spread into and merge with the normal cerebral tissue without recognizable
demarcation Operative procedures, howsoever radical (block extirpations
repeated on signs of recurrence; saturation with the X-rays or radium emanations 
after wide decompression with or without surgical interference with the tumour), 
have done little more than to prolong life, save vision, and alleviate headache for 
an average of a few months."
1926 Bailey and Cushing
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1.1. Role of radiotherapy in the treatment of glioma:
Development of practice
The therapy of malignant glioma continues to pose major challenges to tumour 
biologists and clinicians alike. Central nervous system tumours comprise 9% of all 
adult neoplasms; of these, 40 % are glioma, of varying grade of malignancy. 
Hence an average regional neuroscience and neuro-oncology practice serving a 
population of 3 million might be expected to diagnose and treat 100 new cases of 
malignant glioma per annum.
Although considerably rarer than the major epithelial malignancies, such as 
carcinomas of the lung, colon, breast, and prostate, malignant glioma has a 
particularly difficult clinical course. It is often diagnosed when producing significant 
impairment of neurological function, in a younger cohort of patients than the 
aforementioned tumours. Moreover, there are as yet few clues as to the aetiology 
of these tumours to guide any form of "preventive" intervention, nor prospect of 
diagnosis at a pre-malignant stage of the disease. It is likely that many cases will 
continue to present with overt neurological deficits, and bulky intracranial tumours.
There has recently been speculation that the actual incidence of these tumours 
may be increasing in the elderly, though the part played by altered diagnostic 
practice in determining estimates of prevalence is not clear.
Efforts have been made by many groups to improve the outcome for patients with 
malignant glioma, both by the investigation of its biology and by the adoption of 
empirical clinical strategies based on likely mechanisms of treatment failure.
The optimal therapy of malignant glioma has been the subject of investigation by 
large cooperative groups such as the Medical Research Council, EORTC, and 
Brain Tumour Cooperative Group(BTSG) since the early 1970's. During this time 
the management of these tumours has evolved, with corresponding modest 
increments in survival.
However, despite the frequent use of regimens employing cytoreductive surgery, 
"adjuvant" external beam radiotherapy, and adjuvant chemotherapy, the prognosis 
for patients with grade III and IV glioma remains poor. Whilst combined modality 
therapy offers prolongation of median survival, usually with symptomatic benefit, 
the median survival of grade IV glioma is 40 weeks, with no survivors at 3 years.
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The outcome for grade III tumours is slightly better. It is this group from which the 
16% of 5 year survivors are obtained [Nelson et al, 1985].
Malignant glioma is judged to be clinically radioresponsive, but not radiocurable. 
Moreover, it is often cited as an example of a radioresistant human tumour 
[Malaise etal, 1987]. The mechanistic basis of these clinical observations are not 
clear, and despite many empirical attempts to circumvent radioresistance in the 
clinic, usually based on theoretical assumptions, there has been remarkably little 
direct investgation of the radiobiology of human glia.
The object of this section is to review the in vitro and clinical evidence that human 
glioma is at an extreme of clinical radioresistance, compared with other human 
tumour types, and discuss the possible mechanistic basis of radioresistance in this 
disease.
1.1.1.The concept of clinical radioresistance.
"For any given set of circumstances there must be an optimal point or range of 
volume, time, and dose yielding the maximum probability of cure”
Patterson, 1952
The clinical term "radioresponsiveness" and its in vitro counterpart 
"radiosensitivity" are widely used in discussion of the radiation response of both 
normal and malignant human tissues. The clinical therapeutic ratio at a given 
anatomical site is determined by the relative radiosensitivity of tumour and dose- 
limiting normal tissue in the treatment volume.
The concept of the variability of radioresponsiveness in clinical radiotherapy was 
advanced by workers at the Paterson Institute, Manchester, where clinical 
radiation dosimetry was pioneered. Careful clinical observation led Ralston 
Patterson to classify human tumour response into 3 broad categories:
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Tumour response Tumour type
1) Radioresponsive - lymphoma; seminoma
2) Limited radiosensitivity- squamous and adeno-carcinomas
3) Radioresistant- sarcoma; melanoma;
G-l tract adenocarcinoma
The objective of clinical radiotherapy is the eradication of tumour at a specific site 
with the lowest rate of treatment complication. It therefore follows that the concept 
of clinical radioresistance in a tumour is both operational, relative and site- 
dependent.
Two specific aspects of the biology of human glioma render the tumour type of 
particular interest to radiotherapists. Firstly, the growth pattern and extension of 
glioma is essentially a localised and compartmental process, with few exceptions. 
Secondly, the close relationship between tumour and critical normal brain render 
surgical extirpation with wide excision margins, the classical "cancer" operation, 
inapplicable.[Kaplan,1987]
1.1.2. Development of the radiotherapeutic management of 
malignant glioma
The use of radiotherapy to treat glioma is recorded in the earliest observations on 
the use of radiation in human tumours. In 1921 Ewing made observations on the 
relationship between histology and radiosensitivity of different CNS tumours.
The current conventional management of high grade glioma would be considered 
to be optimal debulking surgery, followed by external beam radiotherapy delivering 
a tumour dose of approximately 60Gy, in daily fractions, over 6 weeks.
There is clear evidence from both retrospective,uncontrolled and prospective, 
randomised studies that a combination of surgery, and postoperative radiotherapy 
increases the median survival of patients, compared with surgery alone.
The first randomised prospective study demonstrating a clear survival benefit was 
published by the Brain Tumour Study Group (BTSG) 6901, in 1978.Patients were 
randomised to receive radiotherapy or radiotherapy and adjuvant BCNU following 
surgery. A prolongation of median survival to 36 weeks was observed in the
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group receiving radiotherapy, compared to 14 weeks in those receiving supportive 
therapy alone [Walker et al, 1978].
1.1.3. Prognostic factors influencing outcome following radiotherapy
The clinical trials in radiotherapy of glioma have identified several important 
clinical prognostic factors influencing outcome as independent variables[Nelson et 
a/,1985; MRC Brain Tumour working party, 1990]. Four positive prognostic factors 
have been identified in multiple studies:
1) Tumour histological grade
2) Clinical performance status
3) Patient age
4) Extent of surgery
The predictive power of tumour grade, age, and performance status is such that 
some consider it desirable to prospectively stratify the assignment of patients to 
experimental treatment arms in clinical studies by these factors. [Hamilton, 1987]
The biological basis of these prognostic factors is poorly understood. In particular, 
the effect of tumour grade on response to radiation or cytotoxic chemotherapy has 
not been explored in vitro. It is possible that variations in the radiosensitivity of 
individuals influences the outcome. No study has been undertaken to assess in 
vitro heterogeneity of radiosensitivity in glioma. One of the aims of this study was 
to assess the heterogeneity of radiosensitivity in primary culture or low passage 
cell lines derived from human glioma.
1.1.4.Clinical evidence of a radiation dose-response in glioma.
Although few cures are achieved by adjuvant postoperative radiotherapy, three 
bodies of evidence would suggest a radiation dose response relationship in 
human glioma. These include:
a) retrospective dose-effect analyses
b) prospective, randomised studies using several dose levels
c) recent experience with stereotactic, focal boost techniques
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Salazar et al reported a significant increase both in the number of survivors at 1 
year and median survival in grade IV glioma, for those patients receiving a total 
tumour dose of 70-80Gy, when compared with a cohort receiving "standard" 
therapy of 50-60Gy [Salazar e ta l, 1976].
Walker used the pooled data from three sucessive BTSG studies to examine the 
relationship between dose of radiation received and survival in 621 patients.
Nominal dose(rad) No. Med
0 194 18
<4500 61 13.5
5000 56 28
5500 33 36
6000 270 42
An increment in survival of 1.3 was noted with the increase in dose from 5000- 
6000 rads. However, it should be noted that the period over which patients were 
accrued to the three studies in this meta-analysis was 1966-1975, with most of 
those receiving the higher radiotherapy doses treated in the last years (BTSG 72-
01). Despite these limitations, it was concluded that evidence of a dose-response 
relationship did exist [Walker e ta l, 1979].
The first study addressing dose-response in a prospective manner was conducted 
by the RTOG-ECOG, and reported by Chang in 1983. Two hundred and fifty three 
patients were randomised between two arms, to receive 60Gy in 6-7 weeks, or 
70Gy in 7-8 weeks with conventional daily fractions. No statistical difference was 
found between the two arms, with a lower median survival in the higher dose 
cohort (8.2 months vs. 9.3 months)[Chang etal, 1983].
Within the last five years there has been a resurgence of interest in clinical dose- 
response relationships in the management of glioma, with the development of 
stereotactic technology, and major improvements in the radiological localisation of 
CNS tumours. Computerised tomography and magnetic resonance imaging can 
both be employed to construct 3D tumour volumes. Combined with stereotactic 
frames much more precise localisation of tumours is obtained. This approach has 
had a major impact on the accuracy of tumour biopsy, and offers the ability to 
define target volumes for either interstitial or external beam radiotherapy , using 
stereotactic localisation[Kelly, 1987].
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The results are now awaited from those studies employing higher total tumour 
doses by stereotactic techiques, as primary treatment. This information should 
contribute further to our understanding of radiation dose-response relationships in 
normal CNS and glioma.
1.1.5.Causes of clinical radioresistance in human glioma.
On the basis of clinical experience human glioma exhibits considerable 
radioresistance, relative to many human tumour types. The purpose of this section 
is to review the theoretical basis of such resistance. The results of clinical studies 
which have been designed to circumvent a particular mode of resistance are 
presented, and the results of in vitro studies pertinent to specific mechanisms are 
discussed.
Mechanisms of clinical radioresistance are usually grouped under three 
categories:
1) Tumour related factors
2) Host related factors
3) Technical factors
Thes factors, and clinical strategies adopted to circumvent them are shown in 
table:1.1.
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Table 1.1. Mechanisms influencing clinical radioresistance in glioma
1) TUMOUR FACTORS
Size
total clonogen number
kinetics
cell contact effect 
metabolism
Kinetics
% G o clonogens
repopulation
cell cycle distribution
Hypoxia
cellular radioresistance 
Increase in G0 clonogens
Intrinsic cellular radioresistance
DNA damage induction 
repair
CLINICAL STRATEGY
Combined cytoreduction 
surgery, 
radiation 
chemotherapy
Accelerated radiation 
Low dose rate radiation
Neutronsjhiah LET) 
Hyperbaric 0 2  
Electron-affinic drugs
Increase RT dose
(hyperfractionation;
brachytherapy;external
stereotactic boost)
Halogenated pyrimidine 
sensitisation
2) HOST FACTORS
Volume effect Focal irradiation
Radiosensitivity of dose-limiting normal tissue Hyperfractionation
Pathophysiology
Hb; vascular disease
31 TECHNICAL FACTORS
Tumour localisation Improved imaging and
Quality control in planning, dose delivery localisation(MRI, CT,
stereotactic biopsy)
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Tumour-related factors.
Two related factors complicate the management of large tumours at any site. 
They require larger doses to be controlled, and the target volume and hence 
treatment volume increase. The biological basis of this close relationship between 
tumour size and local control probability is considered to be related to total 
clonogen number, and alterations in the tumour microenviroment ie. cell-cell 
contact, availably of metabolites, and changes in kinetics.
For clonogenic tumour cells of a given "intrinsic" radiosensitivity, the probability of 
overall tumour control is related to the number of such cells, and the Poisson 
statistics resulting from the randomness of radiation distribution in the tumour 
volume [Peters e ta l , 1982].
In vitro radiation survival curves place great emphasis on the relevance of colony 
forming cells in measuring response of tumours. Whilst clinical experience reveals 
a good correlation between tumour size and local control by radiation at many 
tumour sites, there are no direct assays of the number of clonogenic cells in 
human tumours. ( The relevance of colony-forming cells in vitro to "stem" cells, 
and the measurement of clonogenic cells in primary cultures of human glioma is 
discussed in chapter 5)
In human glioma an analysis of the relationship between tumour size and local 
control has been complicated by two factors. Few cures have been obtained in 
high grade tumours by radiation, therefore it might be considered that currently 
employed radiation schedules are not delivering doses on the dose-response 
curve for glioma, where local control is the endpoint. In addition, the difficulties in 
imaging CNS tumours have delayed the development of a clinical prognostic 
staging system such as the widely employed UICC T.N.M. classification, in which 
tumour size is a major factor determining the predictive power of the classification. 
The wider availability of more sophisticated imaging techniques, such as magnetic 
resonance imaging and enhanced computerised tomographic resolution, together 
with a trend towards detection of smaller volume, low grade tumours, may 
facilitate the development and validation of a staging system for glioma. This 
would aid the analysis of dose-response relationships and further refine prognostic 
information.
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It is estimated that optimal surgical debulking of glioma achieves at best a 90% 
reduction in overall tumour burden. [Moser,1988] At the time of presentation most 
gliomas represent over 1gm of tumour, therefore the potential number of cells to 
be sterilsed by radiation even after surgical cytoreduction is 109 or greater. By 
contrast, some of the best results with radiotherapy are obtained from common 
epithelial tumours in which tumour has been debulked to leave "microscopic" 
disease, containing some 106-108 cells (eg conservative breast cancer therapy; 
head and neck) [Dutreix etal, 1988].
An attempt to circumvent the "probabilistic radioresistance" [Peters,1982] of 
human glioma has been made both by increasing total dose of irradiation, and 
attempting cytoreduction by adjuvant chemotherapy. Between 1973 and 1985 a 
total of 13 randomised studies containing over 1500 patients evaluated the role of 
chemotherapy combined with radiation in high grade glioma [Shapiro,1986]. 
Agents used included CCNU,BCNU,MeCCNU,VM26,cisplatin,and AZQ. In 10 of 
these studies the chemotherapy given was a single agent nitrosourea. In a meta­
analysis reported by Stenning for the MRC in 1987 only a 9% survival advantage 
could be detected at 1 year, by the addition of a nitrosourea to radiation, and this 
difference was reduced to 3.5% at 2 years [Stenning et a/,1987]. Although it was 
concluded that the benefit afforded by the addition of single agent chemotherapy 
was statistically valid, the real clinical gains have been disputed, and adjuvant 
chemotherapy does not form part of the routine management of glioma patients, 
outside the context of clinical trials.
Glioma kinetics
Both the population doubling time of a tumour, and variations in radiosensitivty 
throughout the cell cycle might influence the radioresponsiveness of a tumour 
[Tubiana,1982]. Cell kinetic factors pertinent to the clinical outcome in human 
glioma have been thoroughly reviewed by Steel[Steel, 1980].
Early studies employed thymidine labelling to measure the labelling index (LI) of 
glioma, and derived typical values of 4-8% for grade III glioma and 9% for grade 
IV.Results have now been obtained for human glioma using both 
bromodeoxyuridine(BUdR) labelling, and the monoclonal antibody KI-67.
The values obtained for BUdR S phase labelling compare well with thymidine 
labelling, at 4-8% in high grade tumours. Calculated tumour potential doubling 
times(Tpot) ranged from 7 to 26 days, with a median of 11 days, in 6 gliomas 
examined [Danova et al, 1988]. These values are very similar to previous
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estimations of potential doubling time obtained from thymidine 
incorporation[Hoshino,1984].
The use of BUdR labelling in predictive testing on a wide range of human tumour 
samples suggests that glioma is relatively slow growing by comparison with 
common epithelial tumours.Over half the squamous carcinoma samples evaluated 
as part of the CHART study (continuous, hyperfractionated, accelerated 
radiotherapy) have Tpot values of less than 5 days[ McNally, 1989].
Most studies examining cell kinetic parameters in glioma have contained too few 
samples to enable any assessment of the predictive value of glioma kinetics as an 
independent prognostic variable.
Clinical trials have evaluated the role of experimental fractionation schedules in 
the radiotherapy of glioma. Accelerated schedules shortening overall treatment 
time have been used to try to circumvent tumour repopulation during therapy. 
Hyperfractionated schedules giving multiple small daily fractions, with the aim of 
dose escalating but avoiding complications in late responding normal tissue , are 
still being fully evaluated.
In studies claiming a benefit for accelerated radiotherapy, the survival of patients 
in a conventionally treated arm was significantly lower than in other 
studies[Douglas,1982]. Five further studies (1 nonrandomised, 4 randomised) 
incorporating a further 500 patients, have failed to show any benefit for 
accelerated radiotherapy in glioma [Davis, 1989]. The major benefit of accelerated 
fractionation in glioma would therefore appear to be a useful shortening of the 
overall treatment period for each patient. Small randomised studies of 
hyperfractionation have suggested little survival advantage to date, although an 
optimal total dose escalation may not have not yet been reached! Fulton et al, 
1984; Ludgate etal, 1988].
Tumour hypoxia in glioma.
The potential of hypoxia to modify the radiosensitivity of human cells is accepted, 
but the degree to which the process might influence radiocurability in particular 
tumour sites remains unclear.
Compared with well-oxygenated tissue, hypoxic cells are more resistant to 
conventional irradiation by a dose factor of 2.5-3.0 . The importance of the oxygen 
concentration at the time of radiotherapy has been clearly demonstrated in studies
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rendering human skin hypoxic; radiation dose must be doubled to achieve similar 
results when compared with radiation under oxic conditions[Dische etal, 1976].
There is now little doubt that such hypoxic cells do occur in human tumours. 
Enhanced responses to radiation have been obtained using hyperbaric oxygen or 
chemical radiosensitisers in patients with multiple tumour nodules, giving indirect 
evidence of the existence of hypoxic cells [Thomlinson et a/,1976]. Estimates have 
also been made of the hypoxic fraction of human tumours using radiolabelled 
misonidazole.
Grade IV gliomata contain regions of coagulation necrosis, and it been presumed 
that there were likely to be regions of hypoxic but viable clonogens. Using human 
glioma cell lines, Millar demonstrated that the effect of hypoxia required a doubling 
of radiation dose to achieve one log of cell kill [Millar,1985]. No estimates have 
been made of hypoxia occurring in transplanted human glioma.
No evidence has been found of hypoxia in vivo in high grade glioma, within the 
limits of the 1-1.5cm resolution imposed by current positron emission tomographic 
scanners, using 1502 as the tracer [Brooks, 1990]. However, a clinical study has 
measured oxygen tensions in 10 gliomas perioperatively. Comparisons were 
made between tumour, surrounding normal tissue and arterial oxygen levels under 
anaesthesia. The range of intratumoral oxgen levels was 6-38 mmHg, with a 
mean of 14mmHg, while mean normal brain levels were significantly higher at 
112mmHg. No correlation was found between tumour oxygen levels, vascularity 
on angiography, or the presence of CT scan enhancement [Kayama, 1988].
There is therefore evidence in human glioma that hypoxia modifies the cellular 
response to radiation in vitro, and some clinical evidence that tumour hypoxia 
does occur in vivo.
Considerable clinical effort has been invested in studies attempting to overcome 
the presumed hypoxia problem in glioma, using strategies including hyperbaric 
oxygen, chemical radiosensitisers, and neutron therapy.
In conclusion, while there is both in vitro evidence that hypoxia might modify 
radiosensitivity of glioma, and some clinical evidence that gliomas have low 
oxygen tensions, survival benefits have not accrued in clinical studies designed 
to circumvent hypoxic radioresistance. An explanation of this might be that with 
currently fractionated radiotherapy, reoxygenation between treatments is
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adequate, and the overall response is dominated by low intrinsic radiosensitivity 
of well-oxygenated cells.
Host factors
Radiosensitivity of dose limiting normal tissues and the volume effect
The correlation between the tumour volume and the dose required to obtain 
tumour control has been appreciated since the early days of clinical 
radiotherapy[Fletcher,1986]. It was also rapidly noted that with increasing target 
volume size for a given dose the incidence of normal tissue damage increased. 
This so called Volume effect' is not explained fully at the cellular level. The total 
biological dose of radiation that can be given to a tumour varies according to the 
dose-limiting critical tissue in the irradiated volume, therefore relative clinical 
radioresistance is closely dependent on the radiosensitivity of adjacent normal 
tissue. Given that the clinical circumstances most often dictate treating 
macroscopic residual glioma even after surgical debulking, the relative 
radiosensitivity of normal brain tissue is an important consideration.
Early technical difficulties in the tissue culture of normal cellular components of the 
human brain have dictated that much of the literature on the radiosensitivity of the 
normal CNS is clinically based. The earliest detailed attempts to suggest 
guidelines for avoidance of excess CNS toxicity were proposed by 
Lindgren.[Lindgren,1958] The time -dose curves for the incidence of radionecrosis 
reported in this study formed the basis of knowledge of radiation tolerance of the 
normal CNS for years.
The more subtle neuro-psychcological deficits attributed to irradiation of normal 
brain in long term survivors of glioma require the development of alternative 
models for analysing dose-response relationships in the CNS[Ross,1988J.
The single study comparing the intrinsic radiosensitivity of normal and malignant 
glia suggested much greater sensitivity in normal glia[Nilsson et ai, 1980]. There 
is no human in vitro data examining the radiosensitivity of other potential target 
cells for late radiation damage, which might include oligodendroglia, neurons, and 
endothelium.
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\ln summary, to date radiation 'tolerance' of the normal brain has been defined by 
identifying radiation dose schedules with low incidence of frank radionecrosis. 
With the routine use of protocols treating within these guidelines, it has become 
clear that this endpoint is inappropriate given the more complex functional deficits 
in glioma patients, and the likelihood of underestimating true toxicity due to a 
significant proportion of patients dying before expression of damage. Given the 
especially devastating consequences of late radiation damage in the CNS, the 
radiosensitivity of normal brain relative to glioma is critical. Further data on the 
comparative radiosensitivity of glioma and potential normal target cells for the 
expression of late damage is required.
1.2. In vitro models of human glioma
The major objectives of the work undertaken for this thesis were an evaluation of 
both cellular and molecular processes determining radiation resistance in human 
glioma. An important part of this work was therefore obtaining appropriate models 
for the study of human glioma in vitro, and reaching a conclusion on the relevance 
of such models to clinical disease.
Progress in tissue culture techniques has yielded an increasing number of 
human tumour cell lines. Since the first report of a successful culture of malignant 
glia by Fisher in 1925, over 85 different long term human glioma lines have been 
established, albeit with varying degrees of detail in reported biological 
characterisation [Collins,1983;Studer etal, 1985;Jacobsen etal, 1987;Rutkaetal, 
1987; Knott etal, 1990].
In an ideal situation, continuous cell lines would be near-diploid, with little genetic 
drift, whilst maintaining unequivocal evidence of malignancy, and cell lineage. In 
practice few human continuous cell lines fulfill these criteria.
1.2.1. Heterogeneity in glioma cell lines.
An important feature of malignant glioma in the clinical setting is considerable 
heterogeneity of outcome between individual cases, managed apparently 
identically. A major clinical prognostic factor is the "grade" of malignancy 
established at biopsy by conventional histological and immunocytochemical 
techniques. It is clear that many of the phenotypic and genetic variables observed 
in fresh tumour specimens are also represented in the panels of established 
human glioma lines available.
Considerable cellular heterogeneity is observed in vitro, both between individual 
lines and occasionally within single cultures cloned at relatively high passage 
level [Bigner etal, 1981 ]. Several workers have classified morphological types of 
glioma lines, and in some cases correlated morphology with other phenotypic 
characteristics in vitro, in an attempt to identify a more differentiated phenotype in 
vitro. However, as our knowledge of human cells in culture increases, the strong 
dependency of such phenotypic characteristics on tissue culture conditions 
becomes apparent.
1.2.2. Markers of the glial phenotype.
The classification system of human CNS tumours proposed by Bailey and Cushing 
dominated the study of glial malignancy in the first half of this century [Bailey and 
Cushing, 1926 ]. It proposed that CNS cells of a particular lineage could be 
distinguished by careful morphological study. It was believed that the committment 
of a cell to a particular differentiation pathway, the degree of differentiation, and 
"transitional" forms could be distinguished by similar light microscopic techniques 
[Russell and Rubinstein, 1977 ].
It is now recognised that our knowledge of the developmental biology of normal 
human glia is still rudimentary. It has become clear that much more detailed 
analysis of markers of cell lineage and "differentiation" are required. This is a 
prerequisite to begin to understand the mechanisms of glial transformation, and 
to facilitate better clinical prognostic grading.
The development of cell-type specific antibodies has already refined the 
classification of glial cell populations, and permitted an analysis of developmental 
pathways in the rat CNS[Raff and Noble, 1983 ].
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Expression of cytoplasmic glial fibrillary acidic protein (GFAP) is a specific marker 
of astrocytic lineage. Examination of GFAP expression and patterns of cell 
surface gangliosides have been used to attempt to define lineage in cultures of 
human glia, and to make correlations between the phenotypic profile of cell lines, 
and behavior in vitro.
1.2.2.1.Glial fibrillary acidic protein expression
Intermediate filaments are 8-10 nm fibres that form part of the cytoskeleton of 
virtually all cell types in higher eukaryotes. On the basis of their tissue-specific 
distribution, intermediate filaments have been divided into 5 classes: 
GFAP;desmin;vimentin;keratins; and neurofilaments. GFAP is considered to be a 
marker of the astrocytic lineage [Bignami etal, 1972 ]. However,a high proportion 
of cell lines derived from human malignant glioma do not express GFAP [Kennedy 
etal, 1987].
While there is limited experimental data suggesting that high levels of expression 
of GFAP might reduce the motility of malignant astrocytes, there is no consistent 
evidence that loss of this cytoskeletal protein defines a more malignant phenotype. 
[Duffy et at, 1982 ]
1.2.2.2.Cell surface ganglioside expression in human glioma.
Gangliosides are a family of acidic glycolipids characterised by the presence of 
sialic acid, which selectively localise in the plasma membrane. Their functional 
significance is poorly documented, though a role has been suggested in 
influencing both cell morphology and regulating myelination in the developing 
nervous system [Knott et a/,1990].
The potential value of gangliosides in elucidating cell lineage in the developing 
nervous system has been highlighted by studies using the monoclonal antibodies 
LB1 and A2B5. This latter antibody recognises several different cell surface 
gangliosides. In vitro studies on astrocytes derived from normal rat optic nerve 
have revealed two pathways of differentiation in astrocytes, on the basis of 
expression of gangliosides recognised by A2B5, together with other markers 
(GFAP, galactocerebroside, Gal C) [Miller and Raff, 1984; Raff and Noble, 1983]. 
These workers have identified a common progenitor cell (the 02A cell) capable of
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differentiating into either an astrocyte (type II) or a myelin-producing 
oligodendrocyte, depending on growth factor stimulation conditions.
The ability of patterns of cell surface ganglioside and GFAP expression to define 
such cell populations representing varying degrees of astrocytic" differentiation" 
in the rat has led to similar studies in both normal and malignant human 
astrocytes.
Kennedy and Fok-Seang [1986 ] investigated the relationship between antigenic 
phenotype and function of normal human glia in vitro. Using dissociated cell 
cultures from fetal optic nerve , it was demonstrated that two populations of GFAP 
+ astrocytes could be identified on the basis of A2B5 monoclonal positivity; the 
subsequent proportion of A2B5+ astrocytes ( analogous to rat type II 
astrocytes?) or oligodendrocytes developing in culture was dependent on the 
presence of serum in culture medium. Cortical astrocytes were A2B5 negative. It 
is of interest that after 3 days in culture, up to half the astrocytes expressed no 
GFAP or the oligodendroglial marker recognised by Gal C.
It was not possible to define unequivocally a bipotential cell analogous to the rat 
02A cell in this system. However, it is possible that using human fetal material at a 
specific time point in embryonic development (16-18 weeks) might not be 
representative. It seems more likely that the specific pattern of surface 
gangliosides recognised by the A2B5 monoclonal which help define a rat astrocyte 
progenitor cell are not shared by a similar human astrocyte.
These studies were extended to investigate the relationship between 
morphological and antigenic characteristics of human gliomata cultures [Kennedy 
et al 1987 ]. Only 6 out of 60 cultures were found to express GFAP; none of the 
11 cultures derived from oligodendroglial tumours expressed antigens recognised 
by monoclonals raised to the markers of the oligodendroglial lineage, including 
galactocerebroside, and 04. By contrast, 80% of glioma- derived cultures were 
found to express fibronectin on their cell surface. This extracellular matrix protein 
usually forms characteristic fibrils on the surface of epithelial cells, fibroblasts, and 
meningeal cells, but not astrocytes. Fibronectin positive, GFAP negative cultures 
were demonstrated to be aneuploid (mean chromosome number 63), and to have 
lost contact inhibition of cell division, thus corroborating a malignant glial 
phenotype. Two important conclusions could be drawn from this work. Firstly, 
antigenic analysis can classify categories of glioma that can not be resolved by 
classical morphological criteria. Secondly, there may be considerable selection of 
cell populations inherent in the establishment of human glial cultures in vitro.
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1.2.2.3.Production of glutamine synthetase.
The cytosol enzyme, glutamine synthetase, is produced by normal, reactive and 
malignant astrocytes, and has been regarded as a marker of the astrocytic lineage 
[Pilkington and Lantos, 1982]. Its production can be monitored by both 
biochemical and immunological methods. Together with other biochemical 
markers of astrocytic function, for example, high affinity y amino butyric acid 
uptake, it has been cited as evidence of astrocytic differentiation in human glioma 
cultures in which GFAP has been lost [Frame eta l, 1984 ].
1.2.3. Cytogenetics of human glioma cell lines
The value of studying cytogenetic abnormalities in a given tumour type is two­
fold. Firstly, it offers the potential to identify nonrandom abnormalities which might 
be associated with a particular natural history or treated prognostic phenotype. 
Secondly, the approach may give clues to the involvement of specific, mapped 
oncogenes or tumour suppressor genes in tumour induction or progression.
Established human glioma lines differ in their cytogenetics from biopsies or low 
passage level cultures, and the extent to which tissue culture favours the 
selection of a particular genetic type is poorly understood. It is therefore important 
to consider how the genetic changes found in glioma cell lines might alter their 
relevance as models of human glial malignancy.
Cytogenetic changes in glioma have been examined both at the level of gross 
abnormality of ploidy, and specific chromosomes. Using flow cytometry, Hoshino 
[1984] has documented highly variable DNA content in high grade glioma, with 
populations of diploid and tetraploid cells even within regions of the same tumour 
biopsy. It must therefore be concluded that there is considerable genetic diversity 
within a high grade glioma at the time of clinical presentation.
At the karyotypic level, sufficient information has been gathered to recognise 
certain, non-random patterns of chromosomal abnormality. Bigner et a /[1989] 
have developed a large database of chromosomal defects occurring in glioma of 
varying grade, and have monitored evolution of these abnormalities with 
sequential passage in vitro.
See table 1.2
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Over 90% of malignant gliomata have abnormal chromosome number, and 40% of 
biopsies have multiple co-existing karyotypic patterns, identified on Giemsa 
staining without banding. This finding would be in keeping with the heterogeneity 
of ploidy documented by Hoshino. Some 10% of glioma karyotypes examined 
contain predominantly normal metaphase spreads, or show loss of 1 sex 
chromosome alone.
Cytogenetic and molecular changes noted in continuous glioma lines differ from 
those observed in fresh glioma material in two specific areas.
1) Permanent cell lines rapidly establish major ploidy changes in vitro, usually 
becoming tri - or tetraploid within the first 50 passages. There is no evidence that 
glioma material exhibiting marked abnormality of ploidy is more likely to give rise 
to continuous lines.
2) The phenomenon of double minutes , often representing major changes in the 
epidermal growth factor receptor gene, is common in fresh glioma material, but 
lost in tissue culture.
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Table 1.2 MOLECULAR AND CHROMOSOMAL ABNORMALITIES IN HUMAN GLIOMA
Tumour
Glioma(IV)
Glioma(lll)
Glioma I/ll
Abbreviations:
RFLP
Southern
dmins
EGFR+
Defect Technique Incidence
(%)
Ref.
+7 karyotype 80 Bigner,89
-10 RFLP 80-99 James,88
-10 karyotype 60 Bigner,89
dmins karyotype 30-40 Mark,71
-9p13-24 it 30 Bigner,89
-17p RFLP 30 James,89
45,XO/ normal karyotype 15-20 Bigner,89
-22 u ii 5-10 Bigner,89
EGFR gene + Southern 30-40 Liberman,85
N-myc/Gli + Southern 3-5 Bigner,89
45,XO/normal karyotype 86 Bigner,89
EGFR + Southern 0-20 James,88
45,XO/ normal karyotype 95 Jenkins,89
-17p RFLP 30 James,89
restriction fragment length polymorphisms 
Southern blotting 
double minutes
epidermal growth factor receptor amplification
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1.2.4. Does clinical tumour grade influence establishment of cell lines?
Reviews of the human glioma lines available suggest a strong association 
between grade of malignancy and likelihood of establishment of cell lines 
[Collins, 1983;Darling, 1990]. All continuous lines to date have been established 
from Kernohan grade III or IV tumours, with no significant differences btween 
theses grades. Many technical factors can influence the likelihood of obtaining a 
primary culture, but the relative lack of success in generating continuous lines 
from low grade human glioma may reflect fundamental differences in the biology 
of such tumours, or at least a much greater fastidiousness of culture requirement.
The characterisation of genetic and phenotypic features of the continuous human 
glioma lines used in this thesis are described in Chapter 3, together with a critical 
evaluation of their use as models of human glioma.
1.3. How is cellular radiosensitivity measured?
1.3.1.Radiation cell killing and reproductive cell death
The killing of a cell by radiation is the result of the absorption of energy, followed 
by the production of molecular lesions, finally expressed biologically as cell death. 
A considerable body of data has documented the biophysical stages of the 
interaction of ionising radiation with cells. A wide range of damage can be 
detected within vital subcellular compartments including cell membranes, and 
nuclear DNA. A more detailed review of the lesions produced in DNA is presented 
in chapter 4.
The most widely used endpoint in quantifying the response of cells to radiation to 
ionising radiation is that of reproductive or "clonogenic" cell death [Elkind and 
Whitmore, 1967]. The term reproductive cell death derives from early 
bacteriological studies, in which loss of colony forming ability was one of the few 
quantitative endpoints. It is defined as the loss of unlimited cellular proliferation 
potential. Following ionising radiation a damaged cell may proceed through a 
limited number of divisions, and appear morphologically and functionally intact. 
However, only a surviving cell which has retained reproductive integrity is able to 
proliferate to produce a colony or clone, and is said to be "clonogenic".
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1.3.2. The clonogenic cell survival assay.
The clonogenic cell survival assay is the most widely employed endpoint in cellular 
radiation research, despite the lack of understanding of the molecular basis of 
reproductive cell death. The use of such an operationally defined experimental 
endpoint does not ignore the diversity of biological effects that follow cellular 
irradiation. It is argued that the eradication of potential clonogenic cells is the 
major objective of therapeutic irradiation, therefore the use of such an in vitro 
endpoint is particularly relevant to the measurement of tumour response to 
radiation.
The practical limitations of this experimental endpoint have been particularly 
highlighted with increasing interest in measuring the radiosensitivity of human cells 
in a "predictive" manner. Many normal human tissues have limited or no 
proliferative potential, and the low cloning efficiencies observed in primary 
tumour cultures are major obstacles to the routine measurement of cellular 
radiosensitivity [Peters, 1990 ].
Despite some conceptual and practical difficulties inherent in the clonogenic cell 
assay, it has generated most of the currently available data on mammalian 
cellular radiosensitivity.lt has the advantage of allowing the measurement of 
cellular radiation dose -response over a logarithmic range. This is possible 
because relatively high concentrations of viable cells (105-106/ ml) can be readily 
prepared from continuous cell lines. With the use of dilution techniques the 
probability of cell survival, or surviving fraction, can be measured over 3 to 4 
decades of survival, with fairly uniform levels of experimental error.
1.3.3. The radiation cell survival curve.
The generation of data over such extended ranges of cell survival has lead to the 
presentation of survival curves plotted on semilogarithmic co-ordinates. Radiation 
dose in conventionally plotted on a linear scale, and surviving fraction of 
clonogenic cells on a logarithmic scale. Surviving fraction is calculated from the 
relationship:
surviving fraction = colonies counted
cells seeded x ( PE/100)
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where PE, or plating efficiency of the experiment is the percentage of cells forming 
colonies in control plates.
Given the large range of cell kill observed, statistical considerations require that 
test cell numbers are increased with dose to yield valid colony numbers across 
the experiment. This requires that the relationship between cell density and 
linearity of colony numbers obtained is established for each cell line examined.
The models of radiation action most commonly used to quantify cellular 
radiosensitivity are described in chapter 4.
1.3.4.The concept of intrinsic cellular radiosensitivity.
Until the early 1980's it was widely assumed that the differences in clinical 
radiocurability observed were likely to be attributable to differences in tumour 
kinetics or the presence of hypoxic cells. It was considered that the cellular 
radiosensitivity of most human cells was very similar, and did not contribute to the 
differences seen in clinical radiocurability.
The first mammalian radiation cell survival curve was reported by Puck and 
Marcus in 1956, using cells from a patient with cervical carcinoma. Many 
radiation clonogenic cell survival data have since been reported on rodent and 
human cell types of differing histology [Elkind and Whitmore, 1967]. Various 
biophysical models have been developed to try to explain the shapes of survival 
curves, and the theoretical basis of the models are discussed in more detail in 
Chapter 3. The apparently small differences noted comparing cell lines of differing 
histology, both in size of the shoulder,or final slope of the survival curve, were 
attributed to part to technical considerations: the passage level of the cell line; 
irradiation on glass versus plastic; variable plating efficiency; use of feeder layers; 
quality of X-ray and cloning technique[Weischelbaum eta l, 1976].
In 1981 Fertil and Malaise published the results of their re-analysis of published 
human cell survival curves, which included 36 tumours, and 6 fibroblast lines. 
Values of radiation dose and surviving fraction of clonogenic cells were estimated 
from the published data. Where original data were available for direct comparison 
this method appeared to generate errors of approximately 4% for dose, and 10% 
of surviving fraction. They fitted data with both linear-quadratic and multitarget 
models of radiation action to derive numerical values describing the cellular 
radiosensitivity of the lines. Several important observations were made:
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1) Differences in parameters of cellular radiosensitivity were found between 
individual cell lines, particularly in parameters describing the initial slope of the 
survival curve.
2) A positive correlation was found between the in vitro response of a given cell 
type at 2Gy, and the clinical radioresponsiveness of tumours of the same 
histology, as assessed by the TCD 95%, the dose estimated to give 95% 
probability of tumour control. Although it was acknowledged that technical 
factors varied considerably between laboratories, these were insufficient to mask 
the contribution of cell type to determination of radiation response at 2 Gy.
Fertil and Malaise have since extended their review of human cellular 
radiosensitivity to include over 70 separate tumour cell lines, and human fibroblast 
lines[Fertil and Malaise, 1985; Chavaudra etal, 1989 ]. Parameters of cellular 
radiosensitivity that are most influenced by the low dose region of the survival 
curve ie. 2Gy region, include the actual surviving fraction at 2Gy, and the a 
component of the linear-quadratic model. Considerable heterogeneity of 
radiosensitivity is observed between cell lines of a specific histological type. 
However, the relative ranking of these parameters for cell lines of a specific 
histological type correlates with clinical radioresponsiveness of tumours of the 
same histology.
A similar analysis of human tumour cellular radiosensitivity was performed by 
Deacon and Steel, using both original data on tumour cell lines, and published 
data from other workers [Deacon etal, 1984]. In contrast to the method of Fertil, 
they chose to examine the correlation between response of human cell lines at 
2Gy, and a non-parametric ranking of tumour radiocurability. Cell lines were 
assigned to groups A to E as shown, on the basis of clinical radiocurability of the 
tumour of derivation. See table.1.3.
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Table 1.3. Ranking of clinical radiocurability of human tumours
Deacon and Steel 1984
Mean SF2 Gv SF2 30
Group A 0.19+/-0.04 2.3x1 O'23
Group B 0.22 +/- 0.03 1.8x1 O'20
Group C 0.46+/-0.06 7.6x10"11
Group D 0.43 +/- 0.08 2.3x10 '11
Group E 0.52+/-0.04 2.6x10-9
Group A: neuroblastoma, lymphoma, myeloma (6  cell lines)
Group B: medulloblastoma, small-cell lung carcinoma (8 lines)
Group C: breast, bladder, cervix (4 lines)
Group D: pancreas, colo-rectal,squamous lung (8 lines)
Group E: melanoma, osteosarcoma,glioblastoma,renal carcinoma (25 lines)
SF2 30 denotes total cell kill achieved if intrinsic radiosensitivity
measured at 2 Gy operates over a theoretical 30 treatment 
course of radiotherapy
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They also concluded that considerable differences did exist in the radiation 
survival curves of human cell lines, and a correlation was noted between 
radiosensitivity at 2Gy (SF2), and clinical radioresponsiveness.
A statistical difference was observed in mean SF2 for cell lines derived from 
radiosensitive human tumours eg neuroblastoma, lymphoma, and cell lines 
derived from common epithelial cancers eg. breast, cervix,lung,colon. Group E 
contains cell lines derived from tumours that are usually considered to be more 
radioresistant in the clinic, including 4 glioma cell lines . It was not possible to 
demonstrate a statistically significant difference in the mean SF2Gy between 
groups D and E. ie On the basis of this analysis, lower 'intrinsic' cellular 
radiosensitivity would not account for the observed clinical radioresistance in 
tumour types contained in group E. However, the responses at 2Gy cited for 
glioma cell lines A3 and A7 (0.67, and 0.86 respectively) were significantly higher 
than the mean values for group D and E overall.
The relevance of the ranking of radiosensitivity at the dose of 2Gy was further 
emphasised in this paper. Estimates of total clonogen kill that could be 
theoretically obtained if the surviving fraction at 2 Gy operated over a 30 fraction 
course of treatment were derived by the formula:
Overall surviving fraction after 30x 2Gy = (SF2)30
The differences in clonogenic cell survival observed between cell lines at a given 
dose, irradiated as a well-oxygenated, asynchronous population, have been 
attributed to differences in 'intrinsic cellular radiosensitivity’. This concept 
acknowledges the potential diversity of molecular mechanisms that might operate 
at the cellular level to influence response to ionising radiation. The mechanistic 
basis of this observation has been the subject of much radiobiological research in 
the last decade. Early studies have attempted to make correlations between 
clonogenic cell survival and the potential of cells to 'recover' from irradiation, in 
operationally defined 'repair' experiments [Weichselbaum and Little, 1984]. More 
recent approaches have tended to concentrate on the molecular nature of the 
lesions in DNA which correlate with radiation-induced cell death. These are 
discussed in chapter 5 of this thesis.
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1.3.5. Predictive assays of tumour response.
The measurement of cellular radiosensitivity has served two functions; firstly, to 
ask mechanistic questions regarding an association between cellular 
radiosensitivity and subcellular events; secondly, to provide empirical measures of 
comparative radiosensitivity of possible clinical relevance.
Several laboratories are currently assessing the relationship between inherent 
radiosensitivity of human tumour cells measured in primary or early passage 
culture, and clinical radiation response. The two largest of these studies are based 
on pretreatment assays of radiosensitivity in primary cultures of cancer of the 
head and neck [Brock etal, 1990 ], and uterine cervix [Davidson etal, 1990 ]. Both 
studies have published interim data, showing a wide range of SF2Gy values, with 
coefficients of variation between individual tumour samples of approximately 40%. 
This degree of variation from tumour to tumour has been interpreted as 
encouraging for the future use of SF2GY as a predictive test, as the broader the 
distribution of values in a population , the greater probability of detecting real 
differences between individuals. In both studies, preliminary analyses indicate that 
in tumours that recurred locally, the mean pretreatment values of SF2GY are 
higher than in the overall patient population, although considerable overlap exists. 
Both are discussed in more detail in chapter 5.
Another approach to identifying the part played by differences in individual tumour 
response has been adopted by Weichselbaum et al[1988 ]. The radiosensitivity of 
early passage cell lines derived from recurrent head and neck tumours treated by 
radiotherapy has been defined relative to that of cultures from untreated tumours. 
The mean values of parameters describing radiosensitivity, Do, and SF2 were 
significantly higher in cultures derived from recurrent tumours. They compared 
both parameters with data previously obtained in the same laboratory for cultures 
of normal human diploid fibroblasts. The recurrent carcinoma lines were 
significantly more radioresistant in vitro. Unfortunately, no pretreatment assays 
were performed on these recurrent tumours to assess whether the 
radioresistance observed both clinically and at relapse in vitro, could have been 
detected predictively.
Technical aspects of the selection of an appropriate assay for predictive testing of 
tumour response are discussed in chapter 5.
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1.3.7. Predictive testing of normal tissue radiosensitivity.
Human normal tissues are observed to vary in their radiosensitivity, both in the 
clinic and in vitro [Denekamp, 1988 ]. Variations in radiosensitivity can be 
demonstrated in different normal tissue cell types from the same individual, and in 
cells of the same lineage from different individuals [Weichselbaum etal, 1980 ].
The population distribution of inherent cellular radiosensitivity of normal tissues is 
of considerable importance. The concept of radiotherapy treatment to normal 
tissue tolerance requires that in order to maximise tumour control probability, 
radiotherapy regimens are designed to produce a defined probability of normal 
tissue injury. Tolerance doses are determined empirically from population 
averages without regard for individual variability of response. This must result in 
subtolerance doses being given to a proportion of patients.
This concept has been developed further by the notion that the distribution of 
normal tissue radiosensitivity in individuals in the cancer population may not be 
normal. The work of Swift et al [1987] has revealed that relatives of patients 
homozygous for the radiation hypersensitivity disorder, ataxia telangectasia, 
exhibit an excess incidence of many common tumours.
It has been suggested that the association of human radiation hypersensitivity 
syndromes and cancer proneness could bias the definition of radiation tolerance 
in the treatment population [West etal, 1991]. The maximal radiation doses 
currently employed might be maintaining an acceptable level of late normal 
tissue damage in a cohort of individuals potentially hypersensitive to radiation.
There is currently little data addressing the issue of an association between 
radiosensitivity of normal tissue and tumour in the same individual. If genetically 
determined factors modulate both responses, a relationship might be expected 
between the severity of normal tissue reactions and probability of tumour control, 
when tumours of the same type are treated by a similar regimen. The only clinical 
data lending support to this hypothesis has been reported by the Institute Gustave 
-Roussy. In a series of 135 patients with T3 carcinoma of the cervix, there was a 
highly significant survival advantage was noted for those patients developing 
severe acute and late gastrointestinal treatment complications, compared with 
those developing only mild symptoms [Peters, 1990]. This sugested the possibility 
of a shared hypersensitivity to radiation of target cells in both tumour and normal 
bowel of an individual.
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Several laboratory studies have attempted to demonstrate unusual cellular 
radiosensitivity in normal cells derived from patients exhibiting adverse treatment 
reactions. In most of these studies it was concluded that fibroblasts from such 
patients exhibited greater cellular radiosensitivity, defined relative to controls 
derived from healthy volunteers, or patients with 'normal' responses 
[Weichselbaum etal, 1976 ;Smith, etal, 1980 ; Loeffler etal, 1990 ].
1.3.8. Evidence for cellular radioresistance in human glioma
The role played by intrinsic cellular radioresistance in determining clinical 
radioresistance in human glioma has been unclear.Studies addressing this 
question form the subject of Chapter 4 of this thesis.
Human glioma cell lines have been available for in vitro studies since the late 
1960's. Given the poor prognosis generally observed in high grade glioma even 
after optimal therapy there has been surprisingly little direct investigation of the 
cellular radiobiology of glioma.
See table. 1.3.
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Weichselbaum compared the cellular radiosensitivity of a panel of human tumour 
cell lines, including a glioma, TX13.Using clonogenic cell survival as the endpoint, 
survival curves were fitted by the multitarget model of radiation action. The values 
of Do representing the final slope of the curve, were found to lie within a range of 
131-150 for the 7 lines studied.These included cell lines derived from both 
radiocurable tumour types, such as neuroblastoma, and radioresistant tumours, 
such as melanoma, and osteogenic sarcoma. The values for Do obtained were not 
statistically different between cell lines [Weichselbaum et a/,1976].
Gerweck et al [1977] investigated the radiosensitivity of malignant glioma at low 
passage level. Cultures were initiated from 9 astrocytomas, and 2 normal brain 
biopsies. Normal glia proliferated very slowly and growth ceased after 20-40 
passages. Growth adequate to permit radiation clonogenic assay appears to have 
been acheived in only 3 of the gliomas. The experimental system used 250 kV X- 
rays, cells were cloned with feeder cells on plastic, and survival curves were fitted 
by eye. The only estimate of radiosensitivity cited was the surviving fraction of 
cells after a single dose of 6Gy ( range 0.13-0.17). The survival curves were 
compared to those obtained from the human tumour cell lines published in the 
Weichselbaum study, as well as normal human fibroblasts. They concluded that 2 
of the 3 glioma lines had large initial shoulders to the survival curve, suggesting a 
capacity to accumulate and repair radiation damage, and that the overall survival 
curve for these two gliomas was suggestive of greater radioresistance than the 
other tumour types.
Nilsson has reported the only comparative study of the radiosensitivity of both 
normal and malignant human glia [Nilsson et a/,1980]. A specialised technique 
was developed permitting assessment of clonal cell survival, with high density 
cultures. Palladium grids were used to limit the migration of cells on a 1% agarose 
base. The technique was validated by comparison of the radiation survival in 
Chinese hamster cells using this procedure and classical agar cloning. 
Radiosensitivity was assessed over 1-2 logs of cell kill, and data fitted by both 
multitarget single hit and linear-quadratic models of radiation action. Significant 
differences were observed in the shape of the survival curves for the 2 gliomas, 
U118MG, and U251MG, when compared with the normal glia. It was concluded 
that malignant glioma cells were more radioresistant than normal glia.
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1.3.9. Inherent radiosensitivity of both normal tissue and tumour as 
predictors of radiotherapy response.
On the basis of observations on human cells in culture, and variability of clinical 
outcome following tumour radiotherapy, it has been suggested that heterogeneity 
in tumour response might be determined by intrinsic cellular radiosensitivity. An 
extension of this hypothesis is that genetically determined variability might also 
occur in the radiosensitivity of normal tissues from individuals, with important 
considerations for possible dose escalation in radiotherapy treatments [Peters, 
1990].
1.4. The study of DNA repair in mammalian and human cells and its role in 
determination of cellular radiosensitivity.
The molecular basis of the variability observed in intrinsic cellular sensitivity to 
cancer therapy remains one of the most important areas in cancer biology. A large 
body of evidence supports the idea that DNA is the most important biological 
target of radiation damage [Elkind, 1985 ]. There is speculation that repair of DNA 
damage is a critical process in determining biological outcome, through a 
spectrum of functional cellular events including mutation, carcinogenesis, and 
cell death in response to therapeutic DNA damage [Lindahl, 1987 ].
1.4.1.Human syndromes with hypersensitivity to DNA damaging agents
Evidence for the potential involvement of DNA repair disorders in determining 
response to radiation comes from the rare human genetic syndromes in which 
partially characterised defects in DNA repair mechanisms are part of a pleiotropic 
phenotype together with hypersensitivity to DNA damaging agents, and often 
cancer-proneness [Thacker, 1989 ].
The recognised syndromes are summarised in table: 1.5
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Table 1.5. HUMAN SYNDROMES ASSOCIATED WITH 
HYPERSENSITIVITY TO DNA DAMAGE.
SYNDROME
Ataxia
Telangectasia
Bloom's
Cockayne's
Xeroderma
Pigmentosum
Fanconi's
Anaemia
PHENOTYPE
Cerebellar dysfunction 
Skin telangectasia 
Increased incidence of 
epithelial and lymphoid 
tumours
Photosensitivity, 
Immuno-deficiency. 
Growth retardation
Photosensitivity 
Dwarfism,ataxia 
Neural deafness 
Retinitis pigmentosum 
Progeria-like
Neurological defects 
Telangectasis 
Melanoma,squamous Ca 
Basal cell Ca
Hypoplastic anaemia, 
Skeletal defects 
Hypogonadism 
Thrombocytopenia 
Leukaemia
HYPERSENSITIVITY
Ionising radiation 
Bleomycin
UV
Bifunctional alkylators 
UV
UV
Bifunctional alkylators
Bifunctional alkylators
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1.4.2. Ataxia telangectasia as a model of human ionising radiation 
hypersensitivity.
The human paradigm of ionising radiation hypersensitivity is the disorder ataxia 
telangectasia [Taylor et al, 1975 ]. It is a recessively inherited disorder in which 
patients show a progressive cerellar ataxia presenting in infancy or early 
childhood.Common neurological features include diminished deep 
reflexes,choreoathetosis, oculomotor apraxia, and dysarthria.
Laboratory abnormalities include a defect of cell mediated immunity, and 
increased levels of spontaneously occurring chromosome abnormalities in 
peripheral lymphocytes [Taylor et al, 1989 ]. Genetic differences exist between 
patients as evidenced by the identifcation of separate complementation groups by 
somatic cell fusion studies [Jaspers and Bootsma, 1982 ]. An excess of both 
lymphoid and epithelial malignancy has been documented in both AT 
homozygotes, and heterozygous relatives [Swift etal, 1987 ].
Patients with AT are of particular interest in studying the relationship between 
hypersensitivity to ionising radiation and DNA repair processes.
1) Their cultured cells exhibit hypersensitivity to radiation in vitro as measured by 
clonogenic cell survival [Arlett and Harcourt, 1980 ].
2) Cells fail to display the radiation-induced inhibition of DNA synthesis 
considered part of the normal cellular response to ionising radiation damage 
[Painter and Young, 1980 ].
3) Cellular and in vitro DNA repair systems suggest a defect in the fidelity of 
rejoining of DNA double strand breaks as a mechanistic basis of the cellular 
hypersensitivity to ionising radiation [Debenham etal, 1988 ; North etal, 1990].
Although AT is a rare condition, it is estimated that approximately 1% of the 
population are heterozygous for the gene. Such individuals may constitute a 
significant percentage of the cancer treatment population as previously discussed. 
If a defect could be measured in cellular radiosensitivity it might form the basis of 
a screening test for radiation hypersensitive individuals . Fibroblasts, and 
lymphocytes from such AT heterozygotes have been demonstrated to have a
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cellular radiosensitivity intermediate between that defined for the normal 
population, and homozygous AT cases [Cole et al, 1988 ].
Data on AT and other human syndromes with less well-defined defects in cellular 
radiosensitivity lend credence to the idea that at least part of the observed 
variability in both tumour and normal tissue response to radiation is genetically 
determined.
Further support for this idea derives from data showing that human lymphocyte 
radiosensitivity measured by low dose rate irradiation in 260 healthy donors 
showed a greater variation than expected from a normal distribution [Gentner etal, 
1990 ]. This study was also able to demonstrate a hypersensitivity to radiation in 
the lymphocytes derived from a cohort of cancer patients identified as displaying 
severe normal tissue reactions to radiotherapy. The control samples from cancer 
patients showing a normal reaction could not be differentiated from normal donors. 
They concluded that patients developing treatment -related complications from 
radiation are not "statistical outfalls' of the population presenting for treatment, but 
constitute a heterogeneous subset.
1.4.3. DNA repair systems.
DNA damage may be defined as the modification of DNA structure sufficient to 
alter coding or normal transcription. Its repairability is dependent on proteins 
recognising damage then initiating a sequence of biochemical changes to restore 
the intact duplex DNA molecule. DNA repair is therefore the cellular process of 
restoration of normal nucleotide sequence and stereochemistry of the DNA 
molecule. Study of prokaryotic, simple eukaryotic and mammalian cells suggest a 
remarkable degree of conservation of some aspects of the processes involved. 
They have served to counteract a wide spectrum of DNA damage, including heat 
hydrolysis, UV light, ionising radiation, and enviromental chemicals.
It is now recognised that a variety of both constitutive and inducible DNA repair 
pathways exist, with varying degrees of characterisation of genes and protein 
products involved [Lindahl, 1982 ; Sancar and Sancar, 1988 ].
The study of the excision repair pathway of UV induced DNA damage, and other 
repair mechanisms in bacterial systems has provided the basis for much 
fundamental knowledge, facilitated by the existence of a large number of repair 
mutants. Somatic genetic complementation approaches that have proved so 
successful in simpler organisms have been complicated in the study of human
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DNA repair by absence of a large number of repair deficient mutants, and 
difficulties transfecting human cells with foreign DNA [Thompson, 1989 ].
Extrapolation from bacterial DNA repair systems to mammalian or human cells is 
complicated at a number of conceptual and practical levels.
1) In bacteria DNA is essentially a naked molecule, whilst in higher organisms it 
has a complex chromatin associated tertiary structure .This may impose significant 
constraints on repair activity requiring enzyme access [Sidik and Smerdon, 1990].
2) Mammalian systems demonstrate heterogeneity of repair within different 
regions of the genome [Bohr et al, 1987 ], with some evidence of preferential 
repair of actively transcribed genes.
3) Any mutation affecting DNA repair must be compatible with viability of the 
human fetus, thus the span of diversity of human mutant systems to facilitate the 
characterisation of repair pathways is inherently limited.
It is expected that DNA repair will show further levels of complexity related to 
effects of the cell cycle, induction by DNA damage, or even constitutive variations 
in different tissues dependent on cell lineage [Mitchell and Hartman, 1990 ].
1.4.4.1 DNA excision repair pathways.
The generic term “excision repair” has been superceded by the identification of 
three biochemically distinct pathways of removing damaged, or inappropriate 
bases from DNA. These are designated nucleotide excision repair, base excision 
repair, and mismatch repair. The nucleotide excision pathway was described 
following the classic studies on removal of cyclobutane pyrimidine dimers from 
DNA following UV irradiation, but has since been implicated in the repair of a wide 
range of DNA helix-distorting lesions [Epstein,1990].
In contrast to prokaryotes, little is known about damage-specific recognition and 
incision of DNA in eukaryotic cells.
A role for the involvement of DNA base damage has not been directly 
demonstrated in radiation-induced cell killing. However, it is recognised in the 
spectrum of radiation-induced lesions, and undoubtedly plays a part in point 
mutation. Removal of base damage, as measured by endonuclease-sensitive
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sites, has been shown to be prolonged in one cell line derived from a patient with 
ataxia telangectasia, [Paterson and Smith, 1979 ], and in fibroblasts derived from 
patients with Xeroderma pigmentosum. [Fornace etal, 1986 ]
1.4.4.2.Recombination.
Genetic recombination involves the exchange of DNA sequence between strands. 
The homologous pairing of DNA strands, strand exchange, and branch migration 
require a series of enzymic events. Recombination can occur extra-, inter- or 
intra-chromosomally.These processes are ubiquitous in nature, and can be 
demonstrated in both germ lines, and somatic cells [Bollag etal, 1989]. Different 
classes of DNA rearrangements, for example, crossing over (reciprocal 
exchange), gene conversion (non-reciprocal exchange), deletion, inversion, 
duplication etc are the end-products of such events.
The process of genetic recombination has been proposed as a possible 
mechanism for the repair of radiation -induced strand breakage [Resnick, 1976 ] .  
Recombination can be demonstrated to participate in the resolution of DNA 
double strand breaks in yeast. The repair of a double strand break involving 
damaged bases and sugar moieties on adjacent strands might involve this 
process.
1.4.5.ldentification of DNA repair genes.
Considerable efforts are being made in many laboratories to identify and clone the 
genes involved in the inherited human disorders that exhibit hypersensitivity to 
DNA damaging agents, including ionising radiation. See table 1.6.
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iTable 1.6 Cloned Human DNA repair genes
Gene Chromosomal
location
Gene
size
No.of aa 
in 
protein
Activity of 
gene product
ERCC-1 19q13 15-17 297 ?
ERCC-2 (XP-D) 19q13 20 760 DNA helicase1
ERCC-3 (XP-B) 2q21 45 782 1
ERCC-5 13q 32
ERCC-6 10q11 100 >1500 DNA helicase1
XP-A 9q34 25 273
DNA ligase I 19q13 919 DNA ligase
HHR6A Xq24 15 152 Ubiquitin-
conjugating
enzyme
HHR6B 5q23 152
Poly ADP 1q42 43 1043
ribose
polymerase
MGMT 10 207 0 6-methyl
guanine-DNA
methyltransferase
ANPG 230 Alkyl-N-purine- 
DNA glycosylase
UNG15 12 304 Uracil DNA 
glycosylase
XRCC-1 19q13 33 633
KIN17 10p 200
1= presumed from amino acid sequence 
aa=aminoacid
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Somatic cell genetic techniques rely on the isolation of hypersensitive mutants of a 
"wild type" cell, identified by their abnormal sensitivity to the DNA damaging agent 
of interest. It is assumed that the mutation involved is in a gene comprising at least 
part of the relevant repair pathway. Genomic DNA or a cDNA expression library 
derived from cells exhibiting a normal phenotype is then transfected into the 
mutant cells in an attempt to restore or'complement’ the repair defect. This 
approach has led to the chromosomal mapping of 5 human genes involved in the 
excision repair pathway, ERCC 1-5, with the cloning of of 3 human genes 
ERCC1, 2 and 6. Three genes involved in the repair of ionising radiation have 
been mapped, designated XRCC 1-3, with XRCC 1 successfully cloned 
[Thompson etal, 1990; Bootsma etal, 1988; Troelstra etal, 1990 ].
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Cell fusion studies have also identified subclasses or 'complementation groups' of 
both human and mammalian cells exhibiting a hypersensitive phenotype to a given 
DNA damaging agent. The implication is that many different genes can be 
involved in regulation of a specific repair pathway, with different mutations leading 
to a similar hypersensitive phenotype [Jones et al, 1990 ].
The study of human DNA repair has been further facilitated by the development of 
immortalised cell lines from patients with recognised DNA repair defects, including 
Xeroderma pigmentosum, Blooms syndrome, Fanconi's anaemia, and ataxia 
telangectasia [Cox et al, 1986 ; Collins and Johnson, 1987 ].
1.4.6. Rodent mutants selected for ionising radiation hypersensitivity
A number of rodent cell lines have been mutated with the specific purpose of 
selecting for ionising radiation hypersensitive phenotypes, to permit further 
mechanistic studies.
The V79 -4 irs mutants cell lines were established by the Thacker group as 
models for the study of mechanism underlying ionising radiation hypersensitivity 
[Jones et al, 1987 ]. The mutant lines exhibit a 2-3 fold enhancement in 
radiosensitivity as measured by the Do, in comparison with the parental line. The 
molecular basis of the defect underlying this radiation hypersensitivity is unclear.
In comparison with the parental line no alteration of dsb induction or repair kinetics 
can be demonstrated [Jones etal, 1990 ]. The irs 1 mutant has been 
demonstrated to show lack of fidelity of rejoining of a transfected plasmid 
containing a restriction endonuclease ds [Thacker, 1989 ].
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The CHO ionising radiation sensitive mutant strains (xrs) , are described in the 
following section.
1.4.7. Evidence for the importance of the DNA double strand break in 
determining cellular radiosensitivity.
The biochemical nature of the lesions induced in DNA by ionising radiation are 
diverse, and include alterations of bases, sugars, single strand breaks, double 
strand breaks, and DNA-protein cross-links. For many of these lesions the 
induction and kinetics of repair have been elucidated in biochemical assays, with 
the relative correlations with cellular radiosensitivity [George and Cramp, 1988 ; 
Frankenberg-Schwager, 1990 ; Ward, 1985 ].
The association of X-ray-induced cell death and chromosomal abberrations is well 
established [Grote and Revell 1972 ]. Far less is understood regarding the 
transition from the biochemical stage of DNA damage to such chromosome 
damage. Bender proposed a model for the formation of chromosome aberrations 
involving nonrepair or misrepair of DNA double strand breaks[Bender et al, 1974].
Experimental evidence for the relationship between dsb and chromosome 
aberrations was first provided by Natarajan. An increased level of chromosome 
aberrations was produced by the action of single strand specific endonucleases on 
cells already bearing radiation induced single strand breaks[Natarajan etal, 1980].
Bryant demonstrated the production of chromosome aberrations in mammalian 
cells by restriction endonuclease induced dsb. Using Sendai virus permeabilised 
V79 cells, an 10 fold increased level of chromosome aberration was noted 
following treatment with the restriction enzyme, Pvu I I ,which generates non- 
cohesive dsb; such an effect was not observed with the enzyme Bam H1, which 
produces cohesive dsb [Bryant, 1984 ].
Genetic mutants of bacteria [Krasin and Hutchinson, 1977 ], yeast [Ho, 1975 ], 
and mammalian cells deficient in repair of dsb demonstrate cellular 
hypersensitivity to ionising radiation [Jeggo and Kemp, 1983 ]. This is associated 
with an observed increase in the number of chromosome aberrations [Bryant etal, 
1987].
It has been estimated that approximately 40 dsb are induced per mean lethal 
event in the mammalian genome following irradiation , with the implication that
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cells must normally possess effective repair of such lesions [Blocher and Pohlit, 
1982].
The strength of the association between dsb, chromosome aberrations, and 
cellular hypersensitivity to radiation in dsb repair deficient mutants is not disputed. 
However, it has proven much more difficult to demonstrate a direct causal 
relationship between dsb and cell death in mammalian cells. This is in part due to 
the biochemical multiplicity of DNA lesions induced when genomic DNA is 
irradiated, and the low level of resolution of assays for residual DNA damage 
when cells are irradiated at clinically relevant doses.
The difficulties are well-exemplified by the complex set of observations relating to 
one well characterised rodent mutant system. An association between a defect in 
rejoining of dsb and hypersensitivity to ionising radiation has been demonstrated 
in the xrs (X-ray sensitive)mutants of CHO K1 cells, using neutral elution [Kemp 
etal, 1984 ]. The strength of this association was consolidated by confirming that 
xrs lines 5,6,and 7 exhibited higher than expected levels of chromosomal 
aberration in response to both X-irradiation, and restriction enzyme-induced 
damage [Kemp and Jeggo, 1986 ; Bryant etal, 1987 ]. Despite the compelling 
nature of these data, the precise defect leading to ionising radiation 
hypersensitivity in the xrs mutants has yet to be proven. The observation of a high 
frequency of chromosomal exchange aberrations has led to the speculation that 
an associated defect in recombination might increase misrejoining.
Neutral elution of DNA following cellular irradiation has also demonstrated an 
association between increased induction of dsb and enhanced cellular 
radiosensitivity, when conditions are modified to increase radiation toxicity eg 
hyperthermia, or hypoxia [Radford, 1986 ]. Further evidence for a relationship 
between initial induction of dsb and cellular radiosensitivity was the demonstration 
of an elevated level of dsb in radiosensitive murine mutant cell lines[Wlodek and 
Hittelman,1987 ].
Several authors have, however, been unable to demonstrate a relationship 
between initial induction of dsb and cellular radiosensitivity [lliakis and Okayasu, 
1988 ; Van Ankeren eta l, 1988 ]. Similarly, it has not proved possible to show a 
consistent relationship between the induction or removal of dsb in human 
tumour cells of widely differing radiosensitivity [McMillan etal, 1990 ].
It is of particular interest that techniques such as neutral elution, which measure 
overall genomic dsb after radiation, have not been able to reveal a defect in
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several radiation hypersensitive mutants, including the irs hamster lines, [Jones 
eta l, 1990 ], or VC 4, VE 5, VG 8 [Zdzienicka etal, 1990 ] .  Similarly neutral 
elution has not revealed any overall defect in dsb repair in cell lines derived from 
patients with AT [Thacker, 1989 ].
1.4.8. Methods for the quantitative study of DNA repair.
The precise measurement of DNA damage by ionising radiation at clinically 
relevant doses has been the goal of much research.
General methods used for the study of DNA repair fall into 3 broad categories:
1) DNA "damage” assays, in which repair is inferred from the disappearance of 
damage in genomic DNA with time.
2) Quantification of unscheduled DNA “repair synthesis” following DNA damaging 
events.
3) Host cell reactivation assays, in which the fate of exogenous, damaged DNA is 
monitored after introduction to the “host cell” under study.
This section will concentrate on the methods relevant particularly to the study of 
DNA double strand breaks.
Two overall concepts are pertinent to the quantitative evaluation of DNA repair. 
Firstly, approaches concentrating on the disappearance of damage must take 
account of both rate and completeness of lesion clearance. Secondly, it is likely 
that the accuracy of repair is as significant as the extent in maintaining integrity of 
genetic information. A degree of residual damage might be tolerated at the cellular 
level, or expressed as an altered phenotype. The nature of the contribution of 
misrepairto determination of subsequent cell death is poorly understood in 
mammalian cells.
Studies of induction of dsb suggest that naked DNA suffers as much as 80 times 
the damage of genomic DNA, stressing the need to develop assays which 
evaluate the processing of DNA dsb in the cellular milieu [Ljungman etal, 1991].
The situation is further complicated by evidence that the fate of DNA double 
strand breaks vary throughout the cell cycle [Wlodek and Hittelman, 1987 ]. The 
usual cellular response to ionising radiation damage is delay of DNA synthesis.
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Hence there is likely to be a complex relationship between the timing of damage in 
the cell cycle, and consequences of residual, unrepaired lesions. Whilst a defect in 
radiation-induced delay of DNA synthesis is part of the pleiotropic AT phenotype, a 
general relationship between extent of damage-induced cell cycle delay and 
radiosensitivity is lacking [Musk, 1991 ].
DNA damage assays which have shed light on the relationship between the dose 
-induction, and disappearance of DNA double strand breaks include velocity 
sedimentation, neutral filter elution, and more recently, pulsed field gel 
electrophoresis (PFGE).Conditions are established to study DNA fragmentation in 
non-denaturing conditions. Protein-free DNA fragments are physically separated 
by centrifugation, elution or gel electrophoresis.
The neutral elution assay is based on the principle that small (broken or 
“unrepaired”) radiolabelled DNA fragments will elute through a filter more rapidly 
than large fragments. The technique has been widely used to measure the 
kinetics of dsb, and is more sensitive than velocity sedimentation at lower doses of 
radiation. Major concerns have been the lack of a linear radiation dose-DNA 
damage response, and the inability of the method to include molecular weight 
markers. These factors, together with a number of other methodological problems 
have resulted in increasing interest in alternative methods such as PFGE.
Radiolabelled cells are embedded as plugs in low temperature gelling agarose, 
irradiated, lysed, and the DNA subject to electrophoresis. Neutral conditions have 
been developed to favour study of double strand breaks. The technique offers the 
advantage of detecting induction of damage at doses as low as 1Gy, and residual 
damage after a “repair” period at 5Gy and above. This enables the study of lesions 
that are likely to be involved in determining cell fate at clinical doses [Blocher etal, 
1989 ]. Resolution of fragments between 200 Kb and 6 megabases are obtained.
In addition, it offers the potential of permitting study of specific areas of the 
genome, if used in conjunction with hybridisation techniques.Using this assay, 
estimates of 3-5x10-9 induced dsb/ per base pair/ per Gy have been made for 
diploid mammalian cells.
A number of promising DNA damage assays are currently being evaluated, 
include the halo technique [Wynstra etal, 1990 ], and the comet assay [Olive et 
a/,1991].
The single cell microgel or “Comet” assay enables the study of DNA damage in 
individual cells. It has the theoretical advantage of requiring no radiolabelling of
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cells (visualised by staining DNA with fluorescent dyes), and requiring relatively 
few cells. When run under neutral lysis conditions it is felt to be selective for dsb, 
and therefore holds the promise of potentially showing a correlation of DNA 
damage with cellular radiosensitivity.
1.4.9.The contribution of recombinant DNA techniques and in vitro systems 
to the study of DNA repair.
Modern recombinant DNA techniques have made a major impact on the 
experimental approach to the study of DNA repair over the last 5 years, though 
conclusions reached with regard to the role of DNA repair as a modulator of 
cellular radiosensitivity have been mixed. The use of defined DNA substrate 
molecules, together with the ability to 'model' specific classes of biochemical 
damage using restriction endonucleases, has proved the tools to examine DNA 
repair processes relevant to ionising radiation at a new level of precision 
[Thacker, 1986 ]. It has proven difficult in the complex mamalian genome to 
make simple quantitative correlations between overall genomic biochemical 
damage to DNA, and subsequent cellular events. There is therefore increasing 
interest in systems which study DNA repair at the level of specific genes within 
cellular systems, [Hanawalt, 1989 ] , or permit more precise evaluation of the 
repair of specific classes of DNA damage in defined recombinant DNA substrate 
molecules.
1.4.9.1 .The use of exogenous plasmid or viral DNA as a repair substrate.
The theoretical attraction of the necessity to study DNA damage within the cellular 
enviroment led to the development of “host cell reactivation” assays. Exogenous, 
damaged DNA, in the form of plasmid, or virus is introduced into the cell under 
study by standard transfection techniques.
The reactivation of damaged virus is mediated by host cell repair mechanisms 
[Defais and Hanawalt, 1983 j.The “repair’ is measured by viral plaque formation, 
or expression of viral antigens. Using such a system, cell lines from patients with 
XP have been shown to be defective in the reactivation of UV-irradiated virus. In 
contrast, using ionising radiation of viral DNA there have been conflicting 
conclusions as to the ability of the assay to detect a form of repair predictive of 
cellular sensitivity. Whilst Rainbow etal [1981 ] found decreased reactivation of
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irradiated adenovirus by XP fibroblasts,no defect could be detected in reactivation 
of herpes simplex in host AT lymphoid lines [Henderson and Long, 1981 ]. As 
reactivation of viral sequences is largely the result of single strand break repair, 
the lack of correlation with cellular sensitivity is not surprising. This has lead to the 
more recent interest in plasmid DNA as a model for genomic DNA repair events.
There is now a large body of data employing the "host cell reactivation" approach 
to the processing of plasmid DNA damage. The conclusions from the data up to 
1989 were reviewed in detail by Vos and Hanawalt [1989 ].
Plasmid DNA has been used as a substrate to model the repair of genomic DNA 
in both cellular and in vitro, cell-free repair systems. The use of plasmid DNA to 
! study radiation-induced DNA damage , repair and genetic change in mammalian
i
cells has been reviewed in detail by Thacker [ Thacker, 1986 ; 1989 ]. Substrate 
plasmid molecules have been produced by both UV and ionising radiation, 
restriction enzyme digestion, and cytotoxic drugs.Repair events can be inferred 
from a transient or stable alteration of phenotype of the host cell, conferred by the 
plasmid-encoded genes.
Experimental systems using plasmid DNA have yielded interesting and 
important information on two DNA repair events, namely recombination, and 
rejoining of DNA dsb.
Substrates for the analysis of recombination were constructed from pBR 322 
sequences in SV 40 virus, subsequently transfected into CV-1 cells to give 
information on the sequence homology requirements for both homologous and 
non-homologous recombination! Roth et al, 1985]. A similar approach has 
revealed that damaged DNA in the form of a dsb can itself stimulate 
recombination occurring in a range of mammalian cells types [Rubnitz and 
Subramani,1985; Brenner et al, 1986], raising the possibility that such a 
mechanism might be invoked in the cellular repair of radiation -induced dsb.
Difficulties associated with poor cell transfection efficiency were circumvented by 
Wong et al, using microinjection of plasmid DNA bearing dsb into mammalian 
cells, to confirm the recombinogenic effect of dsb [Wong and Capecchi, 1986].
Plasmid molecules have been used to assess cellular repair proficiency for both 
cytotoxic drug-induced damage, as well as radiation lesions. The technique of 
introducing drug damage within plasmid DNA eg platination, followed by
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transfection into the cell type of interest has been extensively employed to monitor 
modification of DNA damage 'in vivo' [Chu and Berg, 1987 ].
Several studies have used irradiated plasmid molecules to assess DNA repair in 
the cellular enviroment. Model systems have been reported based on the 
megavoltage irradiation of recombinant plasmids bearing the bacterial genes neo 
or g p t, subsequently transfected into mammalian cells.. Although the processes of 
cellular plasmid uptake, integration and expression are not fully understood, 
measurable frequencies of plasmid -mediated mammalian cell transformation 
can be obtained, with an approximate two-fold reproducibility. A radiation dose- 
dependent reduction in the number of successfully transformed CHO cells has 
been demonstrated in one such study [Thacker, 1986 ].
Spivak eta l 11984 ] used transfected, UV irradiated pSV2-gpt plasmid to assess 
the repair proficiency of a cell line derived from a patient with the excision repair 
defect, xeroderma pigmentosa. Whilst the approach was interesting, the study 
illustrated two absolute requirements of this transfection / gene expression 
approach: 1) to show that the effects of gene transfer itself do not influence cell 
viability.; 2 ) the need for an expression time of the plasmid encoded genes prior to 
cell selection was not acknowledged.
Some of the most innovative studies have employed plasmid DNA as integrating 
vectors to study repair in intact human cells derived from AT patients, or rodent 
cells with presumed dsb rejoining deficiencies.
Recombinant plasmid molecules such as the pPM 17, pPMH16, and pSV vectors 
engineered by Mulligan and Berg [1980 ] encode small, well-characterised genes 
gpt and neo, which express in mammalian cells. Human cells containing these 
genes can be detected using selective growth media . Restriction endonucleases 
(RE) have been used to generate a dsb within one of the selectable genes, the 
second plasmid-encoded gene acting as a marker of transfection efficiency.
Repair 'fidelity' of RE induced dsb has been assessed by comparing numbers of 
colonies integrating and expressing plasmid DNA encoded genes, following 
transfection of intact or linear plasmid .
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1.4.9.2. Restriction endonucleases as models of ionising radiation-induced 
DNA damage.
The type II restriction endonucleases (RE) are bacterial enzymes. They are 
thought to serve a function in bacterial cells analogous to the immunological 
surveillance mechanisms of higher organisms, ie the elimination of foreign DNA by 
digestion. Many such enzymes are now isolated from bacteria, available 
commercially, and are crucial to modern recombinant DNA technology.
Their application in the study of DNA repair in mammalian cells has been reviewed 
in detail by Bryant [Bryant, 1988 ]. RE are of particular interest in the context of 
modelling ionising radiation DNA damage. They recognise specific base 
sequences in DNA to produce a double strand scission bearing either cohesive or 
blunt termini. The overlapping ends of the cohesive or 'sticky' termini can have 
either 5 'phosphoryl or 3'hydroxyl structure. The property of RE of specific interest 
in the context of this thesis is their application to produce defined DNA repair 
substrates in 'simple' DNA molecules, such as plasmid DNA. The choice of RE 
can generate a variety of dsb configurations to mimic the diversity of such lesions 
following irradiation of genomic DNA.
A disadvantage of the use of RE to model radiation-induced dsb is the relative 
'cleaness" of the termini generated, with intact 3’ hydroxyl and 5' phosphoryl 
groups. In theory such termini might be rejoined by the action of a single enzyme, 
a DNA ligase. Analysis of the end -structure of single strand radiation breaks 
suggests that radiation dsb are likely to have 'dirty' ends requiring exonuclease 
action prior to religation. However, despite the apparent chemical differences, 
restriction enzymes have been shown to generate a similar spectrum of cellular 
endpoints to those observed to occur following true ionising radiation damage, 
namely both chromosome aberration, and cell death. This is suggestive that the 
cellular processing of dsb is similar despite the different biophysical origins of 
the lesions.
1.4.10.Concept of DNA repair fidelity.
Repair fidelity has been asessed in a number of radiation hypersensitive 
mutants, including transformed cells from AT patients [Thacker, 1989 ] .  
AT5BIVA cells showed a significant reduction in fidelity of rejoining of both 
cohesive and blunt dsb, when compared with a transformed normal human
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fibroblast line, MRC5BIVA, with comparable transformation frequencies in both 
lines. A similar defect was demonstrated in only one of the ionising radiation- 
sensitive rodent lines, irs 1. It was of note that no reduction of fidelity could be 
demonstrated in this assay in the V79 xrs I ines previously shown to be deficient 
in dsb rejoining in neutral elution studies. However, the xrs lines had a much lower 
overall transformation efficiency.
The approach of using integrating plasmid DNA vectors to assess repair fidelity 
has been employed to study human tumour lines of differing cellular 
radiosensitivity [Powell etal, 1992] .Using a similar system to that described 
above, the fidelity of rejoining in a radioresistant human tumour cell line, RT112, 
was shown to have only a repair fidelity of 17%, ie 83% of successful plasmid 
integrations occurred with sufficient loss of information at the site of the dsb to 
inactivate expression of the gpt gene. The interpretation of these authors was the 
controversial suggestion that some human cell lines might be resistant to radiation 
induced cell kill by virtue, not of repair proficiency, but ability to ’tolerate' a higher 
level of residual genomic damage.
A discussion of some of the technical difficulties and conceptual compromises in 
the use of such integrating vector systems is pertinent. It can be argued that the 
validity of using plasmid DNA damaged prior to its introduction into mammalian 
cells as essentially foreign DNA is a limited model of genomic DNA repair. The 
presence of damage within the plasmid DNA is itself a stimulus to host 
chromosomal integration, thus making comparisons of transformation frequencies 
achieved with the control undamaged plasmid difficult. Comparisons of rejoin 
fidelity would need to be made ideally at 'equal integration" frequencies. The 
plasmid copy number within each transformed cell can vary, with only limited 
screening for this phenomenon by Southern analysis of genomic digests. The 
picture is further complicated in studies using transient plasmid transfection and 
gene expression, as a type of host cell reactivation assay. Such episomal plasmid 
is likely to be subject to quite different cellular processing than chromosomal 
DNA.
1.4.11. Use of in vitro systems to study DNA repair in mammalian cells
A cell-free system is a fractionated cell extract that maintains a biological 
function.The use of cell-free, in vitro systems has made a major contribution to the 
study of many complex cellular processes. The ultimate goal is to analyse and 
reconstruct a particular cellular process in a test-tube, from constituent parts.
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Cell-free extracts can be prepared from whole cells, the cytoplasmic or nuclear 
protein fraction. A complex range of cellular functions have been reproduced in 
such cell-free systems.
1) The transcription of purified genes has been initiated in vitro by the RNA 
polymerase II activity of extracts of mammalian nuclei [Dignam eta l, 1983 ].
2) Nuclear extracts derived from human cells have catalysed SV 40 DNA 
replication and supercoiling [Stillman and Gluzman, 1985 ].
3) Homologous recombination has been initiated using extracts' derived from 
mammalian cells [ Lopez etal, 1987 ; Kucherlapati and Moore, 1988 ].
In vitro systems have been applied to the study of both excision repair events, and 
rejoining of DNA dsb.
1.4.11.1 .Excision repair in vitro.
The in vitro approach to investigating excision repair of DNA has proved a 
valuable adjunct to the cloning of repair genes.
Excision repair of apurininc / apyrimidinic sites and excision of pyrimidine dimers 
has been demonstrated in Hela extracts, using UV treated SV 40 
minichromosomes as substrates [Evans and Linn, 1984 ] .
It has been possible to demonstrate that the likely defect in the group A 
complementation group of xeroderma pigmentosa (XP) resides in an inability of 
the cells to excise pyrimidine dimers in native chromatin, rather than a specific 
enzyme deficiency, by showing that extracts prepared from the cells could perform 
the required excision step in naked E.coli DNA [Kano and Fujiwara, 1983 ].
Wood et a /[1988 ] have developed an in vitro repair synthesis assay to model the 
excision repair pathway using plasmid substrates, and human cell free extracts. 
Extract-mediated excision of UV or drug-induced adducts within the plasmid 
molecule is monitored by the subsequent incorporation of radiolabelled 
nucleotides to generate a 'repair patch' within the plasmid DNA.
One of the major attractions of using cell extract systems is the possibilty of 
'complementing' biochemically any defect revealed in extracts from a
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hypersensitive cell line. This can be attempted in a mutant system by the use of 
extracts from the wild type cell, or alternatively, by addition of specific purified 
proteins or known enzymes.
Important results to date using this assay have shown that the defect in several 
complementation groups of XP lies in the incision step of excision repair. This 
was demonstrated by showing that extracts of these cells (complementation 
groups A,B,C,D, H, and V) could perform repair patch synthesis on UV irradiated 
plasmid, but only if the incisional step was first initiated by the M.luteus 
pyrimidine dimer DNA glycosylase.
Hansson has further demonstrated that the incision defect in these XP lines can 
be complemented in such a cell free assay by addition of the E.coli UVr ABC 
protein complex [Hansson etal, 1990 ].
1.4.11.2.Application of in vitro repair systems to the study of DNA dsb 
rejoining.
At the time of initiating this study, in vitro repair systems had been successfully 
applied to demonstrate DNA dsb rejoining in fertilised Xenopus eggs, [Pfeiffer and 
Vielmetter, 1988 ] but not mammalian cells.
Thacker et al have since reported the use of an in vitro repair assay to evaluate a 
possible defect in the rejoining of DNA dsb in cell extracts derived from the ataxia 
telangectasia fibroblast cell line, AT5BIVA [North etal, 1990 ].
The assay system used a plasmid DNA substrate, pUC18, bearing 2 bacterial 
genes, one encoding ampicillin resistance in a bacterial host, and the LacZ  
gene, confering b-galactosidase activity. The plasmid molecule was linearised by 
the generation of a single dsb in the circular molecule, by restriction enzymes.
This molecule was then a substrate for rejoining mediated by the cell extracts, 
under appropriate ligation conditions.
The use of a range of restriction enzymes cutting once in the region of the 
multicloning site of pUC18 allowed the analysis of rejoining of 6  different 
biochemical forms of dsb termini. The plasmid products of the ligation reaction 
were evaluated by examination of the pattern of plasmid DNA migration on gel,
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assessed by Southern blotting, and plasmid-mediated transformation of the 
phenotype of competent DH5 a E.coli.
Rejoin proficiency was assessed as the number of ampicillin resistant bacterial 
colonies per 1 0 5 viable bacteria growing through ampicillin selection on agar. 
Rejoin fidelity was assessed as the percentage of these colonies which 
expressed b-galactosidase activity ie. had rejoined the cut site with sufficient 
preservation of sequence to permit expression of the second selectable marker, 
the LacZ  gene.
The rejoin activity in AT 5 extracts was compared with that of extracts of the 
human fibroblast line MRC5, which exhibits normal radiosensitivity. Efficiency of 
rejoining mediated by both types of extract varied depending on the class of dsb, 
with far greater rejoining of the Sal I (5' TCGA) and Hind III (5 ' AGCT) sites. 
Enzymes generating cohesive termini were ligated much more readily than those 
producing blunt ends.
No significant difference in extent of rejoining was demonstrated between AT5 
and MRC5 extracts at any of the 6 sites examined, although rejoin efficiency 
varied for different types of termini. However the main observation of the study 
was that the fidelity of the rejoining achieved by AT extracts was much lower than 
MRC5 using substrates generated by the enzyme EcoR1.
It was concluded that part of the explanation of the cellular radiation 
hypersensitivity of AT might reside in a reduction of dsb repair fidelity at sites of 
DNA damage which were less efficiently ligated. This might permit the 
degradation of ends prior to successful religation, with consequent loss of 
sequence. It was further postulated that a possible defect in AT might involve the 
lack of proteins which 'protect' broken DNA strands prior to religation, as identified 
in human HeLa cells [de Vries etal, 1989 ]. However, no data has been obtained 
to substantiate this hypothesis to date.
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1.5.Rationale for the work undertaken in this thesis.
Given that human glioma exhibits considerable clinical radioresistance, it has been 
postulated that a significant determinant of treatment failure might be the intrinsic 
cellular radioresistance of this tumour.
1) At the time of undertaking this study no laboratory had conducted a detailed 
evaluation of the cellular radiosensitivity of human glioma. Although a limited 
amount of data existed to suggest that human glioma cell lines might lie at an 
extreme end of the spectrum of human cellular radiosensitivity, few of the cell lines 
cited had been well-characterised as models of human glioma. Chapter 3 
describes the establishment of primary human glioma cultures, and the 
characterisation of 5 continuous cell lines.
2)No single worker had previously made a direct comparison of the cellular 
radiosensitivity of human glioma and cell lines derived from human tumours of 
different histological type, particularly the more radiocurable epithelial carcinomas.
The objectives of the work undertaken and described in chapter 4 of this thesis 
was therefore to measure the cellular radiosensitivity of a panel of 5 well- 
characterised , continuous cell lines derived from human glioma, using clonogenic 
cell survival as the experimental endpoint. Comparison has been made with the 
cellular radiosensitivity of 8  other human tumour cell lines, including both 
embryonic and epithelial cell types, as cell lines representing tumours of widely 
differing clinical radiocurability.
♦
3) An extension of the idea of the" measurability" of cellular radiosensitivity is the 
concept of predictive testing of tumour radiosensitivity in vitro. There is at present 
little data on the prognostic value of measuring the cellular radiosensitivity of 
human tumour biopsies [West, 1990].
An objective of this study was therefore, to assess the feasibility of using 
clonogenic cell survival to measure cellular radiosensitivity in primary cultures 
derived from human glioma biopsies, as a possible prognostic variable. The 
establishment of 17 of these cultures, and an evaluation of the radiosensitivity at 
the clinically relevant dose of 2 Gy is described in chapter 6  .
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4) The ability of cells to recover from ionising radiation can be measured by 
enhancement of clonogenic cell survival in operationally defined systems which 
modify the delivery of radiation eg. low dose rate irradiation, or "split dose” 
irradiation, or by manipulation of the post irradiation cultures conditions eg. 
delayed subculture.
A comparative evaluation of the cellular recovery potential of human glioma cell 
lines has been made using the split dose technique, and the work is presented in 
chapter 5 .
5) Whilst it is now accepted that human tumour cells do differ in their cellular 
radiosensitivity, the subcellular mechanisms that determine this variability are 
poorly understood. The relevance of the induction of specific classes of DNA 
damage by ionising radiation, and the role played by DNA repair processes in 
modulating the subsequent cytotoxicity of these lesions is one of the most 
important areas in molecular radiobiology. There is a relative paucity of 
information on the possible role played by differing DNA repair proficiency in 
determining the response of human cells to DNA damaging agents such as 
ionising radiation.
Chapter 7 describes the use of an in vitro system designed to measure the 
proficiency of DNA double strand break rejoining mediated by human tumour cell 
extracts. The assay was initially established in this laboratory to evaluate dsb 
rejoining efficiency in the ionising radiation hypersensitive mutants (irs) of the V79 
Chinese hamster cell line.
Part of the work undertaken for this thesis included an evaluation of this assay as 
a means of measuring dsb rejoining mediated by human tumour cell extracts. Data 
obtained on the dsb rejoining proficiency of extracts from 4 human tumour cell 
lines is presented.
A variety of experimental endpoints have been used to assess the dsb rejoining 
activity exhibited by nuclear protein extracts derived from these human tumour 
cells. The results obtained are discussed , and the validity of the system as a 
model of the repair of genomic DNA damage reviewed.
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Chapter 2 General materials and methods
2.1 General tissue culture techniques
2.1.1 Maintenance of cell lines
All tissue culture was carried out in class 2 microbiological safety hoods, with 
vertical laminar airflow. Non-disposable equipment was sterilised by dry heat at 
160° C for 1 hour. Heat stable solutions were sterilised by autoclaving at 120 °C 
for 40 minutes.
Cells were maintained subconfluent in appropriate tissue culture medium (see 
table 2 .1 .), incubated at 37° C, in an atmosphere of 5% C02, 20% 02.
Human glioma lines, continuous and primary, were maintained in a 50:50 mixture 
of Ham's F10 ( Flow Labs) and Dulbecco's modification of Eagle's Basal medium 
( Gibco, DMEM), supplemented with 10% foetal calf serum ( Northumbria), 2 mM 
glutamine, and buffered with sodium bicarbonate.
Cells were passaged as required by population doubling times, using 0.25% 
trypsin in 1mM EDTA, with phosphate buffered saline ( P.E.T. solution)
Routine cell counting was performed on a Coulter counter, with settings calibrated 
separately for each cell line. A haemocytometer was used to count single cell 
suspensions for cloning asays. Cell viability was determined by exclusion of 0.1% 
trypan blue dye.
Morphological observations were usually made by phase-contrast microscopy of 
living cultures, or by bright field microscopy of monolayer cultures, after fixing in 
methanol, and staining with 0 .1% crystal violet.
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Table 2.1 Tissue culture requirements of continuous human cell lines
Line Primary Histology Medium Growth Passage
Human
gliomas
UK Glioma Ham's F10 Adherent 3/week
CCM Glioma +DMEM monolayer 21 week
UVW Glioma
(50:50)
i i i i i i
U251 Glioma ii i i i i
IPSB18 Glioma i t i i i i
Human
carcinomas
A549 Lung,adenocarcinoma •i i i i i
SKMES " squamous. i i i i i i
HT29 Colon ,adenocarci noma i i i i i i
MCF-7 Breast,adenocarcinoma i i i i i t
A2780 Ovary,adenocarcinoma RPM11640 i« 3/ week
Human
embryonal
lines
SKNSH Neuroblastoma Ham's F10 i i 2 / week
IMR32 Neuroblastoma +DMEM i i i i
NB 1 Neuroblastoma
(50:50)
n i i i i
Susa Teratoma i i n 3/ week
RPMI 1640
DMEM, Dulbecco’s modification of Eagle’s minimum essential medium
All lines were cultured with 10 % fetal calf serum, 2 mM glutamine, and buffered
for 5% C 0 2  gas phase.
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2.1.2 Cell storage and handling of stock
All continuous cell lines were stored in liquid nitrogen, suspended in complete 
medium, with 10% DMSO. Cells were frozen at 1-2x10® per ml. with a cooling 
rate of 1° C per minute. Following thawing and maintenance in culture, lines were 
maintained for no more than 12  passages, before discarding, and use of fresh 
stock.
Stocks of each cell line were grown up at the start of this project, and frozen to 
provide material of similar passage level throughout the research, unless 
otherwise stated.
2.1.3. Mycoplasma testing
All lines were screened for mycoplasmal contamination monthly, and prior to 
freezing. Cells were fixed at 50 % confluence in petri dishes, with 25% acetic acid 
in methanol, and incubated with the fluorescent DNA stain Hoechst 33258 at 
0.05mg per ml, for 15 minutes at room temperature. Cells were then screened by 
fluorescence microscopy for the extra-nuclear DNA pattern indicative of 
mycoplasmal infection.
2.1.4. Origins of human cell lines.
Continuous lines
Three human glioma cell lines had been established in this laboratory by previous 
workers; G-CCM; G-IJK-T; and G-UVW. The clinical origins of these lines , and 
the primary glioma cultures established in this study are summarised in table 3.2
At the time of undertaking these studies all three lines were at passage levels in 
excess of 100, and had been donated to the ECACC at Porton Down.
U251, a continous human glioma cell line, was kindly donated by 
Dr.B.Westermark, Uppsala. IP-SB 18 was derived from a high grade human 
glioma, and provided at passage 23 by Dr.Jeff Pilkington, and Joanna Knott, Dept, 
of Neuropathology, Institute of Psychiatry, London.
Epithelial and embryonic human tumour lines were obtained from ATCC, 
Rockville and stocks were all in regular use as part of the research program of the 
Dept.of Medical Oncology, Glasgow University.
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2.2. Clonogenic cell survival assays.
2.2.1.Monolayer colony formation assay.
The colony forming ability of tumour cells irradiated in vitro was examined 
according to the following protocol. Exponential cultures of adherent monolayer 
tumour cells were trypsinised using P.E.T, harvested in complete culture medium 
and mechanically disaggregated by pipetting, and finally passed through a 25 
gauge hypodermic needle. The quality of the single cell suspension was checked 
by microscopy, and cell numbers counted using a haemocytometer. All 5 glioma 
cell lines yielded successful single cell suspensions by this method. All epithelial 
human tumour lines were subject to the same procedure. The 2 human 
neuroblastoma cell lines, IMR 32, and SKHSH required vigorous mechanical 
disaggregation to give acceptable single cell suspensions.
Cells were subcultured into T25cm2 culture flasks at varying cell densities. A low 
density feeder layer was added to each separate flask, comprising 1 0 4  heavily 
irradiated homologous cells ( 1 0 0Gy single dose irradiation). This procedure was 
shown in pilot experiments to enhance plating efficiency of all continuous cell lines 
examined, and maintain linearity of plating efficiency over a range of cell densities 
yielding between 50 and 200 colonies per T25cm2 flask.
Flasks containing test and feeder cells were then returned to the incubator and 
maintained at 37° C with gassing, for a period of 4 hours, to minimise any potential 
interaction of trypsin and radiation lesions.
2.2.2.Radiation protocol for cell survival assays
Megavoltage irradiation was carried out using a Mobaltron cobalt-60 therapy 
source, at ambient room temperature. Doses of 1- 1 2Gy were used, at a dose 
rate of 1.3-1.15Gy per minute, using full dose build-up, and backscatter. Dosimetry 
was checked regularly by the Dept.of Clinical Physics.
Cultures were returned to the incubator within minutes of irradiation, then left 
undisturbed in a designated cloning incubator for periods of 1 0 -2 0  days, varying 
with the doubling time of the cell line. Cultures were washed with PBS, fixed for 15 
minutes with methanol, then stained with 0.1% crystal violet. Colonies of greater 
than 50 cells were scored by eye using bright field microscopy, representing cells 
capable of a minimum of 6 doublings after irradiation.
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The plating efficiency (PE) of the experiment was calculated as:
PE= Number of colonies obtained
number .of cells plated
The surviving fraction (SF) of each experimental point was then calculated as:
SF= plating efficiency of treated cells
plating efficiency of control cells
The surviving fractions of cells at each dose point were plotted on logarithmic 
axes, against dose in Gray on a linear axis.
2.3. Molecular techniques 
Plasmid DNA substrates.
The plasmid DNA substrate used for construction of substrates for DNA double 
strand break rejoining studies was the recombinant molecule,plC2 0 H, bearing the 
selectable gene encoding ampicillin resistance in bacteria, and the Lac Z 
sequence. See figure 7.1.
The choice of this substrate is discussed in section 7.1.3.
2.3.1. Large scale plasmid preparation
An overnight culture of the E.coli strain JM 83 containing the plC20H construct 
was established. 5mls was inoculated into 500mls of L-broth containing 50 mgs 
ampicillin and grown to stationary phase overnight. Bacteria were pelleted at 3000 
rpm, and cell lysis achieved by resuspending in 10 mis of 50mM Tris pH 8.0 with 
25% sucrose, followed by the addition of 5mls of 10mg/ml lysosyme. Incubation in 
these reagents was carried out at 4 C for 3 minutes, then 5 mis of 0.2M EDTA 
added, prior to a further 25 minutes on ice. 600 pi of 10% NP-40 in Tris-sucrose 
was added and tubes inverted to promote bacterial lysis. Once the mixture had 
become viscous it was spun at 15,000 rpm for 30 minutes to clear the lysate. The 
supernatant was removed, and extracted with an equal volume of phenol, by 
mixing for 10 minutes. This was followed by a 3000 rpm spin, then the supernatant 
removed and extracted with an equal volume of chloroform:isoamyl alcohol (24:1). 
Ribonuclease A was added at 20pg/ml for 30 minutes at 37° C to remove RNA. 
The RNase was inactivated by a further phenol / chloroform extraction.
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DNA was then precipitated by the addition of 1 volume of isopropanol, and 1/2 
volume of 7.5 M ammonium acetate, left at room temperature for 30 minutes, and 
then spun at 3000 rpm for 20 minutes. The DNA pellet was washed in 100% 
ethanol, followed by 70% ethanol, and finally dried and resuspended in 1 ml TE.
.2.3.2 Restriction endonuclease digestion
Single digests of plC20H by both EcoR1 and Nru 1( Boehringer) were carried out 
overnight at 37° C in a waterbath, using an excess of each enzyme, in buffers 
provided by the manufactors. Enzymes were inactivated by phenol extraction, 
using an equal volume of phenol equilibrated with TE ( 10mM Tris-HCL pH 7.5). 
Organic and aqueous phases were separated by centrifugation, and the aqueous 
phase extracted using an equal volume of chloroform -isoamyl alcohol. ( 
equilibrated with isoamyl alcohol, 24:1). Ether extraction was performed to remove 
residual chloroform, by adding an equal volume of ether to plasmid DNA in 
solution, mixed by inversion, and separated by centrifugation. The organic phase 
(top) was discarded, and residual ether allowed to evaporate in a fume hood.
DNA was then precipitated from solution by the addition of a tenth of a volume of 
3M sodium acetate pH 5.2, followed by 2.5 volumes of 100% ice-cold ethanol. 
Precipitation was completed at -70° C for a minimum of 1 hour, followed by 15 
minutes centrifugation at 13,000 rpm in a microfuge. The pellet was washed with 
70% ethanol, and dried under vacuum in a Speedivac at 37° C for 5 minutes. 
Plasmid DNA was then resuspended in TE.
2.3.3 Assessment of linearity of plC20H substrates.
Completion of restriction digestion was checked by both visualisation of the 
plasmid digestion products on gel electrophoresis, and by bacterial transformation.
A 0.8% TBE/ agarose gel ( 10x stockTBE= 900mM Tris base; 889mM boric 
acid;25mM EDTA) was made by dissolving the required amount of agarose 
( Boehringer electrophoresis grade) in 1xTBE, containing ethidium bromide at 
0.5mg/ml to facilitate visualisation of the plasmid DNA under UV light. The final 
solution was microwaved, and a horizontal slab gel poured.
One mg aliquots of both uncut and each restriction plasmid digest were loaded 
onto the gel using loading buffer (0.25% bromophenol blue; 0.25% xylene 
cyanol;20% Ficoll; 10mM Tris-HCL pH 7.5;1.0 mM EDTA). The gel was run in
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1xTBE containing 0.5mg/ml ethidium bromide, at 50-100 V, then the gel 
examined and photographed under UV light. Plasmid DNA was compared with the 
position of migration of Hind III restricted X DNA, which generated fragment 
markers of 23.6, 9.46, 6.72, 4.34, 2.26,1.98, and 0.58 kb.
The DNA content of uncut and cut plasmid TE stocks were estimated by 
measuring the optical density,(OD ) 260:280 ratio in a spectrophotometer ( 10D 
unit= 50mg./ml). Stocks were then diluted to the 1 0 ng /ml concentration used for 
the dsb rejoining assay, and frozen at -2 0 ° C.
2.4. Preparation of human tumour nuclear extracts.
The method of preparation of extracts used was modified from Dignam.
[Dignam, 1983 ]
.2.4.1 Mass culture techniques
Monolayer cultures of the human tumour lines studied were scaled up into 850cc 
roller bottles. Care was taken to ensure that cultures were maintained in 
exponential phase, and were harvested prior to confluence. Medium was changed 
every day to prevent significant pH changes, and encourage growth. Tissue 
culture media and gas phases were as described in section 2 .1 .
2.4.2. Nuclear protein extract preparation
Between 108and 10 9 cells were harvested for each cell extract prepared, usually 
from 5 to 7 70% confluent roller bottles. Routine trypsinisation was carried out, 
then cells were pelleted at 2 0 0 0 rpm, and resuspended in full medium. Cells were 
pelleted, and then washed in ice-cold PBS.
Cell lysis was achieved by osmotic swelling and detergent, with care taken to 
ensure that all procedures, and solutions used were kept at 4° C. The cell pellets 
were suspended in 10mls of TMS at 4° C, containing protease inhibitors :0.05M 
PMSF; aprotinin, 0.1 mg/ml; chymostatin, 0.1 mg/ml; leupeptin, 0.1 mg/ml; 0.05M 
benzamidine. Cell were pelleted at 2 0 0 0 rpm, and resuspended in 10mls TMS with 
0.25% Triton X100. Nuclei were pelleted at 2000rpm, and washed in TMS three 
times to clear excess detergent. An estimate of the total nuclear yield was made 
by determining the DNA concentration (OD 260nm ) of an aliquot after sonication 
in 1M NaOH. The nuclei were then resuspended in TMS at 7.5mg/ml DNA, and 
genomic DNA salt extracted from the nuclear proteins by addition of 4M NaCL to a 
final concentration of 0.3M NaCI. This solution was left on ice for 30 minutes, then
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cellular debris removed by a 15,000rpm spin. The supernatant was clarified further 
by a 1 hour ultracentrifugation step at 40,000rpm.
Nuclear proteins were then precipitated on ice for 30 minutes by the addition of 
ammonium sulphate at 0.35g/ml. Proteins were pelleted at 10,000rpm, and then 
dissolved in 1 ml of E50 buffer.
Proteins were dialysed overnight at 4° C against storage buffer containing 1mM 
DTT . Extracts were finally clarified at 40,000rpm, and frozen in 100pl aliquots at 
-70° C.
2.4.3. Evaluation of nuclear protein extract activity
Prior to using any tumour nuclear extract in test ligation assays, it was necessary 
to demonstrate that proteins were generally functional, and to estimate total 
protein activity in each cell extract.
Gel retardation assay.
The synthetic oligonucleotide aP3A containing the recognition sequence, CCAAT 
, for the ubiquitously expressed mammalian CCAAT box binding protein [Plumb 
etal, 1989 ]. was synthesised to order. The DNA required radioactive end- 
labelling for protein binding studies.
Kinase P3 2  end- labelling of a P3A oligonucleotide
Two ml of 'cold' oligonucleotide (synthesised in Beatson Institute) were incubated 
with 4 pi of T4 Poly nucleotide kinase (PNK), 4 |il yp32 ATP (Amersham), in low 
salt buffer, and reacted at 37°C for 45 minutes. The kinasing reaction was halted 
by the addition of 1pl 0.5M EDTA, and the oligonucleotide precipitated by routine 
sodium acetate and ethanol techniques. The pellet was resuspended in TE.
Klenow fill-in reaction.
The oligonucleotide was incubated for 30 minutes at room temperature with 1 \i\ 
Klenow enzyme, in Klenow buffer, with a final concentration of 2mM dNTP. This 
'fill-in' reaction was halted by inactivation at 70° C for 5 minutes in a hot water 
bath.
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Purification of the end-labelled oligonucleotide, and subsequent gel retardation 
analysis were carried out using non-denaturing polyacrylamide gel 
electrophoresis. Vertical gels were made by diluting a stock solution of 29:1 
acrilamide:bis to 5% in TBE, and the solution degassed and polymerised using 
ammonium persulphate and TEMED.
The P 32 end labelled oligonucleotide was then separated from unincorporated 
p32 by 0 .5 % TBE, 5% acrilamide gel electrophoresis.The position of the hot 
oligonucleotide was located by autoradiography, cut ou t, and the DNA eluted in 
500pl of TE overnight. The DNA was recovered by centrifugation in Spinnex tubes, 
and the activity of the radiolabelled oligonucleotide determined.
The detection of specific CAATT binding activity in each tumour extract used in 
this study was carried out by incubation of 5pl of extract with 1pl of radiolabelled 
oligonucleotide( approximately 104  cpm incorporated radioactivity), in a final 
volume of 2 0 pl storage buffer, with an excess of a non-specific competitor, poly 
d(l).d(C).
The reaction was halted by the addition of loading buffer, and the binding reaction 
products were then separated on a non-denaturing 0.5% TBE , 5% 
polyacrilamide gel run as a vertical system (Atto kit.) for 2-3 hours at 4° C, at 
150V, with 0.5x TBE circulating buffer. The gel was run until 'free' oligonucleotide 
had reached the lower part of the gel, then dried and auto radiographed at -70°C.
2.4.4. Biorad extract protein estimation
The total protein concentration of all cell extracts was determined by use of the 
Biorad kit employing the assay described by Bradford. On binding to basic and 
aromatic amino acid residues in protein, the absorbance spectrum of the dye 
Coomassie Brilliant Blue G 250 shifts from 465 to 595nm on spectrophotometry. 
This forms the basis of the assay.
Protein concentration of each cell extract was estimated by comparison with a 
standard curve generated by mixing of varying quantities of bovine serum albumin 
with the Biorad dye reagent, and reading the optical density of the solution at 
595nm.
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Cell extracts yielding less than 1 mg /ml total protein concentration were usually 
noted to have insignificant CCAAT binding activity on gel retard analysis, and were 
not used in subsequent assays.
2.5 Plasmid rejoining reaction conditions
The reaction schema is depicted graphically in figure 7.2
Reactions were assessed using 1 0 0 ng of plasmid substrate, in a final volume of 
350jil of ligation buffer. All nuclear extracts were thawed on ice prior to the 
reaction. Test ligations containing varying quantities of the nuclear extract of 
interest were added last to the reaction mix containing 100ng cut or uncut plC20H 
DNA in ligation buffer.
Unless stated otherwise, dsb rejoining reactions were carried out at 14° C, 
overnight, with the following conditions:
A reaction was set up in a final volume 350|il, containing
1) plC20H plasmid DNA ; 100ng of cut or uncut substrate
2) 70 |il of 5x ligation buffer, containing 250mM Tris-HCL, 5mM ATP , 50mM 
MgCl2 , and 5mM DTT.
Varying amounts of nuclear extract were added in storage buffer, containing 
50mM NaCI, 5mM MgCI2,20% glycerol, at pH 7.9. The final reaction volume was 
taken to 350pl using distilled water, or storage buffer.
The reactions were carried out at 14° C in a heated waterbath within a 4°C cold 
room. Reactions were terminated by the addition of an equal volume of phenol/TE, 
spun, the aqueous compartment removed and an equal volume of chloroform 
added. The sample was again centrifuged, the acqueous layer removed, and 
plasmid DNA precipitated by the addition of tenth of a volume of 3M sodium 
acetate, two and a half volumes of ice cold 1 0 0% ethanol, and 1pl glycogen. 
Precipitation of plasmid DNA was carried out at -70°C overnight. The DNA was 
pelleted at 13,000rpm, ethanol removed, and the sample lyophilised in a 
Speedivac at 37° C for 5 minutes. The plasmid DNA was resuspended in 100pl of 
TE, and stored at -20 °C prior to further analysis by bacterial transformation, 
Southern blotting or electron microscopy.
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2.5.1 Assessment of plasmid DNA dsb rejoining: qualitative procedures
.2.5.1.1. Gel electrophoresis, and Southern analysis
Ten ng of plasmid DNA reaction products were loaded onto a horizontal slab 
0.8% TAE agarose gel, using loading buffer. Gel electrophoresis was carried out 
overnight at 30V, with buffer circulating. All gels were run with Hind III digested, 
P3 2  end-labelled, X DNA size markers. Gels were run both with and without 
ethidium bromide at 1pg /ml in gel and running buffer to aid visualisation of 
differently migrating plasmid DNA forms.
Plasmid DNA was then denatured in situ by the action of denaturing buffer, 
changed twice, then neutralised. Gels were washed in 1x Genescreen buffer, and 
DNA transferred to Genescreen nitrocellulose filters by capillary action overnight, 
using 1x genescreen buffer for transfer, as described in Maniatis[Maniatis, 1982 ]. 
Filters were then baked for 1 hour at 80° C, and stored dry prior to probing with 
nick translated plC20H.
Nick translation of plC2 0 H for Southern analysis.
Radiolabelled plC20H was used to probe the nitrocellulose filters carrying 
electrophoretically separated plasmid forms. Amersham nick translation kits were 
used to synthesise (a 32-P) dCTP labelled plasmid probe. See methods 2.6.
100ng of uncut plC20H was incubated with solutions 1 and 2, together with 
100mCi of( a 32-P) dCTP, at 14 °C for 2.5 hours.Unincorporated nucleotides were 
removed by nick column purification, using a Sephadex G-50 packed column. The 
eluate was collected into eppendorfs, and the activity of the probe checked in a 
scintillation counter. The probe was judged to be adequate for hybridisation if the 
activity was greater than 107 cpm.
Hybridisation.
Nitrocellulose filters were soaked briefly in 1x Genescreen , then placed in 
hybridisation boxes with a prehybridisation mix as in 6.2.7, and incubated in a 
shaking waterbath at 42° C for 4 hours. The radiolabelled plC2 0 H probe was then 
denatured by boiling for 10 minutes, then rapidly cooled. It was added carefully to 
the hybridisation box in a fume hood, within the radio-isotope suite, sealed then 
returned to the 42° C waterbath overnight.
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Filters were washed in a solution of 2xSSC /0.1 % SDS to remove unbound probe, 
with a final high astringency wash in 0.1% SSC / 0 .1% SDS for 1 .5 hours at 65° C 
in the shaking waterbath. Filters were monitored to check levels of non-specific 
radioactivity binding prior to sealing in polythene. Autoradiography was then 
carried out at -70° C.
2.5.1.2.Transmission electron microscopy of plasmid DNA forms post­
ligation reactions
In order to corroborate the assumption that bacterial transformation by plC20 H 
was mediated by recircularised plC20H reaction products, samples of plasmid 
DNA were visualised by transmission electron microscopy. This was performed in 
collaboration with Dr.Lesley Coggins, Electron Microscopy Unit, Beatson Institute, 
Glasgow.
The 3D form of plasmid DNA in aqueous solution must be converted to a two 
dimensional form for EM . This was achieved without shearing forces, by mixing 
the nucleic acids with a mixture of ammonium acetate pH 7.5, and cytochrome C, 
and a monolayer generated at the air-fluid interface of the solution. The plasmid 
DNA diffused to the interface and was then 'blotted' on to a supporting film carried 
on an EM grid, for subsequent microscopy.
Samples screened included EcoR1 cut plC2 0 H, T4 ligated EcoR1 substrates, and 
EcoR1 substrate which had been incubated with tumour nuclear extracts.
2.5.2 Assessment of extent and fidelity of plasmid dsb rejoining
A schematic summary of the bacterial selection method is shown in figure 7-2
2.5.2.1 Bacterial host; preparation of competent bacteria
The bacterial host used for these studies was the E.coli strain JM 83 [Yanisch- 
Perron etal, 1985 ] .The choice of this strain was based on its possession of the 
C-terminal portion of the lacZ gene; this was necessary for complementation of 
the LacZ  gene encoded within plC20H.
All bacterial plating, culture, and transformation procedures were carried out in 
category 1 containment.
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Bacteria were stored at -20°C in 50% sterile glycerol. Colonies were maintained 
on L-broth agar plates without antibiotics, at 4° C, sealed with parafilm, for up to 2 
weeks before discarding.
Production of competent cells
Stock JM 83 E.coli were removed from storage at -20° C in 50% glycerol, and 
streaked onto L broth-agar petri dishes using a sterile iridium wire. They were 
incubated overnight at 37° C, then a single colony picked to propagate a 
suspension culture in 25ml L-broth. This was grown up overnight at 37° C in a 
shaking incubator. lOOpI of this culture was inoculated into 25mls of L-broth, and 
incubated under conditions permitting exponential growth. The culture was 
sampled after 3-4 hours, and interrupted by placing on ice, when the optical 
density had reached 3.0 to 5.0units at 600nm. Bacteria were pelleted at 3000 rpm 
at 4° C for 10 minutes, then resuspended in 12.5mls of ice-cold 1 0 0 mM calcium 
chloride, Tris 1 0 mM ph 7.5, and left on ice at 4 °C for 1 hour. Bacteria were 
pelleted as before, then resuspended in a 2.5ml volume of the 100mM calcium 
chloride/Tris solution and left at 4° C overnight. A "test" transformation of 10Ojul of 
the bacterial culture was performed on the day of preparation, using 1 0 ng of uncut 
plasmid DNA.Transformed bacteria were plated and incubated overnight. 
Competence was presumed to be adequate for experimentation if the preliminary 
transformation yielded a minimum of 5x104  bacterial colonies overnight. Following 
overnight incubation at 4°C in 1 0 0 mM CaCl2 bacterial competence was usually 
obtained at a transformation frequency of 5x10 ^ to 2x10 $ ampicillin resistant 
bacterial colonies per |ig uncut plC20H plasmid DNA. It was noted that optimal 
bacterial competence was only obtained if bacteria were maintained strictly at 4°C 
following the exponential growth phase, and fresh 100mM CaCI2 10 mM Tris was 
made up for each batch of bacterial transformations.
2.5.2.2.Bacterial transformation by plC20H ligation reaction products.
Forty ng of each plC2 0 H reaction, suspended in TE, were carefully added to 
10Optl aliquots of freshly made competent JM83 E.coli.The bacteria were left on 
ice at 4°C for 30 minutes, then heat shocked at 37° C in a waterbath for 5 
minutes. One ml of L-broth was then added to each eppendorf, and cultures left at 
37° C for one hour expression time. Cultures were briefly spun at 6500rpm to 
pellet bacteria, excess L-broth decanted, and bacteria carefully resuspended in 
30|itl of L-broth before plating onto preheated selective L-broth agar plates 
containing ampicillin( 100pg/ml), and X-gal (250|j.g/ml). Plates were inverted, and
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cultured overnight at 37° C. Plates were then examined for ampicillin resistant, 
and p-galactosidase positive colonies.
2.5.2.3. Use of pHSG 272 as an internal control for recovery of plasmid DNA, 
and intra-experimental variation in bacterial viability.
Replicate experiments using the reaction schema described, carried out using 
batches of the same tumour nuclear extract, suggested that considerable 
experimental variability was generated by errors in the recovery of the small 
amounts of substrate plasmid DNA used in this assay (100ng). Similarly, the 
possibility of variable bacterial transformation or viability across the experiment 
exists, due to differential toxicity of incomplete removal of nuclear proteins 
between samples, and handling. This latter problem has been addressed by 
Thacker, whose assay technique describes the success of plasmid transformation 
in terms of bacterial viability [North etal, 1990 ].
It was found that the addition of a second, uncut plasmid molecule, pHSG 272, at 
the time of nuclear extract protein extraction by phenol could allow results 
obtained subsequently on the bacterial transformation by plC2 0 H to be 
"normalised ' within an experiment, for variations in DNA recovery. At the end of 
each ligation incubation, an aliquot of reaction plasmid DNA (1 Ong) was removed 
for Southern analysis, and then a fixed quantity of uncut pHSG 272 was added to 
the eppendorf.
At the time of plating bacteria, a fixed aliquot of the mixture was removed from 
each sample, and plated onto agar plates containing 40 units /ml kanamycin.The 
number of bacterial colonies obtained per ng plC2 0 H on the ampicillin plates for 
each test sample was then corrected across the experiment for the number of 
kanamycin resistant bacterial colonies obtained in the co-transformation.
2.5.2.4.Selective culture media for transformed JM83 E.coli.
Selective culture of transformed bacteria was carried out on L-broth agar plates 
containing ampicillin and X-gal, or kanamycin. The constituents of the antibiotic 
selection are detailed in section 2 .6 .
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2.6. Solutions and reagents
Antibiotics: Sigma 
Autoradiography: Kodak
Bacterial materials: L-broth from Gibco; Bacto-agar from Difco.
Dialysis systems : Sartorius
Enzymes: Boehringer Mannheim; Pharmacia; BRL
General chemicals: Sigma;BDH
Nick columns: Pharmacia
Radiochemicals: Amersham International
Tissue culture : plastics from Falcon,Nunc.
media and supplements from Gibco,Paisley, and Northumbria Biologicals 
Transfer membranes:Du Pont
2.6.1. Plasmid DNA preparation, and electrophoresis
Buffers: 10x TBE 900mM Tris base
889mM boric acid 
25mM EDTA
50x TAE 2.0M Tris base 
1M acetic acid 
0.2M EDTA
TJBE-flelS 0 .8 % agarose(electrophoresis grade) with 
TBExI
0.5pg /ml ethidium bromide 
0.8%agarose with TAExITAE gels
Molecular weight markers Hind III digested X DNA, with or without P32 end
labelling.
( fragment sizes: 23.6;9.46;6.72;4.34;2.26;1.98;0.58 
kb)
Gel loading buffer 20% Ficoll
0.25% bromophenol blue 
0.25% xylene cyanol FF 
10mM Tris-HCL pH 7.5 
1.0 mM EDTA
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Southern blotting of plasmid DNA:
Neutralisation buffer
Denaturing buffer: 1.5M NaCI 
0.5M NaOH 
3.0M NaCL
20x Gene Screen
20xSSC
0.5M Tris-HCL pH 7.0 
0.5M Na2P04 
0.5M NaH2 P04 pH 6.5 
3M NaCL 
0.3M Na citrate
Hybridisation procedures:
Prehybridisation solution 25 mis formamide
12.5ml 20x SSC
5ml 20x Genescreen
0.5ml. salmon sperm DNA ( 10mg/ml)
0.5ml 10% SDS
4ml distilled H20
Nick translation of plC20H plasmid DNA for Southern analysis: 
Amersham kit:
Solution 1 :100mM dGTP,dATP,dTTP, in Tris-HCL pH 7.8 
Solution 2 : 5units per 5ml of DNA polymerase 1 ,100pg DNase 1 in 
Tris-HCL pH 7.5 with MgCI2, BSA, and glycerol.
Nick translation reaction:
100ng uncut plC20H plasmid DNA 
10pl solution 1
10^ P32 dCTP (100mCi / 3.7 MBq)
5pl Solution2
Final reaction vol. 50 pi with dH20
(50mls) 2.5mls 100x Denhardts
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Buffers, reagents and solutions used for nuclear protein preparations.
1) TMS 0.25M sucrose
5mM MgCl2  
10mM Tris pH 7.5
2)Storage buffer (SB) 50mM NaCI
20mM HEPES pH 7.9 
0.1 mM EDTA 
5mM MgCl2  
20% glycerol 
1mM DTT
3) E 50
4) Protease inhibitors
50mM NH4  SO4  
20mM HEPES pH 7.9 
5mM MgCI2 
20% glycerol 
0.1 mM EDTA 
0.1% Brij 35
Leupeptin 0.1 mg/ml 
benzamidine 50mM 
Aprotinin 0.1 mg/ml 
Pepstatin 0.1 mg/ml 
Chymostatin 0.1 mg/ml 
PMSF 50mM
Bacterial transformation procedures;
L-broth 1 % w/v tryptone
0.5% w/v yeast extract 
1.0% w/v NaCI
L-agar L broth with 1.5% agar
Selection Ampicillin, 100|ig/ml
X-gal, 250pg / ml 
Kanamycin 40 units /ml
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3.1. Characterisation of human glioma continuous cell lines.
Background and specific methods.
Human glioma lines in regular experimental use include those established by 
Westermark and Ponten at the University of Uppsala, and those established by 
Bigner, at Duke University,USA [Collins, 1983 ; Bigner etal, 1981 ; Ponten, 1975 ]. 
The line U251, used in the work for this thesis, was initially described by Ponten.
Studies in which human glioma lines are reported since 1977, and for which a 
detailed account exists of characterisation of 4 or more individual lines, are 
summarised in table 3.1.
The rationale for the characterisation of existing continuous human glioma lines, 
was two-fold.
1) Review of the literature on the characteristics of the human glioma lines 
available suggested that few met the criteria of an "ideal" model of human 
glioma. In particular, many lines fail to be tumorgenic in nude mice, which may be 
considered the most unequivocal criteria of the malignant phenotype; similarly, 
many "permanent" human glial cultures fail to maintain markers of astrocytic cell 
lineage,eg. glial fibrillary acidic protein, and further evidence of glial lineage has 
often not been sought.
2) Three continuous human glioma cell lines had been established in this lab in 
the early 1980's as part of a study of the phenotypic differences between normal 
and malignant g lia . These were designated G-UVW, G-CCM, and G-IJK-T.
These lines had served as tumour models as part of the Medical Oncology 
research program on the mechanisms of human tumour chemoresistance
[ Merry et a/,1984]. At the time of commencing my study all three lines had 
reached high passage level (>100), and a re-assessment of their biological 
characteristics was considered important.
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Although continuous cell lines may serve as useful in vitro models of human 
tumours, the possibility of in vitro selection highlights the need for complementary 
studies in primary or low passage cultures. Primary and short term cultures of 
human glioma were established to facilitate the studies described in detail in 
Chapter 6.
3.1.1. Origins and establishment of human glioma lines
Continuous lines
Three human glioma cell lines had been established in this laboratory by previous 
workers; G-CCM; G-IJK-T; and G-UVW. The clinical origins of these lines, the 
primary glioma cultures established in this study, and continuous human glioma 
lines contributed to this study by other workers, are summarised in table 3.2
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Table 3.2. Origins of continuous and primary glioma cultures
Cell line Passage level Origin
G-CCM >100 GM
G-IJK-T >100 GM
G-UVW >100 GM
U251 >100 GM
SB18 35-40 GM
SB clone 1 M GM
SB clone 12 •i GM
G-MCN/X* 3-6 GM
G-ELL 10 GM
G-MCF 9 GM
BG 398* 1-7 AA
BG 424* 1-4 GM
BG 488* 1-6 AA
BG 500* 1-5 GM
BG 535* 1-5 GM
BG 550* 1 GM
BG 551* 1-3 GM
BG 555* 1-7 GM
BG 560* 1-3 GM
Source/ comments
Med.Oncology,Glasgow
Dr.Westermark, Uppsala 
Dr.Pilkington, London
INS; xenografted at P3 
INS
Maudsley Hospital 
Edinburgh
INS
GM= glioblastoma multiforme, grade IV glioma 
AA= anaplastic astrocytoma, grade III glioma 
* = low passage cell lines established in this study 
INS; Institute of Neurological Sciences, Glasgow
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U251, a continous human glioma cell line derived from a high grade human 
glioma, was kindly donated by Dr.B.Westermark, Uppsala.
IPSB 18 was derived from a high grade human glioma, and provided for 
collaborative studies at passage 35 by Dr.Jeff Pilkington, and Joanna Knott, Dept, 
of Neuropathology, Institute of Psychiatry, London.
The methods used to establish and maintain human glioma cell lines are 
described in Chapter 2, section 2.
3.2.1. Phenotypic characteristics
3.2.1.1. Morphology in monolayer
Human glioma lines exhibit considerable cellular heterogeneity in early passage, 
and distinct morphological forms can persist in established lines.
Several workers have assigned descriptive categories to the morphology of 
human glioma lines [Ponten, 1975 ]. Three broad groups can be distinguished:
1) Fasicular / fusiform / fibroblastic
2) Polygonal / epithelioid
3) Glial / multipolar
The cell lines used in this study grew as adherent monolayer cultures on tissue 
culture grade plastic. Assessment of morphology was made in mid-log phase 
growth, using both phase-contrast microscopy, or fixation , Giemsa staining, and 
bright field microscopy.
Typical morphology of each of the 5 continuous lines used most extensively in this 
study are shown in section 3.3., figures 3.1-3. The morphology of an early 
passage human glioma culture, BG 488, established froma grade 3 tumour, is 
shown in figure 3.4.
3.2.1.2. Population doubling times in monolayer culture.
An assessment of the rate of cell doubling in exponential phase growth, and 
terminal density was made for each of the five glioma cell lines. 104cells were 
seeded into 2 individual 24 multiwell plates, and allowed to adhere. Three wells 
were trypsinised per day and cell numbers counted using a Coulter counter
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calibrated for each cell line independently. Medium was gently removed and 1 ml 
fresh medium added each day to maintain exponential growth. Terminal density 
was judged to have been achieved when cell counts showed a plateau on 3 
consecutive readings.
Mean counts obtained in 3 experiments were plotted on semilogarithmic axes, 
and a curve fitted by eye. All lines except IJK-T exhibited a lag phase of 24-48 
hours, followed by exponential growth.Population doubling times were calculated 
from the slope of the exponential part of the growth curve.
Results are shown in figure 3.5
3.2.1.3. Loss of anchorage- dependent growth; multicellular spheroids, and 
soft agar cloning
Evidence of anchorage -independent growth was sought as a marker of the 
malignant phenotype. The capacity to form multi cellular aggregates and colony 
formation in soft agar was evaluated in the 5 glioma lines, and all successful 
primary cultures. 106 cells were harvested from exponential monolayer cultures, 
and seeded into T25cm2 flask base-coated with 1% agar, to prevent adherence.
All 5 lines formed multicellular spheroids within 24 hours and were then 
transferred into spinner flasks containing 100ml medium, and cultured for a further 
48 hours.
All 5 continuous glioma lines demonstrated colony formation in 0.3% agar. Eleven 
of seventeen primary glioma cultures showed colony formation in 0.3% agar. (See 
Chapter 6) The remaining 6 cultures exhibited multicellular spheroid formation 
only, without growth in soft agar.
See figure 3.4
3.2.1.4. Expression of the intermediate filament, glial fibrillary acidic protein 
(GFAP).
The significance of positivity for the astrocytic lineage marker, GFAP, was 
discussed in Chapter 1.
104 tumour cells were seeded in 10Opil of medium onto polylysine- coated sterile 
coverslips in 24 well plates, and allowed to adhere. The wells were fed with 1 ml of 
medium and incubated overnight. Cells were fixed with ice-cold methanol, and left
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for 15 minutes, at -20° C, prior to brief rehydration with Hanks staining medium. 
Rabbit anti-human GFAP (Dako) was added in 50ml Hanks medium (1:200 
dilution), and left for 45 minutes. Coverslips were then washed in Hanks medium, 
and a goat anti -rabbit GFAP polyclonal second antibody conjugated with 
fluorescein (Southern Biotechnology) added at 1:100 dilution. Coverslips were 
treated with Cityflor antifade, and mounted cell-down on microscope slides, and 
sealed with nail varnish to prevent movement, and drying. Cells were then 
examined for fluorescence using a Reikert Polyvar microscope, and an estimate of 
percentage total cells staining , as well as intensity. A negative control was 
included (human lung carcinoma line, A549)
3.2.1.5. Expression of the cytosol enzyme, glutamine synthetase(GS)
The production of GS was evaluated in the 5 continuous glioma lines, using 
immunocytochemical techniques. This work was carried out by Dr.G.Pilkington, 
using rabbit polyclonal antibody (Sigma) raised against ovine GS.
3.2.1.6 . Cell surface ganglioside and glycoprotein expression
There is increasing interest in elucidating whether cell surface properties of 
transformed human glioma cells might determine a more aggressive phenotype. 
Both surface gangliosides and membrane glycoproteins have been suggested as 
molecules which might participate in determination of cell motility, and both cell­
cell, or cell-extracellular matrix interactions [Knott etal, 1990] .An evaluation of the 
expression of gangliosides recognised by the monoclonal antibody, A2B5, and 
glycoproteins recognised by the anti-CD 44 monoclonal, 44D10, was undertaken 
on the 5 human glioma lines. This work was done in collaboration with 
Dr.G.Pilkington, Dept.of Neuropathology, Institute of Psychiatry.
Cells examined for A2B5 positivity were prepared as described for GFAP staining, 
but were stained unfixed with undiluted mouse monoclonal A2B5 antibody (gift of 
Dr.Pilkington).A biotinylated anti-mouse Ig (Amersham) was used as second 
layer, and staining visualised by the fluorochrome FITC.
3.2.1.7. Immunostaining of glioma cell membrane glycoproteins by CD44
(P80)
CD 44 (cluster of differentiation) is a polymorphic family of membrane 
glycoproteins associated with cell adhesion. The monoclonal antibody, 44D10 
recognises a 80 kDa glycoprotein antigen thought to be part of the CD 44 cluster
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in the membrane of astrocytes [Girgrah etal, 1991 ]. Hyaluronic acid is an 
extracellular matrix component involved in the control of motility in developing and 
neoplastic cells. The 44D10 antibody also recognises the hyaluronic acid receptor 
(HA) on cell membranes.
The 5 glioma cell lines were examined for Mab 44D10 positivity, using the 
protocol as described for A2B5 staining, using unfixed cells adherent to glass 
cover slips. Cells treated with Mab 44D10 were stained with 1:10 dilution of FITC- 
conjugated goat anti-mouse IgG for 30 mins at 0° C prior to fluorescence 
microscopy.
3.2.1.8 . Tumorgenicity in nude mice.
The tumorgenicity of the 5 continuous glioma lines was evaluated by innoculation 
of female nu/nu athymic mice at a flank site, using 106 tumour cells in 0.5ml 
sterile saline.
Animals were housed in negative pressure isolators, and fed Sprat's SDI diet with 
autoclaved water ad lib. They were sacrificed by cervical dislocation when tumours 
reached 2cm diameter.
Tumour tissue was removed for histology, immunohistochemistry, and electron 
microscopy.(performed by Prof.D.Graham, Institute of Neurosciences,Glasgow) 
See section 3.3.
3.2.2 Genetic characteristics
3.2.2.1. Lactic dehydrogenase isoenzyme expression.
Confirmation of the human origin of the glioma cell lines, and exclusion of 
interspecies contamination was performed by examination of lactate 
dehydrogenase (LDH) isoenzyme profiles. The species of origin can be 
determined for cell lines by a variety of tests, including isoenzymology and 
cytogenetics. The ability of isoenzyme analysis performed on homogenates of cell 
lines derived from over 25 separate species has been demonstrated [Hay,1986], 
and the technique can be reliably used to monitor for cross-contamination in 
laboratories routinely handling cell lines of differing species. The cell line G-MCN 
had been propagated via a xenograft, therefore it was considered particularly 
important to confirm the human nature of the culture.
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In man LDH production is controlled by 2 genes,each responsible for the synthesis 
of a unique peptide, which combines with itself to form a tetramer. Two tetrameric 
proteins are thus formed, ie LDH-1 and LDH-5, which migrate differently in an 
electrophoretic field. LDH-1 represents the most anodic form, and LDH-5 the most 
cathodic form. Isoenzymes of intermediate migratory position , designated LDH 2, 
3, and 4 , are hybrids formed by random association of LDH 1 and 5 subunits.
By contrast, well-documented isoenzyme profiles of LDH in other mammalian 
species, including mouse, rat and hamster, reveal quite distinct zymograms, 
differing from human forms in both number and migratory positon on gel 
electrophoresis.
LDH isoenzymes contained within whole cell extracts, prepared by rapid freeze/ 
thawing of tumour cell pellets, were separated by electrophoresis on agarose 
gels, and the areas of enzyme activity visualised by histochemical procedures, 
according to the following reactions:
1) L (+) Lactate + NAD----------------------  Pyruvate + NADH
2) NADH + PMS ---------------------  NAD + PMS-H
3) PMS-H + TNBT ---------------------  PMS + TNBT-formazan
Abbreviations:
NAD - nicotinamide adenine dinucleotide 
NADH - " " ", reduced
PMS - phenazine methosulphate 
TNBT - tetranitroblue tetrazolium
Staining reagents and protocol were obtained from Sigma chemicals.
Analysis of LDH isoenzyme pattern was performed on each of 5 continuous 
glioma lines (and G-MCN, p6) on two separate occasions. The results of the 
analysis were recorded, with respect to both the number, and electrophoretic 
position of the enzyme forms in the tumour lines under study, together with the 
human and mouse LDH standards.
3.2.2.2. Cytogenetics, ploidy, and cell cycle analysis.
The objectives of these studies were:
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1) To document the cell cycle characteristics and DNA content of each line by 
flow cytometric analysis.
2) To document the heterogeneity of karyotype within each cell line and identify 
any marker chromosomes.
Chromosome analysis
(Adapted from Freshney,1987)
Cell lines were grown to mid exponential phase in T175cc flasks, then exposed to 
colcemid (Sigma)at a final concentration of 10-7 M for periods of time varying from 
1-8 hours. Considerable modification of this general protocol was required for 
each glioma cell line, to compensate for large differences in cell cycle time, and to 
avoid excessive colcemid- induced chromosome condensation.
Cells were then harvested by routine trypsinisation into 2 separate universals, 
pelleted at 100g for 5 minutes, and the supernatant containing trypsin removed. 
Each pellet was resuspended in 5mls of a hypotonic solution at one of two 
different molarities (0.04M KCL, 0.025M sodium citrate or half this molarity) and 
incubated at 37° C to produce cell swelling. Time to produce adequate swelling 
without undue lysis required individualisation for each line examined, but varied 
between 15- 30 minutes.
An equal volume of freshly made, ice-cold fixative (1 part glacial acetic acid, 3 
parts methanol) was added slowly on a vortex mixer, then cells pelleted, and 
resuspended in 5mls fresh fixative, and left on ice for 20 minutes. The suspension 
was finally pelleted, and carefully resuspened on a vortex mixer with 0.5mls of 
fixative.
The suspension was dropped onto cleaned, cold microscopy slides. Slides were 
rapidly air-dried, and checked under the microscope for adequate dilution of the 
sample. Preparations were dried completely before staining with neat Giemsa, or 
G-banding.
G-banding was performed by incubation of fixed spreads in phosphate buffer 
(0.025M KH2P04, pH 6.8 ) at 60° C for 10 minutes, followed by addition of a 
freshly made staining solution.( 6.5mls phosphate buffer, 0.55mls 1% trypsin, 2.5 
mis 100% methanol, 0.22mls stock Giemsa solution).
After 15 minutes cells were rinsed in distilled water and airdried. Preparations 
were examined unmounted under bright-field microscopy using a Leitz
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microscope, and the number of chromosomes counted for a minimum of 50 
spreads per cell line.
Photographs of representative spreads were taken on high definition Kodak 
Panatomic X film rated at 12 ASA to obtain optimal definition.
Considerable individualisation of each of the major steps in this method were 
required to obtain evaluable spreads for the 6 glioma lines.
Evaluation of karyotype was enhanced by use of a dedicated Cytoscan image 
analysis system, in collaboration with the Department of Cytogenetics, Institute of 
Cancer Research, London.
Cell cycle analysis.
These analyses were performed with the kind assistance of Dr.Campbell, Dept, of 
Biochemistry, Glasgow University, using a Becton Dickenson FACS 440.
Nuclei were prepared for flow cytometry by a modified trypsin-NP 40 detergent 
method ; it has been demonstrated to yield uniform staining, with minimal 
clumping of human tumour cells, and relies on detergent lysis of cell membranes, 
together with digestion of cytoplasmic proteins by trypsin. Nuclei are stabilised 
during this detergent -trypsin stage by spermine. Using this procedure for human 
tumour cells it has been possible to produce "clean" nuclei, and reduce the 
coefficient of variation in fluorescence obtained, by eliminating clumping and 
nonspecific cytoplasmic staining.
An exponential culture of cells (T175cc flask) was harvested for each cell line by 
trypsinisation, pelleted, and resuspended in 200 microlitres of a citrate buffer 
(sucrose 250 mM, trisodium citrate 40mM, 5% DMSO, pH 7.6). At this stage cells 
could be stored at -70° C or further processed for cytometry.
Clean nuclei were prepared by the addition of 1800pl of Solution A ( trypsin 15mg 
/ 500mls, NP 40 0.1% v/v, spermine tetrachloride 1.5mM, Tris 0.5mM , trisodium 
citrate 3.4mM) for 10 minutes at room temperature. Trypsinisation was halted by 
the addition of 1500pl of Solution B (trypsin inhibitor 250mg/500mls, Sigma, 
ribonuclease A 50mg/500mls) for 10 minutes.
Nuclei were finally stained by ice-cold Solution C ( propidium iodide 
208mgs/500mls, spermine tetrachloride 1.5mM, pH 7.6 ) for 15 minutes on ice, 
covered with foil.
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Cytometry was performed on the Becton Dickenson FACS using controlled 
aliquots of the suspension of stained nuclei in sheath fluid.
Both chick red blood cells and human lymphocytes were used as internal 
standards for determination of GO / G1 cell DNA content.
Cell cycle analysis was performed using Becton Dickinson software, employing 
both sum of broadened rectangles and polynomial models. Each analysis was the 
result of 10,000 "nuclear" counts on each sample.
3.3. Results.
3.3.1. Morphology of glioma cell lines.
Typical phase contrast micrographs of each of the 5 human glioma cell lines 
growing in monolayer, are shown in figures 3.1-3
The morphological features of each of the 5 continuous glioma lines was 
compared with published reviews, and the descriptive class is summarised in table
3.3.
For comparison, a plate illustrating the morphology of one of the early passage 
glioma cultures established in this study, BG 488, is shown in figure 3.4. This 
culture has morphological features in keeping with the description of "glial / 
multipolar" cultures described by Ponten [Ponten, 1975].
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Figure 3.1. Morphology of human glioma cell lines, a) SB18, and b) U251
Phase contrast micrographs, x150 magnification
A
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Figure 3.2 Morphology of human glioma cell lines, a)UVW, and b) CCM
phase contrast micrographs, x150 magnification
Figure 3.3 Morphology of human glioma cell line, UK, and UK multicellular
spheroid
200mm diameter spheroid
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Figure 3.4. Morphology of human glioma culture, BG 488, at passage 1
Phase contrast micrograph, x150 magnification
3.3.2 Population doubling times of continuous glioma lines in monolayer.
Growth curves obtained for the 5 continuous cell lines are shown in figure 3.5 All 
lines except UK exhibited a lag phase of growth of 24-48 hours before achieving 
exponential growth. Population doubling times, calculated from the exponential 
slope of the curve are contained in table 3.2. All 5 lines achieved saturation cell 
densities at significantly higher cell numbers than non-transformed glia, that is, 
approximately 7x104 per cm2-
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Figure 3.5 Monolayer growth curves of 5 glioma cell lines
UK
U 251
SB 18
IVW
CCM
201 00
Days in monolayer culture
Data points for each cell line represent mean and standard error.
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3.3.3. Expression of biochemical and immunological markers.
Results obtained by immunostaining for the intermediate filament GFAP, 
glutamine synthetase, CD 44, and A2B5 are shown in table 3.3
Colour micrographs of fluoroescence images obtained are shown in figures 3. 6-8. 
FITC conjugated antibody staining fluoresces green within cytoplasm (GFAP), or 
at the cell membrane (CD 44). Nuclei have been counterstained with propidium 
iodide, which is seen to fluoresce as a yellow/red stain.
Figs.3.6-8 follow on the next 3 pages
3.6. Fluorescence micrograph of cell line UVW. Cell surface fluorescence of 
FITC-conjugated Mab anti CD 44 antigens.
3.7. Fluorescence micrograph of cell line CCM. Cytoplasmic fluorescence of 
FITC-conjugated Mab anti- GFAP, the intermediate filament protein. 
Nuclei counterstained with propidium iodide
3.8. Fluorescence micrograph of cell line SB18, GFAP staining
108
109
110
111
Table 3.3. Phenotypic and genetic characteristics of human glioma cell lines.
Cell line UVW CCM U251 UK SB 18
Passage level >100 >100 >100 >100 35
Morphology fusiform fusiform epithelioid fusiform fusiform
Cloning efficiency 20 10 30 28 29
Doubling time (hrs) 48 70 26 16 45
Terminal cell density 3.5x105 3.6x105 8.87x105 9.9x105 4.23x105
(cells/cm2)
Growth:
monolayer +++ +++ +++ ++ + +++
spheroid +++ +++ +++ +++ +++
xenograft " +++
GFAP (% cells +ve) 1-5 20-90 90+ 100
GS (% cells +ve) - 100 100 100 100
A2B5 (% cells +ve) 0.1 1 5 - 70
CD 44 (% cells +ve) 100 100 100 " 100
DNA index 1.3 1.36 0.9 1.0
S phase fraction1 - - 37 25 16
(% nuclei per cell cycle)
GO / G1 " - - 59 66 67
G2/ M - - 4 9 18
1 cell cycle analysis on mid log phase, exponentially growing culture.
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3.3.4 Tumorgenicity in nude mice.
G-IJK, and G-MCN (passage 6) proved highly tumorgenic, with 100% take rate in 
6 mice per line.Three primary cultures which exhibited vigorous monolayer 
growth, requiring passage within a week of initiation, were also examined for 
tumorgenicity. ( BG 424; BG 550; BG 566) All three failed to be tumorgenic.
The xenografts were excised following sacrifice of the animals and 
immunohistochemistry, and electron microscopy kindly performed by 
Prof.DI.Graham, Dept.of Neuropathology, Institute of Neurological 
Sciences,Glasgow.
Both xenografts exhibited highly cellular growth, with anaplastic small cell/ 
storiform morphology. Both tumours had approximately 3-5 mitoses per high 
power field( x400). G-IJK showed both muscle and skin invasion, on haematoxylin 
and eosin staining.
Tumours were evaluated by routine immunohistochemical techniques for a panel 
of markers of astrocytic or neural crest origin including: GFAP, and S100 protein. 
Production of other intermediate filament proteins, vimentin, and fibronectin were 
examined. Epithelial specific markers included epithelial membrane antigen 
(EMA),and cytokeratin.
UK xenograft MCN xenograft
GFAP
cytokeratin
EMA
vimentin - +/-
fibronectin
s100 - +
Nuclear and cytoplasmic appearances on electron microscopy were assessed in 
collaboration with Dr.J.Pilkington,Institute of Psychiatry. Figure 3.9 contains 2 
electron micrographs showing a) mouse muscle infiltration by UK tumour cells; b) 
the highly cellular G-MCN xenograft. Both tumours types gave rise to cells with a 
large nuclear/ cytoplasmic ratio, and very prominent nucleoli, and marginated 
heterochromatin. Phagocytic activity is seen in some cells, a feature of both 
reactive and malignant glia. Evidence of 10nm intermediate filaments could be 
detected in the cytoplasm in both tumours, and probably represents vimentin,
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rather than GFAP, in keeping with the immunohistochemistry results. 
Desmosomal intercellular junctions , features of epithelial cells, were not seen.
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3.9. Electron micrograph of UK and G-MCN xenografts.
a) UK: showing invasion of mouse flank musculature. Mag.x 3000
b) MCN: densely cellular tumour, high nuclear/cytoplasmic ratio, with marginated 
heterochromatin. Mag.x3000
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3.3.5. LDH isoenzyme analysis
On the basis of the LDH isoenzyme profiles all 6 glioma lines would be considered 
to be of human origin, and to have zymograms differing considerably from all 
published for other routine laboratory mammals, including mouse, rat and 
hamster.
Glioma cell lines UVW, CCM, IJK-T, and SB18 had LDH isoenzyme profiles 
compatible with human origin, showing prominent LDH 1, 2 and 3. (the most 
anodic forms). LDH 4 was present at a lower intensity, and LDH 5 not discernible 
by eye.
U251 showed reversal of the above pattern, with greatest activity in LDH 4 and 5. 
The early passage line propagated via xenograft, G-MCN, revealed activity in this 
sytem at LDH 1 alone.
The mouse standard gave rise to a prominent band intermediate in mobility 
between human LDH 2 and 3, and dissimilar to the enzyme profiles of the 6 
glioma cell lines, or the human LDH standard.
The LDH enzyme profile of G-MCN is interesting, with apparently no activity in 
LDH 5, or intemediate forms requiring the LDH 5 subunits. This result would be 
compatible with significant mutation at the site of the second human gene 
encoding LDH 5, leading to the production of an inactive form of the enzyme 
incapable of the biochemical reduction of formazan required by this assay. An 
alternative explanation might be complete deletion of this gene as part of the 
transformation of this cell line.
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Figure 3.10 Gel electrophoresis, and staining for LDH isoenzymes in 6 
human glioma lines
LDH1—
- cathode 
+ anode
lane 1= Sigma human standard, 2ml
lane 2= UVW extract, 2ml
lane 3= CCM extract,2ml
lane 4= UK extract, 2ml
lane 5= SB 18 extract, 2ml
lane 6= U251 extract, 2ml
lane 7=MCN extract, 2ml
lane 8= Balb C mouse serum, 2ml
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3.3.6.Cell cycle analysis by flow cytometry
See figure 3.11
Representative cytofluorograms are displayed for each cell line, with the normal 
human diploid lymphocyte distribution for comparison. Chick red blood cell internal 
standard diploid peaks appear at "27" on the horizontal scale of fluorescence. 
Normal human diploid DNA content gives a single peak at '66' on the horizontal 
scale.
DNA index is expressed as the ratio of G0/G1 peak channel number for each cell 
line, relative to that of the normal diploid human lymphocytes.
Table 3.3 contains the data obtained on 5 cell lines, for DNA index relative to 
normal human lymphocytes, and cell cycle analysis.Cell cycle analysis failed for 
samples from UVW, and CCM, using both polynomial and sum of broadened 
squares models due to the large coefficient of variation on peaks of fluorescence.
G-IJK shows a well-defined, hypodiploid peak at channel position "60", with a 
significant population of s phase cells. SB 18 shows a normal diploid DNA content, 
with a large G2/ M peak.
U 251 was highly aneuploid , with a broad GO / G1 peak at channel "90".
Both G-CCM and G-UVW showed heterogeneity of ploidy, with evidence in both 
cell lines of two distinct cell populations. G-UVW contained a small hypodiploid 
peak at '42'. A broad second peak at '84', suggested the presence of a second 
cell population with a near-triploid DNA content. Similarly G-CCM shows a near- 
triploid cell population with peaks at 85 /176, and a second, near tetraploid 
population with peaks at 150/300 on this scale.
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Figure 3.11 Flow cytometry profiles of 5 glioma cell lines
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3.3.7. Cytogenetics.
Results are depicted as a representative karyotype of 4 of the continuous cell 
lines.
All lines demonstrated heterogeneity of populations within an individual cell line. 
A range of chromosome numbers was observed within a given cell line.
The modal chromosome number in UVW was 45, with evidence of a smaller 
second population of cells with a triploid chromosomal complement.Consistent 
chromosomal abnormalities noted were monosomy of chromosomes 4, and 10.
CCM had a modal chromosome number of 66, with monosomies for 
chromosomes 10,11, and 18. Trisomy was frequently noted in chromosomes 
1,3,4,5,6,7,8,9,19,20,and X.
SB 18 had a modal chromosome number of 49. Monosomy for chromosome 10 
was a typical abnormality, with loss of the Y sex chromosome, in a line derived 
from a male patient.
U251 had a modal chromosome number of 81, with cells showing frequent 
trisomies, and tetrasomal chromosome complements.
In all these 4 lines chromosome morphology was human.
Formal karyotyping of these lines was not available until the work for this thesis 
was being completed. At this time evidence of a phenotypic change was evident 
in late frozen stocks of UK, with reduced cell size, and rapid population doubling 
times. Rodent contamination of the cell line UK was found , on the basis of a 
population of cells having typical rodent chromosomal morphology. This had not 
been evident on the basis of LDH isoenzyme analysis undertaken at the start of 
these studies.
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Figure 3.12 Karyotypes of cell lines UVW, CCM.
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Figure 3.13 Karyotypes of cell lines U251, SB 18.
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3.4. Discussion
The continuous human glioma cell lines used in these studies display a 
heterogeneous range of phenotypic and genetic features , but fulfill criteria 
required to be considered valid models of the malignant glial phenotype. Their 
properties are discussed in reference to other human glioma cell lines, and in 
knowledge of the heterogeneity observed in biopsies of human glioma.
The purpose of characterising human glioma lines at relatively high passage level 
can be justified on a number of grounds. Human cell lines are recognised to 
undergo genetic drift in sequential passage, often leading to changes in the 
phenotypic features of a specific cell lineage. Those human tumour lines 
preserving near-diploid status, and persistent markers of a particular pathway of 
differentiation are of considerable value in research. The 3 continuous lines G-IJK 
; G-CCM;G-UVW had been established in this lab prior to commencing this study, 
but no details of their characterisation at high passage had been published.
The aim of undertaking both genetic and phenotypic studies in the 5 human 
glioma lines used throughout this thesis was therefore to permit a critical 
assessment of the value of this particular panel of lines as models of human 
glioma. Secondly, as an extension of the notion that in vitro conditions permit 
evolution of cell lines, it was considered necessary to examine intrinsic cellular 
radiosensitivity in both continuous and low passage glioma cultures, thus requiring 
the establishment of primary glioma cultures.
The ideal human glioma cell line would be near-diploid, but with unequivocal 
evidence of malignancy, for example, tumorgenicity in nude mice. It would show 
persistent expression of recognised markers of astrocytic lineage, the most 
accepted of which remains expression of the intermediate filament protein , glial 
fibrillary acidic protein. A summary of phenotypic and genetic characteristics often 
sought in the characterisation of human glioma cell lines is presented in figure 
3.14
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In practice, many human tumour lines at the time of establishment, by definition, 
passage 70 or above, fail to fulfill idealised criteria. Review of the literature 
available on human glioma lines suggested that few cultures had been well- 
documented at high passage levels, whilst remaining in use as models of human 
glioma [Rutka etal, 1987; Studer etal, 1985 ].
.Although lineage markers are important in the assessment of the nature of cells 
maintained in vitro, variations in their expression, both qualitatively and 
quantitatively are observed. Indeed, these observations are themselves subject to 
variation depending on method employed. For example, detection of the presence 
of GFAP is variable; decreasingly low levels can be found by staining with 
monoclonals to GFAP using immunofluorescent techniques; immunblots to the 
protein; or detection of mRNA transcripts from the GFAP gene [Bongcam- Rudloff 
et a/,1991].
Equally, patterns of such markers are progressively altered with serial passage. 
Whether this represents culture selection of more" aggressive’”, less 
"differentiated" clones, lacking GFAP expression as part of their successful 
malignant phenotype, or merely reflects the inadequacy of current tissue culture 
techniques to maintain clonal diversity representative of the initial culture, is 
debatable. Indeed, there is very little data obtained from sequential biopsy of 
human glioma to state that such clonal changes observed in vitro may not be part 
of a biological progression in vivo.The pattern of expression of lineage/ 
differentiation markers such as GFAP, or surface gangliosides, is likely to be 
heavily influenced by culture conditions, making comparisons of results between 
labs difficult [ Westphal etal, 1990].
Groups who regularly employ explant or mechanical disaggregation without 
enzymes, claim a higher percentage of cultures maintaining GFAP 
expression.(personal communication:Dr.J.Pilkington) The biological relevance of 
persistence of GFAP expression in early passage cell lines is not clear; many 
workers report loss of GFAP positivity within the first 3-5 passages of malignant 
glial culture [Kennedy etal, 1987 ].
All 5 cell lines used in these studies have been demonstrated to express one or 
both of the accepted markers of astrocytic lineage within the CNS, namely GFAP 
or glutamine synthetase. In the cases of CCM, U251, and SB 18 both markers 
were expressed in most cells of each line. UK produced glutamine synthetase, but
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failed to express GFAP at high passage level, having expressed GFAP at low 
passage level [Frame et a/,1984].
Whilst only UK proved frankly tumorgenic in nude mice, the 4 other lines 
displayed unequivocal evidence of the transformed, malignant phenotype: U251, 
CCM, and UVW were highly aneuploid, containing populations of cells with near- 
triploid complement of chromosomes; all lines displayed anchorage-independent 
growth, both in soft agar, and as multicellular spheroids; high saturation density 
was reached in monolayer culture, with failure of contact inhibition of growth.
Of the 5 human glioma lines used in these studies, SB 18 would be regarded as 
approximating to the most satisfactory in vitro model of human glioma. The line 
remains near-diploid, and expresses markers of the differentiated astrocytic 
phenotype, GFAP and glutamine synthetase in a high percentage of cells. While it 
grows readily in monolayer and as multicellular spheroids, it is not tumorgenic. 
Although the cell line was established by Dr.Pilkington, the evaluation of its cloning 
efficiency, karyotype, cell cycle analysis, tumorgenicity, and radiosensitivity have 
not been been previously undertaken.
All 5 cell lines exhibited satisfactory colony formation in monolayer, giving plating 
efficiencies ranging from 10-30%. This was achieved using 10% fetal calf serum, 
without specific growth factors. Plating efficiency was maintained most 
consistently by the use of a low density feeder layer of homologous, heavily 
irradiated cells. This system provided the basis for the use of colony formation as 
an endpoint for the measurement of cellular radiosensitivity in these 5 glioma 
lines.
It was also observed that these 5 glioma cell lines grew readily as multicellular 
spheroids. These provide models of human glioma in a multlicellular, non- 
vascularised enviroment, and might well prove useful given the generally low level 
of tumorgenicity in glioma cell lines. Such models could be used for both 
fundamental or applied studies.
How relevant are current "in vitro" models of human glioma to clinical 
disease?
The relative ease with which human glioma cultures are established (30-40% of 
short term lines go on to form permanent lines [ Maunoury,1977]) is partly 
explained by the relative lack of stromal fibroblastic overgrowth which complicates 
the establishment of epithelial tumour lines. However, it is important to address
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the issue of the relevance of both short-term and established glioma cell lines to 
clinical disease.
Human malignant glioma exhibits considerable heterogeneity of clinical outcome. 
The histopathological assessment of biopsy material assigns a "grade" of 
malignancy on a three or four point scale, which is partly predictive of this clinical 
diversity of outcome. However, intratumour heterogeneity can complicate grading.
Similar morphological variation is observed in successful short-term glioma 
cultures and continuous cell lines. This observation of biological heterogeneity 
extends to many phenotypic and genetic parameters. A major goal of neuro­
oncology is the refinement of prognostic assessment for patients with malignant 
glioma, based on both clinical and biological parameters. There is therefore 
considerable value in the careful documentation of in vitro characteristics of 
human glioma cell lines at a variety of passage levels.
Given the acknowledged selection of cells in long term culture, there are, 
however, still considerable attractions to the use of well-defined continuous cell 
lines. The more wide-spread use of short-term human glioma cultures has 
revealed some difficulties in characterising the exact nature of cells grown. There 
is evidence that bona fide tumour cells lose expression of GFAP in culture, whilst 
predominantly GFAP positive low passage cultures may fail to show unequivocal 
evidence of malignancy, for example, tumorgenicity in nude mice, or aneuploidy.
Doubts over lineage and malignancy could be resolved in the future by routine 
use of modern molecular techniques. For example , probing for GFAP specific 
mRNA has been demonstrated to be a very sensitive technique for the non- 
immunological detection of GFAP expression in glia [Bongcam-Rudloff etal, 
1990]. Similarly, probing for the presence of either activated oncogenes, or loss of 
heterozygosity at known tumour suppressor loci might provide evidence of a 
successful culture of malignant cells, where no change in ploidy can be detected 
[Bigner etal, 1989 ].
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4.1. Measuring human cellular radiosensitivity
4.1.1. Models of radiation action and mathematical parameters of 
radiosensitivity.
A major objective of this study was a comparison of the cellular radiosensitivity of 
various human cell lines. It was therefore necessary to review the methods of 
describing radiosensitivity in mathematical terms. Whilst it is possible to compare 
clonogenic cell survival at a given dose of radiation eg 2Gy, the routine 
measurement of radiation action over several logs of kill has led to the 
development of formal models of radiation action. Different models can be fitted to 
survival data to generate mathematical parameters of radiosensitivity [Alper,
1979].
A detailed review of the various models of radiation action is not appropriate to 
the work contained in this thesis. Broadly, the purpose of such biophysical models 
could be regarded as primarily phenomenological or mechanistic. The former 
approach has sought a mathematical description which 'fits' the data set well, with 
no specific need to be related to actual physical mechanisms or subcellular 
biological processes. The success of the model is judged predominantly by the 
accuracy of fit to data sets. Mechanistic models of radiation action have sought to 
establish a greater understanding of the biophysics involved, but have been 
criticised for their inability to to distinguish alternative mechanistic assumptions 
[Goodhead, 1985 ].
Although there is no widespread agreement on which model of radiation action is 
most valid, it is acknowledged that models with a minimum of 2 components are 
necessary to obtain adequate fits to experimental data on radiation cell survival 
[Steel, 1989 ]. Cell survival curves from human tumours invariably have a finite 
initial slope, and can usually be fitted well by the 2 models used in this study, 
namely the multitarget (with initial slope) and linear -quadratic models [Stephens 
etal, 1987; Malaise etal, 1987 LThese models have been used extensively to 
describe human tumour radiosensitivity. It therefore enabled a comparison of 
parameters obtained in this study with the published literature on human tumour 
radiosensitivity.
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4.1.2. Multitarget models of radiation action.
Sparsely ionising radiation, such as the megavoltage X or gamma rays used in 
radiotherapy, generate survival curves of characteristic shape in mammalian cells 
in vitro. At low doses there is an initial shoulder, followed by a response which 
becomes almost straight on a semilogarithmic plot. This observation indicates that 
the effectiveness of cell killing is not uniform per unit dose, and that simple 
Poisson statistics based on the assumption of random radiation deposition cannot 
determine the overall shape of the survival curve.
The multitarget parameter, Do, represents mathematically the dose of radiation 
which delivers on average, 1 lethal event per cell, but by virtue of the random 
nature of radiation deposition, described by Poisson statistics, reduces the cell 
population to 37% of the original number.
The dose-response characteristics of the ‘simple’ multitarget model require that 2 
parameters must be specified:
a) the slope of the final near-exponential portion, expressed as the Do reciprocal 
slope
b) a measure of the extent of the initial shoulder region, expressed as the 
extrapolation number n, determined by extrapolating the final slope back to the 
surviving fraction axis. An alternative measure of the initial shoulder region, where 
cell killing appears to be less effective per unit dose, is the quasithreshold dose, 
Dq. This quantity is the dose at which the straight portion of the survival curve 
extrapolated backwards cuts the dose axis drawn through a surviving fraction of 
unity.
The 3 parameters Do, Dq, and n are related by the expression:
loge n = Dq / D0
The mechanistic interpretation of the multitarget model postulates that the cell 
contains n sensitive targets. All of these must be inactivated or "hit" to produce cell 
sterilisation. Therefore the probability of hitting one target is given by:
Pi = (1- e"d/Do) 
where d= dose for multitarget expression.
Therefore the probability of a cell surviving a given dose of radiation is:
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S (d) = 1 - (1 - e - dl 0 0 ) n
At high doses the survival curve predicted from this model approximates to a pure 
exponential, appearing as a straight line on a log-linear plot, with a slope of 
-1 / DO.
In practice, much mammalian cell survival data does not appear to have a zero 
initial slope at zero dose, leading to the modification of the basic multitarget 
equation to include a single event component at low doses
S (d) = e -d/Ds [ 1 - (1 - e - d/ Do ) ] n
where d is given dose, Do is the final slope, Ds is the initial slope, and n the 
extrapolation number.
This model has been fitted to the cell survival data obtained in human tumour 
cells examined in this study, to obtain the parameters Do, n, and Ds for each of 
the cell lines.
The "goodness of fit" of the model is discussed in the context of the results 
obtained.
4.1.3 The linear-quadratic model.
In recent years cellular radiosensitivity has been most commonly described by the 
parameters of the linear-quadratic model of radiation action. It was developed on 
the basis of a proposed relationship between dose-related induction of double 
strand breaks within DNA , popularised by the work of Keller and Rossi, the "dual 
radiation action theory". [1973 ] ,  and the molecular theory of Chadwick and 
Leenhouts.[1973 ]
The model is specified by the equation:
S (d) = e - (« d + pd 2 )
where S (d) is the fraction of cells surviving after a dose d , and a and (3 are 
constants.
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The linear term was considered to estimate the direct induction of lethal DNA 
double strand breaks, whilst the quadratic term was felt to represent the statistical 
probabilty that two adjacent single strand breaks, each arising by chance, could 
interact biologically to produce a lethal DNA lesion.
Although a mechanistic basis has been postulated for this model, its wide 
acceptance as a means of describing cellular radiosensitivity can be more readily 
attributed to the fact that as a simple, continuously bending survival equation it 
simulates much of the observed experimental data in mammalian systems[Steel 
and Peacock, 1989 ].
The linear-quadratic model has been fitted to experimental clonogenic survival 
data in this study, to obtain the parameters a and p for each cell line examined. 
The statistical methods used to fit the survival curves are described in the 
methods section of this chapter.
4.1.4. Use of the surviving fraction at 2 Gy as a measure of cellular 
radiosensitivity.
In recent years there has been a trend towards the use of a model-free parameter 
of radiosensitivity, the surviving fraction of clonogenic cells after a single dose of 
2Gy. (SF2) There are several reasons for this development.
1) Doubts have been expressed concerning the need to describe radiosensitivity 
over a large dose range. Acute radiation survival curves are generated by 
measuring the response to varying single doses of radiation, usually between 1 
and 12Gy.The models require replicate data points at each of a minimum of 4 
different doses to permit acceptable statistical fits. In the case of the multitarget 
model, the most frequently cited parameter of response, the Do, is determined by 
the response beyond the initial shoulder region, and describes in the case of most 
tumours, the response to doses of radiation far in excess of those employed in 
clinical practice.
2) The work of Fertil and Malaise, followed by Deacon and Steel, drew attention 
to the variation between tumour types in clonogenic cell survival at doses of 
clinical relevance ie 2Gy. This is a single dose of radiation often given daily over 
a fractionated course of treatment. The large literature reviews of human tumour 
radiosensitivity carried out by these groups suggested that the variance in SF2
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estimation between human tumours of differing histology might be sufficient to 
explain the observed range of clinical radiocurability.
3) The original studies by Fertil and Deacon cited SF2 values obtained from 
published cell survival curves ie were obtained by model fitting then interpolation. 
The measurement of actual SF2Gy, as opposed to "fitted" SF2 values, is 
potentially more applicable to a primary cell culture. It requires fewer cell numbers, 
as response is assessed at only one dose. This is an obvious advantage in 
dealing with primary biopsy material in which clonogenicity is usually low.
4.1.5.Experimental objectives
The objectives of the experiments described in this chapter were:
1) To measure the response of 5 human glioma continuous lines to acute doses of 
megavoltage irradiation.
2) To describe the cellular radiosensitivity of the these lines in terms of the 2 major 
models of radiation action, and the model-free parameter, the surviving fraction of 
cells after a single dose of 2Gy.(SF2)
3) To compare the distribution of cellular radiosensitivity observed in the glioma 
lines with a panel of 8 other human tumour lines, derived from tumours of greater 
clinical radiocurability, including carcinoma and embryonal cell lines.
4) To conduct a detailed statistical comparison of the differences in intrinsic 
radiosensitivity measured in these 13 lines, using the model-free estimate of 
radiosensitivity, the SF2Gy. The purpose of this analysis was to examine the 
hypothesis that human glioma cell lines differed significantly in their 
radiosensitivity from cell lines derived from the more clinically radiocurable 
carcinomas.
5) To derive estimates of the radiation doses required to control human glioma, 
based on in vitro measurements of cellular radiosensitivity, by using Poisson 
statistics.
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4.2. Materials and methods.
4.2.1 .General tissue culture techniques, and maintenance of cell lines.
A summary of the lines used in this study and their culture requirements is detailed 
in table 2.1. Similarly, the protocol observed for clonogenic cell survival assays, 
and irradiation of cells is described in detail in section 2.3.
4.2.2.Determination of feeder cell requirements and linearity of plating 
efficiency
Pilot experiments were performed on each continuous cell line to establish the 
range of linearity of plating efficiency, ascertain feeder layer requirements, and 
determine the optimal incubation period to obtain colonies of greater than 50 cells. 
In subsequent experiments cell numbers were chosen to produce approximately 
150 colonies per experimental data point.
4.2.3.Effect of experimental protocol: timing of subculture in relation to 
irradiation.
An alternative experimental protocol was evaluated, in which test cells were 
irradiated as exponentially growing monolayers, then subcultured at cloning 
densities immediately following irradiation. In all lines examined, this procedure 
resulted in a small, statisically insignificant fall in plating efficiency, but similar 
survival curves to those obtained by irradiation as preplated cultures.
4.2.4.Acute radiosensitivity data analysis.
Survival curves were fitted to the data plotted on semilogarithmic axes, using both 
multitarget (MT) and linear-quadratic (LQ) models of radiation action. A minimum 
of 5 different dose points were studied, to examine dose-response over at least 
2 logs of cell kill. Within each experiment between 3 and 6 replicate flasks were 
treated per data point.
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Both LQ , and MT models were fitted to the data by non-linear regression, using 
the error-minimising programme of Koschel, kindly provided by Prof.Gordon Steel 
[ Millar, 1978] The surviving fractions, weighted by the inverse of their variances, 
were fitted by the least-squares method to the linear-quadratic equation
S = exp - ( ad+ p d2 )
where S is the surviving fraction, d is the dose of radiation, and a and p are the 
constants describing the linear and quadratic components of the response.
The simple multitarget model was fitted according to the equation:
S = 1- (1-e -d/Do) n
where d is given dose of radiation, S is surviving fraction measured, and Do the 
! slope of the exponential part of the response, and n the extrapolation number,
representing the derived parameters of radiosensitivity.
I
I
The multitarget model with inital slope was fitted by the equation:
i
S (d) = e -d/Ds [ 1 - (1 - e - &  0 0 ) ] n 
where Ds is the initial slope.
Ii
! Data was pooled for a minimum of 4 separate experiments on each cell line, to
determine parameters of radiosensitivity according to the mulitarget and LQ 
models.
4.2.5 Statistical analysis of SF2 data.
The variance of any single SF2 estimation on a cell line is made up of two 
components: a degree of variance is attributable to the experiment ( a  2 exp ), 
and a further component contributed by replicates within the same experiment 
( cf 2 rep )• The variance of the mean of replicates within experiments is given 
by:
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g  2  exp + 2 rep/ r where r is the number of
replicates
The mean SF2 calculated f rom the means of repeat experiments on the same 
cell line is used as an estimate of the "true" SF2 value for that line. The variance of 
this estimate for a theoretical study containing 3 independent experiments, each 
containing 3 replicates, is specified by:
Estimates of all the above variances have been obtained by analysis of variance, 
using a nested design to specify these contributions to variance independently.
Data transformation.
Analysis of variance assumes that the variance of all the observations on different 
cell lines was similar. This was not valid for the SF2 observations on the 13 cell 
lines studied. They were therefore transformed by a log odds procedure to 
generate new observations, termed Z as follows:
The transformed observations were noted to have a normal distribution , required 
for analysis of variance. The analysis of variance was carried out on Z values of 
SF2 for each of the 13 cell lines, to assess the effect of both intra and 
interexperimental variation on estimates of SF2.
g  2  exp /  3 + g  2  rep/9
The standard error of this estimate is given by:
Z = log ( SE2 )
1-SF2
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Multiple pairwise comparisons of mean SF2 values between cell lines.
The SF2 data on each of the 13 tumour lines was further assessed by use of the 
Tukey HSD test for post hoc pairwise comparisons of means. There are 78 
pairwise comparisons of mean estimations of SF2, contained in the data set on 
the 13 cell lines. A comparison was made, specifiying an overall minimum 
significance level of 5%.
4.2.6 Tumour radiocurability calculations based on intrinsic cellular 
radiosensitivity, repopulation kinetics, and clonogen number.
Tumour radiocurability calculations were based on a simple Poisson cure model. 
This incorporates the assumption that tumour cure requires that zero clonogens 
should survive treatment. If Sk is the average surviving fraction following k 
radiotherapy treatments, and N 0 is the average number of clonogens initially 
I present, then N , the average final number of clonogens will bei
i
N = Sk No (1)
If N is the average number of surviving clonogens per tumour, Poisson theory 
gives the probability that any particular tumour contains exactly zero clonogens at 
the end of treatment, ie is cured. The theory states that this probability is the first 
term of a Poisson series with a mean N* The cure probability Pc is given by
Pc = e - N (2)
= e - Sk No (3)
The net surviving fraction Sk after k treatments depends on the balance of log cell 
kill achieved by each treatment, and the repopulation by surviving clonogens 
between treatments. If 2Gy treatment fractions are used throughout, and if S2 is 
the surviving fraction after one treatment of 2Gy , and To the tumour doubling time 
(assumed to be constant throughout treatment) then we have
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Q.693T
TD
Sk = (S2) k e (4)
where T is the total treatment time for the administration of k fractions.
This gives
Equation (5) may be used to calculate the cure probability ( Pc) as a function of 
total dose, for a given assumption regarding the intrinsic radiosensitivity (S2), and 
tumour doubling time (Td). The results presented in section 4.3 have been 
calculated assuming conventional fractionation, ie daily single treatments of 2Gy, 
five times per week.
The total dose required to give a tumour cure probability of 50% is known as the 
TCD-50 value. This parameter can be calculated from equation (5):
0.693T
TD
- ( S 2 ) k . e .No
Pc e (5)
0.693
-In Pc
TD
(S2)k e .No (6)
0.693 (1.4)k 
TD
(S2)k e .No
In (-In Pc) = k In (S2) + 0.693 n  .41. k + In (No) (8)
TD
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or K = f in (- In Pc) - In (No 1 ) 
TD
(9)
For 2 Gy fractions, the total dose D which corresponds to this is
D = 2 ( In (- in Pc) - In (No 1 ) (10)
In (S2) + (Q.693 ) (1.4 )
TD
The dose required to achieve any level of cure probability may be calculated from 
this equation.
In the case of the dose required to give a 50% chance of tumour control (the TCD- 
50)
TCD-50 = ,.:Q,367 -In (No) (11)
In (S2) + JLSZ 
TD
The TCD-50 values presented in section 4.3. based on the human glioma cell 
line intrinsic radiosensitivity were calculated from equation (11)
Equation (10) may also be rearranged to give In No, the initial clonogenic cell 
number which, if treated with a particular regimen, would result in cure 
probability Pc.
For a 50% cure probability In No is given
In No = -0.367 -0.5 D { In (S2) + JQLSZ } (12)
TD
This is the curable cell number at the 50% cure level, for a regimen consisting of 
total dose D, given as 2Gy fractions. For a conventional curative clinical 
treatment regimen (30 x 2Gy fractions, or 60 Gy total dose), this becomes
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In (CCN) = -0.367 -30 { In (S2) + I  } (13)
TD
Equation (13) was used to calculate the curable clonogenic cell number, CCN, 
for the human glioma cell lines, as a function of tumour doubling time. The CCN 
values are presented in tabular form, as logarithms to the base 10.
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4.3. Results
4.3.1. Acute radiosensitivity of the 13 human tumour cell lines.
The acute radiosensitivity of the 13 human tumour cell lines studied are depicted 
in both graphical and tabular form in figures 4.1-9, and tables 4.1-3 respectively.
The acute response to megavoltage irradiation of each of the 5 glioma lines is 
depicted as the semilogarithmic plot of the data obtained on each cell line using 
the surviving fraction of colony forming cells as a function of radiation dose as the 
experimental endpoint.
For each of the five human glioma cell lines studied, survival curves have been 
fitted to the data using the multitarget (both simple, and initial slope) and linear- 
quadratic models of radiation action. Each data point represents the mean 
surviving fraction obtained in replicate experiments. Figures 4.1-5.
Figure 4.8 summates the data obtained for the 13 cell lines. The mean LQ fitted 
curves are depicted for each of the 5 glioma cell lines. The mean LQ curves for 
the 3 embryonal lines, and 5 carcinoma lines are each depicted as single dashed 
lines.
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Figure 4.1. Acute radiation survival data for human glioma cell line. U251
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Figure 4.2. Acute radiation survival data for human glioma line, UVW.
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Figure 4.3 Acute radiation survival data for human glioma line.SB18.
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Figure 4.4. Acute radiation survival data for human glioma line, UK
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Figure 4.5. Acute radiation survival data for human glioma line CCM,
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Figure 4.6. Acute radiation survival data for 3 human embrvonaLcell lines,
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Data points represent values obtained in replicate experiments. Curves fitted by LQ model.
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Figure 4.7a. Acute radiation survival data for human carcinoma cell lines.
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Figure 4.7b. Acute radiation survival data for human carcinoma cell lines.
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Figure 4.8. Pooled acute radiation survival curves for 13 human cell lines
Lines represent the mean LQ curves for each cell line.Individual data points ommitted for clarity.
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Table 4.1. Acute radiation survival curve parameters: human glioma cell
lines
Cell
line
LQ model MT
(initial
slope)
model
SF 2Gy
a (Gy1) P ( G y2) a / (3 Do (Gy) n DS (Gy)
UK 0.076 (0.03) 0.024 (0.003) 3.16 2.17 (0.21) 6.7 (2.3) 15.2 (5.4) 0.82 (0.02)
UVW 0.10(0.03) 0.042 (0.004) 2.38 2.21 (0.61) 10.3 (7.6) 4.14(0.32) 0.66 (0.02)
CCM 0.22 (0.03) 0.048 (0.005) 4.58 1.67 (0.52) 8.78 (8.1) 3.62 (0.47) 0.58 (0.02)
u251 0.21 (0.04) 0.051 (0.006) 4.18 1.69 (0.25) 3.11 (1.7) 10.65 (16.5) 0.56 (0.02)
SB18 0.10(0.02) 0.026 (0.002) 3.84 2.38 (0.51) 8.13(4.8) 6.85 (0.97) 0.77 (0.01)
mean 0.14(0.03) 0.038 (0.006) 3.62 2.02 (0.14) 7.4 (1.22) 8.09 (2.17) 0.68 (0.05)
Figures represent mean value of parameter with standard error, determined on 4 
-6 independent experiments on each cell line.
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Table 4.2 Acute radiation survival curve parameters: human carcinoma cell
lines
Cell line
(tumour type)
LQ model MT( +IS) 
model
SF 2Gy
a  (Gy -1) P (Gy-2) a /  P D 0 (Gy) n Ds
A2780 0.61 0.047 12.9 1.09 1.62 25.2 0.22
(ovary) (0.056) (0.01) (2.1) (1.51) (0.01)
MCF 7 0.19 0.021 9.04 2.41 2.38 24.7 0.67
(breast) (0.025) (0.003) (0.68) (1.17) (0.02)
HT 29 0.086 0.035 2.45 2.79 3.53 8.34 0.77
(colorectal) (0.025) (0.003) (0.38) (1.8) (4.7) (0.03)
SKMES 0.21 0.027 7.78 2.53 2.97 6.54 0.63
(lung,squamous) (0.03) (0.004) (0.4) (1.87) (4.6) (0.03)
A549 0.15 0.025 6.0 2.66 2.55 10.4 0.71
(lung,adeno) (0.03) (0.003) (0.55) (1.7) (15) (0.03)
mean 0.24
(0.09)
0.031
(0.005)
7.63
(1.72)
2.29
(0.31)
2.6
(0.31)
15
(4.1)
0.60
(0.09)
Figures represent mean value of parameter with standard error, determined on 4 
-6 independent experiments on each cell line.
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Table 4.3. Acute radiation survival curve parameters: human embryonal
tumour cell lines
Cell line
(tumour type)
LQ
model
MT
model
SF 2Gy
a (Gy -1) P (Gy-2) a /  p D 0 (Gy) n
Susa 0.76 0.051 14.9 1.23 0.74 0.16
(teratoma) (0.072) (0.014) (0.1) (0.09) (0.01)
IMR 32 0.85 0.032 26.5 0.76 2.3 0.18
(neuroblastoma) (0.079 (0.018) (0.07) (0.43) (0.01)
SKNSH 0.71 0.039 18.2 1.06 1.35 0.21
(neuroblastoma) (0.06) (0.011) (0.11) (0.22) (0.014)
mean 0.77
(0.04)
0.041
(0.006)
19.8
(3.4)
1.01
(0.14)
1.4
(0.45)
0.18
(0.01)
Figures represent mean value of parameters determined on 4-6 independent 
experiments, with standard error.
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The numerical results derived from the fitting of both multitarget and LQ models 
are presented as tables 4. 1-3. The mean and standard error is presented for 
the each of the survival curve parameters obtained from data pooled from a 
minimum of 4 independent experiments on each cell line. In the case of the 3 
embryonal lines, depicted in table 4.3, the simple multitarget parameters are 
given, due to difficulties encountered fitting the MT with initial slope to these very 
radiosensitive lines.
Data has been grouped for presentation by overall histological category ie. human 
glioma data in table 4.1, human carcinoma line data in table 4.2, and embryonic 
line data in table 4.3.
4.3.2. Surviving fraction at 2 Gy as a measure of cellular radiosensitivity
The surviving fraction at 2 GY (SF2) for each cell line was measured directly in the 
clonogenic assay, as a model-free parameter of radiosensitivity. Data is 
presented included in tables 4.1-3 as the mean and standard error for each cell 
line. Data has been pooled from a minimum of 4 independent clonogenic assays 
on each cell line.
The mean values of SF2 are also shown in graph form, as figure 4.9. The error 
bars represent the 95% confidence limits on the estimation of the mean for each 
cell line.
The mean values of SF2 for the three tumour groups reflected the parameters of 
the multitarget and linear-quadratic models. The mean values for the glioma cell 
lines showed considerable overlap with the carcinoma cell lines, with group means 
of 0.68 (SE 0.05) and 0.60 (SE 0.1) respectively. The 3 embryonal cell lines had 
considerably lower values of SF2 , with a mean of 0.18 (SE 0.01)
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Figure 4.9 Clonogenic surviving fraction at 2Gv for 13 human tumpur cell
lines.
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4.3.3. Analysis of tumour control probability as a function of radiosensitivity 
at 2Gy.
The mean surviving fraction at 2Gy obtained on each of the 13 human cell lines 
has been used to calculate the theoretical doses required to control 50% of 
tumours of the same histological type, the so-called TCD-50, based on Poisson 
statistics.
Results are presented as:
1) The TCD-50 in Gray derived from the mean values of SF2 obtained on each of 
the 13 human cell lines, grouped by histology. Fig.4.10
2) The variation in TCD-50 for each of the 3 histological groups, as a function of 
radiosensitivity at 2Gy, and with varying theoretical tumour doubling times, from 2 
days to infinity. Tables 4.-4-6
The calculations are based on a theoretical tumour of 10 10 cells, all of which are 
clonogenic. The radiotherapy fractionation schedule is daily fractions of 2Gy, as 
commonly used in clinical practice.
It can be seen that the range of TCD-50 doses for the 3 histological classes of 
tumours vary considerably. The lowest value of 27Gy was calculated for the 
embryonic tumours, based on the mean SF2Gy for the 3 cell lines, of 0.18. This 
value is based on the presumption that no tumour repopulation occurs during the 
course of therapy.
The TCD-50 for the carcinomas was based on the group mean SF2 Gy of 0.60, 
again assuming no repopulation. The TCD-50 value of 91.6Gy would be 
considered high on the basis of clinical dose-response.
The TCD-50 value for the glioma group, assuming no repopulation, is 122Gy. This 
value is approximately double the total dose usually given in clinical treatment of 
glioma post-operatively.
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Figure 4.10 TCD-50 doses calculated for human tumours of a given 
histological type, based on in vitro SF2Gy data.
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Each symbol represents the dose required to control 50% of tumours, based on 
the in vitro cellular radiosensitivity of each of the 13 human tumour cell lines 
studied, displayed by histological group.
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Table 4.4. Theoretical radiocurability of human glioma as a function of in
vitro estimates of intrinsic radiosensitivity, and tumour doubling times.
Doubling time days) TCD 50% (Gy) log (CCN)
2
3 750 0.65
4 327 1.71
5 244 2.34
10 162 3.60
20 138 4.23
oo 122 4.85
Notes,
Calculation based on the following :
1) Mean SF2Gy of 5 human glioma lines: 0.68
2)Theoretical radiation treatment schedule: 2Gy daily, 5 days per week.
3) TCD 50% is total dose required to give 50% tumour cure probability, for a theoretical tumour 
containing 101^ clonogenic cells, based on Poisson statistics.
4) CCN is th e ' curable cell number* ie. number of clonogenic cells for which a treatment course of 
30x2Gy would give cure probability of 50%
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Table 4.5Theoretical radiocurability of human carcinomas as a function of in
vitro estimates of intrinsic radiosensitivity and tumour doubling time.
Doubling time (days) TCD 50% log CCN
2 1811 0.18
3 250 2.28
4 174 3.34
5 148 3.97
10 113 5.23
20 101 5.86
oo 91.6 6.5
Notes.
Calculation based on the following :
1) Mean SF2Gy of 5 human carcinoma lines: 0.60
2)Theoretical radiation treatment schedule: 2Gy daily, 5 days per week.
3) TCD 50% is total dose required to give 50% tumour cure probability, for a theoretical tumour 
containing 1010 clonogenic cells, based on Poisson statistics.
4) CCN is th e ' curable cell number* ie. number of clonogenic cells for which a treatment course of 
30x2Gy would give cure probability of 50%
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Table 4.6. Theoretical radiocurabilitv of human embryonic tumours as a
function of In vitro estimates of intrinsic radiosensitivitv and tumour
doubling time.
Doubling time (days) TCD 50% log CCN
1 63 9.6
2 38 15.9
4 32 19.0
5 31 19.7
10 29 20.9
20 28 21.6
oo 27 22
Notes.
Calculation based on the following :
1) Mean SF2Gy of 5 human embryonic tumour lines: 0.18
2)Theoretical radiation treatment schedule: 2Gy daily, 5 days per week.
3) TCD 50% is total dose required to give 50% tumour cure probability, for a theoretical tumour 
containing 1010 clonogenic cells, based on Poisson statistics.
4) CCN is th e ' curable cell number* ie. number of clonogenic cells for which a treatment course of 
30x2Gy would give cure probability of 50%
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4.3.4. Analysis of variance on the surviving fraction at 2Gy, SF2
The tumour lines were grouped for analysis of variance by histological type as 
described in tables 4.1-3
1) Group 1 Embryonal lines IMR32; s k n s h ; s u s a
2) Group 2 Carcinoma lines A549; MCF7; A2780; HT29; s k m e s
3) Group3 Glioma lines U251;cCCM; IJK;SB18; u v w
Table 4.7 Analysis of variance on SF2 values
Source Sum of 
squares
Degrees of 
freedom
Mean
square
F-ratio P value
Cell lines 154.327 12 12.861
(1)
38.05
(4)
< 0.001
Experiment 8.782 26 0.338
(2)
5.506
(5)
<0.001
Replicates 4.785 78 0.061 (3)
Mean square value (3) represents cr2 rep
Mean square value (2) represents 3 cr2 exp + cr2 rep
therefore cr2 exp = (0.338- 0.061 )
3
0.0923
The F ratio (5) = (2) / (3)
tested the hypothesis that repeat experiments on the same line generated no 
additional variability in SF2 estimations, ie cr2 exp =0.
This was rejected at the p<0.001 level.
The F ratio (4)
tested the hypothesis that there was no difference between the mean values of 
SF2 of any of the 13 cell lines. This was rejected at the p< 0.001 level.
The variance in the estimate of the "true" (transformed) SF2 value for each cell 
line is specified by:
a2 exp /  3 + a 2 rep/ 9 
= 0.038
therefore the standard error = vu.uj
= 0.194
The analysis of variance showed statistically significant differences between the 
mean values of SF2 for Groupl tumour lines, compared with group 2 or 3 
(p value < 0.001).
Comparison of mean SF2 values in tumour group 2 with tumour group3 was 
also significant at a p value of 0.003. This difference was accounted for 
predominantly by the inclusion in group2 of the ovarian carcinoma line, A2780. 
When this line was excluded from the analysis no significant difference could be 
detected in the mean values for the remaining 4 carcinoma cell lines, and the 5 
glioma cell lines.
4.3.5.Multiple pairwise comparisons of mean SF2 values between cell lines.
The SF2 data on each of the 13 tumour lines was further assessed by use of the 
Tukey HSD test for post hoc pairwise comparisons of means. There are 78 
pairwise comparisons of mean estimations of SF2, contained in the data set on 
the 13 cell lines. A comparison was made, specifiying a minimum significance 
level of 5%. The results of this procedure are shown:
164
SUS2_________IMR32 SKNSH A2780
U251 CCM SKMES_______ UVW MCF7 A549 HT29 SB18 UK
The difference between means on any of two cell lines not joined by an underline 
was statistically significant at the 5% level.
4.4. Discussion
This is the largest study examining the radiosensitivity of human tumour lines, 
where the assays of clonogenic cell survival have all been carried out by one 
worker, using a consistent experimental protocol. These observations are 
particularly relevant to the objectives addressed in this study,namely to evaluate 
whether, allowing for intra- and interexperimental error, significant differences in 
cellular radiosensitivity could be detected between continuous human tumour cell 
lines of specific histological type.
The inclusion of carcinoma and embryonal cell lines served three functions in this 
study. Firstly, it provided a form of quality control for the clonogenic assays, as 
there is published data on the cellular radiosensitivity of both SuSA , the teratoma 
line, [Parris etal, 1988 ] and the colorectal adenocarcinoma line, HT29, [Fertil and 
Malaise, 1981] both of which have been previously determined to represent 
radiosensitive and resistant tumours lines respectively.
Secondly, it provided the opportunity to perform a limited analysis of the spread 
of human tumour cellular radiosensitivity by histological type.With the exception of 
one study using primary cultures, [Rofstad etal, 1987 ] this had previously only 
been conducted on data pooled from several laboratories, with limited quality 
control on the experimental techniques employed.
Within the limits imposed by data available on only 13 different lines, it would 
appear that the distribution of cellular radiosensitivity observed in these continuous
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lines is bimodal, rather than normal. See figure 4.10. A group of radiation- 
hypersensitive lines, as represented by the 3 embryonal lines and A2780 , can 
be separated quite distinctly in their response from the other 9 lines. Considerable 
heterogeneity was observed within the carcinoma and glioma lines, which 
appeared to reflect true biological variability rather than experimental error.
4.4.1. Survival curve fitting.
It was observed that both linear-quadratic and multitarget models of radiation 
action gave reasonable fits to the experimental data obtained for the 13 human 
tumour lines studied. The observed visual fit of the simple multitarget equation 
to data points appeared to be less satisfactory at higher doses, where the 
response of 8 of the 13 cell lines displayed varying degrees of continuous 
curvature, without an apparent true exponential final slope. This observation was 
corroborated by an improved statistical 'quality factor1 for the nonlinear regression 
fits obtained for the linear-quadratic model.
4.4.2. Linear-quadratic model
The linear-quadratic equation was observed to give acceptable fits to the data 
sets obtained on all 13 cell lines, describing mathematically an observed trend 
towards continuous curvature of response with increasing single dose size. This 
was evident both by visual scrutiny, and reflected in small 'residual's on the least- 
squares non-linear regression used to fit curves and derive the parameters a and
P.
The constant a is a measure of the initial slope of the survival curve, considered to 
estimate the linear (ie. exponential) component of cell kill thought to predominate 
over the dose range of clinical interest, 1-2 Gy. It is felt by some 
biomathematicians to represent mathematically the 'intrinsic' cellular 
radiosensitivity of the cell type, independent of any repair capacity [Steel and 
Peacock, 1989 ].
It has been observed in previous studies of human cell lines that at doses of 1 - 
3Gy, the initial slope, as measured by the parameter a, differs considerably 
between cell lines, whilst little variation is noted in the quadratic parameter, p.
One interpretation of this observation is that at clinically relevant doses, recovery 
from acute radiation damage is virtually complete, and therefore cell death is
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determined by the biological processes underlying the determination of the initial 
slope.
The range of values of a obtained for both the carcinoma lines and glioma lines 
overlapped considerably with a range of values between 0.07 -0.61. The mean 
values of a for the 5 glioma lines was 0.14 (0.03), by comparison with values of 
0.24 (0.09) and 0.77 (0.04) for the carcinomas and embryonal lines respectively. 
The mean value of a obtained for the 5 carcinoma lines was heavily influenced by 
the high value measured for the ovarian line, A2780. The trend towards lower a 
values in the glioma cell lines did not reach statistical significance when compared 
with the values obtained for the carcinoma lines. (p=0.39, Student’s t test).
The values for a obtained in this study are comparable with the ranges of a values 
cited by Fertil et al as representative of radiosensitive and resistant human tumour 
lines, namely 0.59 (cv 44%), and 0.33 (cv 66%) respectively [Fertil and Malaise, 
1985].
The parameter p specificies the 'bending' component of the dose-response curve, 
and is proportional to dose2, postulating an interaction of adjacent cellular 
radiation events at higher dose. Low values of p are considered to signify little 
capacity to repair radiation damage, and generate survival curves that are almost 
exponential on a semilogarithmic plot, with the slope determined by the a value.
By contrast, high p values give considerable curvature to the dose-response. This 
may be not be obvious when examining the dose-response curves for lines with 
high a values ie. very radiosensitive lines, and has led to the erroneous 
assumption in the past that radiosensitive lines are "recovery-deficient'' for 
radiation damage.
The mean p values for the glioma and carcinoma cell lines were 0.038 (0.006) 
and 0.031 (0.005) respectively. These values are comparable with the mean 
values cited by Fertil and Malaise [Malaise etal, 1987 ] for moderate to poorly 
responsive tumour types, namely 0.039-0.045. A mean value of .0.041 (0.006) 
was obtained for the 3 embryonal lines. This would suggest little difference in the 
ability of this panel of 13 cell lines to recover from radiation damage on the basis 
the popular interpretation of the LQ model.
The a / p ratio represents the radiation dose at which the cell kill achieved by a 
and p events is equal. As a ratio its numerical value is dependent on those 
obtained for both a and p. Human cells of high radiosensitivity are usually 
observed to have a / p ratios of greater than 8, whilst only the most resistant cells
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have values of less than 5 [Williams et al, 1985 ] .The mean value of the a / (3 
ratio for the 5 glioma cell lines was 3.62 (SE 0.38), reflecting the low 'intrinsic' 
cellular radiosensitivity measured by the a parameter, and the moderate capacity 
for cellular recovery measured by p. The carcinoma lines gave a mean value of 
7.63 (SE 1.72), again heavily influenced by the estimation on one cell line, A2780. 
The mean a / p for the 3 embryonal lines was 19.8 (SE 3.4) and in keeping with 
the expected values for a highly responsive tumour group.
4.4.3. Multitarget model
It was observed that the 5 human glioma cell lines, and 4 of the 5 carcinoma lines 
appeared to exhibit continuous curvature of response with increasing radiation 
dose. Hence evidence for a final exponential slope as predicted by the multitarget 
model of radiation action was lacking. It was also found that the multitarget model 
with initial slope had difficulties achieving convergence in least-squares curve 
fitting, when applied to the most radiosensitive lines. Hence the simple multitarget 
model parameters are cited in table 4.3.
The mean value of the final multitarget slope, Do, for the 5 glioma lines was 
2.02 Gy ( SE , 0.14), with a range of 1.67 to 2.38 Gy. This compared with a mean 
value of 2.29 ( SE 0.31) Gy for the 5 carcinoma lines, and 1.01 (SE 0.14) Gy for 
the embryonic cell lines. This parameter did not therefore appear to discriminate 
cellular radiosensitivity in human glial and carcinoma cell lines; both of these 
tumour types gave considerably higher values than the 3 embryonic lines 
examined.
Malaise et al[1987 ], in their meta-analysis of published data on 110 human 
tumour cell lines, reported mean values of Do of 1.15,1.29 , and 1.25Gy for the 
groups of tumours ranked as highly, moderately, and poorly radiosensitive, 
respectively. The mean values of Do obtained in this study for the glioma and 
carcinoma lines are higher than cited by Fertil, but again within the range reported 
in the literature. It is of note that Fertil also found that the multitarget parameter, 
Do did not appear to differ significantly for cell lines derived from tumour types 
ranked moderately or highly resistant.
The multitarget parameter n is determined largely by the size of the so-called 
'shoulder region"of the survival curve produced by fitting the MT model. The 
mean value of n obtained for the 5 glioma lines was 7.4 Gy (SE 1.22 ), compared 
with 2.6 Gy ( SE 0.31) and 1.4 Gy(SE 0.45) for the carcinomas and embryonal 
lines respectively. The distribution of values for n obtained for the 3 histological
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tumour groups again showed a lower mean value for the embryonic cell lines, but 
little difference between glioma and carcinoma lines, mean values for the 
carcinoma group being heavily influenced by the radiosensitive ovarian line, 
A2780.
According to the mechanistic assumptions underlying the multitarget model, the 
value of n implies a larger number of critical "targets" within the glioma and 
carcinoma lines to be inactivated prior to induction of radiation cell death.
4.4.4. Cellular radiosensitivity of human glioma lines
A major objective of this set of experiments was to examine the hypothesis that 
human glioma might be clinically less radioresponsive than carcinomas by virtue 
of greater intrinsic cellular radioresistance. It had previously been observed by 
Fertil that human continuous cell lines of a given tumour type appeared to 
preserve in vitro a ranking of radiosensitivity that was comparable with the clinical 
radiocurability of the original tumour. It was therefore necessary to derive values 
for the radiosensitivity of human glioma lines alongside internal experimental 
controls representing cell lines of other histological types.
All parameters of cellular radiosensitivity obtained for the 5 human glioma lines 
used in this study lie within the ranges cited for radioresistant human tumours 
[Malaise etal, 1987 ; Steel, 1989 ].
Data obtained in this study show that all 5 glioma lines display a cellular 
radiosensitivity that lies at the most resistant end of the values observed for 
human cell lines, both normal and malignant.
The mean SF2 Gy value of 0.68 for the 5 glioma lines was significantly higher 
than that measured in 5 carcinoma lines, by analysis of variance, (p =0.003). It is 
acknowledged that this result is biased significantly by the unusual 
radiosensitivity of the ovarian carcinoma A2780.
The results obtained on these 5 human glioma lines supported the observations 
made by Yang et al, who reported the relative radioresistance of 3 low passage 
human glioma cell lines. The SF2 values reported ranged from 0.47 to 0.73 , with 
a mean value of 0.59. The relative radioresistance at low doses was also reflected 
in the low values for the LQ parameter, a. Values ranged from 0.04 to 0.36, with a 
mean of 0.24. Although these values might suggest less extreme radioresistance 
than observed in this thesis, no other cell lines were included as internal
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standards in the Yang analysis. Similarly, the 3 glioma lines reported were not 
continuous, therefore direct comparisons are not applicable.
4.4.5. Relevance of in vitro cellular radiosensitivity to clinical practice.
The relevance of in vitro measurements of intrinsic cellular radiosensitivity on 
human continuous cell lines to clinical radiocurability must be addressed.
Attempts have been made to extrapolate from in vitro estimations of 
radiosensitivity on continuous human tumour lines, to the clinical experience of 
radioresponsiveness of the tumours of similar site and histology. Such analyses 
have been conducted with two objectives. Firstly, to assess whether such in vitro 
measurements have any parallels with clinical experience ie. to what extent the 
observed ranking of radiosensitivity in human cell lines is Validated ' by clinical 
response. Secondly, to ask whether such in vitro measurements of tumour 
radiosensitivity might help guide clinical radiotherapy practice.
Several important factors must be acknowledged in assessing the relevance of in 
vitro measurements of radiosensitivity to clinical practice.
Firstly, intrinsic cellular radiosensitivity is likely to be only one factor influencing 
overall cell kill. Other major variables include tumour repopulation, cycle 
progression, oxygenation, and intercellular contact.
The second major concern lies in the reproducibility of estimates of cellular 
radiosensitivity. It has been observed by both Malaise et al [1987] and Suit etal 
[1989 ] that measurements of radiosensitivity made using clonogenic cell survival 
on the same cell line in separate laboratories can yield different absolute values. 
Additionally, it is noted that a similar "ranking” of comparative radiosensitivity 
cannot always be achieved if groups of cell lines of different histological type are 
examined by the two commonly used experimental endpoints, namely growth 
assays or clonogenic assay. These are two technical problems more relevant to 
predictive applications of in vitro radiosensitivity assays, but clearly relate to the 
question of quality control in measuring cellular radiosensitivity generally. [West et 
al, 1991 ]
In this study a high degree of reproducibility was found for repeat experiments on 
each cell line. Interexperimental coefficients of variation for SF2Gy estimations of 
8-20% were found for the 13 cell lines studied, with a mean of 13%. This degree of 
reproducibility may be attributable to several factors: all cell lines were 
continuous, therefore by definition were at high passage level ,with possibly less
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clonal heterogeneity than low passage cultures; repeat experiments were 
conducted on stock expanded and frozen at the outset of this study, there was 
therefore limited potential for biological drift in culture; care was taken to ensure 
that experiments were all performed on exponentially growing cultures in mid-log 
phase.,similarly, the feeder requirements of each of the 13 lines was ascertained, 
and care taken to ensure linearity of controls and test cultures.
4.4.6. Do measurements of SF2Gy in human cell lines reflect clinical 
radiocurability?
Both Fertil e ta l,11981] and Deacon et a /[1984] asked whether there is a 
relationship between predictions of overall tumour kill based on in vitro SF2 
values for different tumour types, and clinical observations. They have tried to 
demonstrate that the apparently small differences in SF2 values for tumours of 
different type might be sufficient to account for the wide spectrum of clinical 
radiocurability observed, when sustained over a fractionated course of 
radiotherapy. This was modelled mathematically, by observing the differences in 
theoretical total cell kill that could be achieved by a conventional course of 30 
treatments at 2 Gy per fraction. By raising the measured SF value for a given 
tumour type, to the power 30, they observed that the total cell kill achieved by 
clinically relevant doses of radiation could differ from 1 0_9to 1 0 -23-
Adopting this approach to the data obtained in these 5 human glioma cell lines, a 
fractionated course of 30 treatments of 2 Gy given over a typical period of 6  
weeks, would achieve between 10-3 and 10‘8 logs of cell kill. For a theoretical 
tumour of 10 10 cells, this level of effect would be compatible with the varying 
degree of radioesponsiveness, but low cure probability observed in the clinic.
4.4.7. Relationship between SF2Gy measurements and tumour control 
probability.
Using Poisson statistics, a tumour control probability at a given total dose of 
radiation, can be be calculated, based on measured SF2 values.
Using SF2 values obtained from the literature for a range of human tumour lines 
(adenocarcinomas; squamous carcinomas; melanoma; glioma), Suit calculated 
the doses needed to acheive a 50% tumour control probability (TCD 5 0 ) for a 
theoretical tumour of 1010 cells. A good correlation with clinical experience was 
found for carcinoma cell lines, with a TCD 50 of 70-75 Gy. However, the TCD50 
calculated for human glioma of 63Gy was clearly inappropriately low, and failed to
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maintain the ranking of relative radiosensitivity usually observed between 
carcinomas, and glioma. The origin of SF2 data used for the glioma cell lines in 
this calculation was not clear [Suit etal, 1989 ].
Several observations should be made on the TCD 50 values calculated in this 
study. (Fig.4.3.10, and tables 4.3.5-7) The TCD 50 value calculated for the 
embryonal tumour group of 27Gy is a much lower dose than would be estimated 
from clinical experience of these tumours. When tumour repopulation is introduced 
as a variable the TCD 50 rises, and doses required to achieve control in 50% of 
cases become more plausible.
Conversely, the TCD 50 dose of 91.6Gy calculated for the carcinoma lines, 
assuming no repopulation, would appear high by comparison with the observed 
radiocurability of human carcinomas. However, this calculation is based on in vitro 
data from several adenocarcinoma lines, including lung adenocarcinoma, and 
colorectal carcinoma; clinical tumours of the same type would not be considered 
to be as responsive as other carcinomas eg. squamous head and neck or cervical 
tumours. In retrospect, the inclusion of more cell lines derived from squamous 
carcinomas , such as those established from carcinomas of the head and neck, or 
cervix, might have produced a more representative assessment of the 
radiosensitivity of the carcinoma group. These are human carcinomas of moderate 
radiocurability, and would have formed the ideal basis of a direct comparison of 
cellular radiosensitivity with human glioma lines. However, there are few well- 
characterised human squamous carcinoma lines available of passage level 
comparable to the human glioma lines used in this study. The lung 
adenocarcinoma line, A549, and a colorectal adenocarcinoma, HT29 , used in 
this study, are derived from human tumours that are considered more 
radioresistant than most squamous tumours.
The mean TCD 50 value calculated by Poisson statistics for the human glioma 
lines used in this study was a dose of 122Gy. This value is approximately double 
the total dose of radiation currently employed in 'conventional1 external beam 
radiotherapy for malignant glioma, and would be regarded as exceeding normal 
CNS tissue tolerance. However, using research techniques such as stereotactic 
external beam boosts or radioactive implants such doses can be delivered to very 
localised, small volume gliomas.
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4.4.8. Conclusions.
1) There is considerable variability in cellular radiosensitivity of human tumour cell 
lines, even at high passage levels. This is particularly evident at low acute doses 
of clinical relevance ie. 2Gy.
2)Such differences would appear to be well discriminated by the model-free 
parameter of radiosensitivity, the surviving fraction at 2Gy. The distribution of 
SF2Gy values observed in this study suggests a bimodal distribution of human 
cellular radiosensitivity; there was considerable overlap of cellular radiosensitivity 
between the 5 human glioma and 5 human carcinoma cell lines studied, but the 3 
embryonal cell lines displayed marked radiosensitivity.
3) The linear-quadratic model of radiation action was observed to give satisfactory 
fits to the data sets obtained on all 13 cell lines studied. The more radioresistant 
cell lines displayed continuous curvature of dose-response, less satisfactorily fitted 
by the multitarget model.
4) The intrinsic cellular radiosensitivity of the 5 human glioma lines studied 
appears to lie at the extreme of values observed for human tumours in vitro. Such 
cellular radio resistance may contribute to the marked clinical radioresistance 
observed in human glioma.
5) The molecular processes determining the intrinsic cellular radiosensitivity of 
human cells is uncertain. Great variability was observed in these 13 cell lines in a , 
the parameter of the linear-quadratic equation considered to reflect differences in 
induction of non-repairable damage. By contrast, there was considerable overlap 
of values for the parameter p, considered to estimate the ability of cells to recover 
from radiation damage.
6) Further investigation of the relevance of intrinsic cellular radiosensitivity to 
clinical radiocurability is needed. This would be accomplished more satisfactorily 
by the use of primary human tumour lines, together with an estimate of tumour 
proliferation.
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5.1.Background and choice of experimental system.
5.1.1. Cellular recovery phenomena.
In clinical radiotherapy it is noted that fractionation of a given total radiation dose is 
less effective in producing tumour response, or normal tissue damage. It has been 
widely assumed that such so-called 'recovery' of cells from radiation damage 
determined the clinical effectiveness of radiotherapy. The molecular basis of 
recovery is poorly understood.
Tumour types displaying poor radioresponsiveness were those assumed to be 
able to accumulate and repair radiation damage proficiently. This later notion was 
further reinforced by the observation in vitro of a shouldered response at lower 
doses of radiation in the human cell survival curve [Hall, 1988].
The extent of cellular recovery from radiation damage has been measured using 
both in vitro and in vivo systems to study single cells, normal tissues and 
experimental tumours, or whole animals. However, the experimental endpoint 
most frequently used has been that of enhancement of clonogenic cell survival in 
operationally-defined 'cellular recovery' assays. The damage to mammalian cells 
produced by irradiation has been divided conceptually into three categories:
1) Lethal damage; irreversible and irreparable lesions leading inevitably to cell 
death.
2)Sublethal damage (SLD); lesions which can be modified and eliminated by 
cellular processes, given time, unless further damage is acquired eg by another 
radiation dose.
3) Potentially lethal (PLD); a component of radiation damage that can be 
influenced by post-irradiation conditions[Elkind and Whitmore, 1967 ].
These processes are operationally-defined, and the precise molecular nature of 
the lesions involved in each category of damage and their inter-relationship are 
still a subject of research. It is now felt appropriate to refer to these cellular 
observations as 'recovery phenomena', reserving the term 'repair* for the 
observation of post-radiation events at the DNA or chromosomal level. [Steel, 
1991],Much of the data available on the comparative ability of human tumours to 
recover from radiation damage at the cellular level has been obtained using such 
approaches.
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Human cellular recovery from radiation damage has been commonly measured 
in three types of experimental system:
1) Post-irradiation plateau -phase holding prior to subculture (Potentially lethal 
damage repair or PLD) [lliakis, 1988 ].
2) Split dose irradiation(Sublethal damage repair, or SLD ) [Peacock e ta l, 1988 ].
3) Low dose-rate irradiation [Steel etal, 1987].
5.1.2.Potentially lethal damage repair (PLD).
Survival of cells exposed to radiation can be modified by post-treatment incubation 
with metabolic inhibitors or under conditions which affect progression through the 
cell cycle. Such modulation of cytotoxicity is considered to represent the induction 
of damage which is only potentially lethal. It is assumed that such PLD can be 
repaired by the cell if not fixed by subsequent cellular processes. Two types of 
experimental system have been used to simulate and measure this class of 
cellular processing: a) treatment with compounds which might 'fix' PLD induced by 
radiation, including DNA synthesis inhibitors, caffeine, anisotonic media; b) the 
use of post-irradiation conditions intended to permit recovery from radiation to 
proceed eg delayed subculture of plateau-phase cultures. This later approach has 
been claimed to simulate the density-inhibited conditions felt to prevail in tumours 
in vivo [Little, 1973 ].
5.1.3.Sublethal damage repair (SLD)
This class of damage and recovery has been defined by the observation of 
enhanced clonogenic cell survival when a total dose of radiation D is given as two 
equal fractions of D/2, separated by increasing time intervals. This process was 
first noted by Elkind, irradiating CHO cells. It was observed that the surviving 
fraction of irradiated cells increased with prolongation of the split dose interval 
from 0 to 6 hours, then reaching a plateau [Elkind and Whitmore, 1967 ]. The 
enhancement in cell survival was attributed to 'repair of sublethal damage' 
accumulated during the first fraction of radiation, and modified by the increasing 
time interval prior to a second dose. Recovery was expressed as the ratio of 
surviving fraction obtained at the plateau of recovery, to that observed when the 
two doses were administered consecutively, ie To.
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5.1.4 Low dose rate sparing
As the acute radiation dose rate is reduced progressively from 2 down to 0.02 Gy 
/ minute, a significant reduction in the final slope of the acute radiation survival 
curve is noted, until the response is virtually exponential on a semilogarithmic 
plot. The major difference between cell lines of differing acute radiosensitivity is 
then manifest by differences in the slope of this plot, which is thought to 
extrapolate the initial slope of the acute high dose-rate survival curve. Below 
0.02Gy/min cell cycle progression events complicate analysis.
The enhancement in cell survival at a given radiation dose gained by a reduction 
in the dose-rate is referred to as low dose-rate sparing. The amount of this sparing 
varies between human cell lines, and is thought to reflect a capacity to repair 
radiation damage.
5.1.5 Cellular recovery in human cell lines.
A number of studies have attempted to evaluate a potential relationship between 
acute radiosensitivity in vitro, and cellular recovery capacity, using both human 
tumour cell lines, and cultures derived from fibroblasts of patients with ataxia 
telangectasia.
Astor etal [ 1989 ] have recently demonstrated deficient PLD recovery in 3 AT 
fibroblast cell lines. All three lines showed recovery from radiation damage, when 
subculture was delayed for 6 hours post-irradiation, when compared with the 
surviving fraction obtained following immediate subculture. However, when the 
extent of recovery was compared with that achieved by 2 normal human fibroblast 
cell lines, at a dose producing similar survival levels, a three-fold reduction was 
observed in the AT lines. This study also provided some evidence for two- 
component recovery kinetics, identifying a 'fast' recovery process, with a half-time 
of 5-7 minutes, in addition to a slower process, completed within 3 to 4 hours. The 
findings in this study are of note. It had previously been assumed that AT cells 
were deficient in cellular recovery. Secondly, this study employed very high dose 
rates, 10Gy/min, such that the time for irradiation would not obscure rapid 
recovery processes. This factor may explain difficulties observed in resolving 
separate kinetics of recovery from radiation damage in PLD experiments.
The radiation response of a panel of 12 human tumours studied by Steel et al 
[1987;1991 ] has demonstrated a seven fold difference in the final slope of the low 
dose -rate response, which appears to accentuate the differences in
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radiosensitivity observed at high dose rate. In two radiosensitive human lines 
examined, HX143 ( a human neuroblastoma), and WX 67 (a bladder carcinoma) 
no such sparing could be demonstrated. Analysis of a further 7 tumour lines gave 
estimates of recovery half-times of 0.1-0.85 hours.
By contrast, using split dose recovery as the endpoint, the same group obtained 
quite different values for 'repair' proficiency in 17 human tumour lines, including 
those studied by low dose rate. Half-time values varied from 0.36 to 2.3 hours, 
with a systematic tendency for split dose half-times to be longer than those 
derived from dose-rate analysis. It was noted that the confidence limits on the 
level of correlation between estimates of recovery proficiency on the same line by 
the two different methods was low (correlation coefficient 0.52)
PLD repair has been measured, using plateau-phase cultures and delayed 
subculture methodology, to investigate recovery potential in cell lines derived from 
a variety of human tumours. Guichard et al reviewed the data available on PLD 
recovery obtained in human tumour cell lines in vitro and in vivo [Guichard et a l , 
1984].
Table 5.1. Potentially lethal damage repair (PLD), in human tumour cell lines
Tumour SF at TO (%) Recoverv ratio
High curability MCF7 (breast) 2.3 1.5
MB231 " 3.5 1-2
LAN-1 (neuroblastoma 5.2 1.6
Low curability PAS (hypernephroma) 1.8 4
GBM(glioma) 1.3 2.8
TX4(osteosarcoma) 0.5 24
C143 (melanoma) 2.6 11.5
C32 (melanoma) 4.7 8.2
MaLL(melanoma) 1 3
SAOS
(osteosarcoma)
1.2 2.8
SF at TO; surviving fraction of clonogenic cells obtained with no delay in plating.
It was noted that a considerable range of recovery proficiency was exhibited by 
lines derived from radioresistant tumours, but that the median value (4) was
179
significantly higher than that of the radiosensitive lines. Data was cited on the 
recovery ratios measured in 4 radioresistant human tumour xenografts, irradiated 
in vivo, then subcultured at varying time intervals. A similar median recovery ratio 
was noted for the resistant tumours.
Marchese et al compared PLD repair, both in exponential and plateau phase 
cultures of 2 human tumour lines (2 melanomas, and an osteosarcoma) and a 
normal fibroblast line.Little evidence of any PLDR could be demonstrated in the 
three human tumours examined, either in exponential or plateau phase. By 
contrast, the normal fibroblasts displayed a 5.7 fold recovery in clonogenic survival 
with the six hour delayed plating post-irradiation. It was noted by these authors 
that the human tumours did not display a true plateau phase at high density, with 
38-50 % of cells remaining in cycle, in contrast with only 19% of the normal 
fibroblasts [Marchese et a/, 1985 ]
5.1.6. Cellular recovery phenomena In human glioma.
To date only 1 study has attempted to assess the cellular recovery proficiency of 
human glioma in any detail. Yang et al investigated both split dose recovery and 
low dose-rate sparing in three human gliomas cell lines [Yang eta l, 1990 ] The 
glioma lines were all at relatively low passage levels (P2-26). All exhibited acute 
radioresistance relative to values obtained in other human tumours.
All three lines showed a definite dose-rate effect, as evidenced by a substantial 
increase in clonogenic survival with reduction in dose rate from 1.5 to 
0.013Gy/min. Values for recovery half-times obtained by low dose rate analysis 
varied from 0.5 to 1 hour.
Using the split dose assay, recovery was assessed at 3 or 4 different dose levels 
per cell line. The values of PRR, the split dose recovery ratio, (see section 5.1.7.) 
were comparable with values obtained in previous studies on relatively resistant 
human tumour cell lines.
No attempt was made in this study to compare 'internally' the acute 
radiosensitivity, or recovery potential of these glioma lines, with other human 
tumour lines.
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5.1.7. Rationale for the choice of the split dose recovery assay to assess 
recovery potential in human glioma cell lines.
The choice of the split dose system to assess comparative recovery potential in 
human glioma lines was based on both technical and theoretical considerations.
Firstly, both plateau-phase delayed plating and low dose-rate approaches have 
considerable operational problems. Human tumour cell lines frequently do not 
exhibit a plateau phase due to loss of contact inhibition, and the percentage of 
cells remaining in cycle can vary considerably between lines. Low dose rate 
sparing studies require the facility to maintain cells strictly at 37° C during 
protracted irradiation.
Secondly, it is recognised that no clear theoretical advantage has been 
demonstrated for any of the 3 operationally defined recovery assays, in terms of a 
precise correlation with acute cellular radiosensitivity.
The work of Peacock et a /[1988 ] has suggested that a satisfactory method of 
comparing recovery potential between cell lines of differing acute radiosensitivity is 
the split dose technique. The linear-quadratic model of radiation action gives 
successful fits to much experimental data on the acute radiosensitivity of human 
cells. If is is assumed that full recovery from a split dose treatment gives a result 
that is the product of the single dose surviving fractions, then the LQ model 
defines the recovery ratio mathematically by the expression:
Recovery ratio (RR) = exp (2 p d2 ) 1)
where p is the coefficient of the dose squared term in the LQ equation, and d is 
the dose per fraction in split treatments [Thames, 1985 ].
This model predicts that recovery ratio should rise steeply with dose, with no finite 
limiting value, and therefore no single numerical value that describes the recovery 
potential of a given cell line. Peacock assessed the split dose recovery potential 
of 4 human tumour lines, and was able to validate the LQ prediction that such 
recovery does increase with dose. He defined a parameter pRR, the split dose 
recovery ratio. This parameter is obtained from the defintion of the recovery ratio 
in equation 1), whereby a plot of the logarithm of (RR) against dose2 should 
produce a straight line with a slope of pRR.
It is currently held that values of recovery (PRR) obtained by such split dose 
analyses give a more robust estimate of the cellular recovery potential of human
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cell lines than p values obtained in acute radiation experiments [Steel,1989;1991]
5.1.8. Experimental objectives.
The objectives of the experiments described in this chapter were:
1) To document the cellular recovery potential of human glioma, using as models 
the 5 human glioma cell lines described in chapter 2.
2) To examine the hypothesis that the difference in acute cellular radiosensitivity 
between the human glioma lines, and embryonic tumour lines might be attributable 
to enhanced cellular recovery from radiation damage.
5.2.Specific methods
5.2.1 .Split dose irradiation protocol for estimation of sublethal damage 
repair.
The recovery potential of the 5 continous glioma lines has been examined, and 
compared with 3 radiosensitive human cell lines, A2780, SuSA, and IMR32.
Monolayer colony formation on plastic, as described in the acute radiation 
protocol, was used as the endpoint in these studies. Exponentially growing cell 
cultres were trypsinised, disaggregated to single cell suspensions, and 
subcultured intoT 25cm3 flasks at a range of cell densities. Low density heavily 
irradiated homologous feeders were used to maintain plating efficiency, and 
minimise the effect of varying cell density across the range of test cell numbers 
used. Flasks were gased at 37° C for 4 hours prior to experimental irradiation.
Replicate flasks were irradiated with 2 equal doses of radiation, with the 2 doses 
given at time intervals ranging from 15 minutes to 24 hours apart. Flasks were 
returned to the incubator between fractions to permit cell cycle progression to 
occur. This procedure was carried out at 3 different dose levels per cell line. For 
the 5 glioma lines studied, split doses were administered as 2+2Gy, 3+3Gy, and 
4+4Gy. Split doses were reduced for the three radiosensitive lines studied, to 
permit a comparison of recovery proficiency over an isoeffective radiation dose 
range. Doses were therefore used of 1 +1 Gy, 1.5+1.5Gy, and 2.5+2.5Gy for cell 
lines A2780, SUSA, and IMR 32.
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Colony formation was allowed to proceed over 10 to 20 days, depending on the 
cell line, then cultures fixed stained and colonies counted according to the 
previously defined criteria.
5.2.2.Data analysis.
The recovery ratio was calculated as the surviving fraction observed in the split 
dose flasks compared with the surviving fraction obtained when the total dose was 
given as a single fraction.
Three parameters were calculated to estimate the cellular recovery potential of 
each cell line examined;
1) The maximum recovery ratio obtained at 3 different dose levels, as a model- 
free measure of recovery proficiency.
2) The maximum recovery ratio obtained at the 10% isoeffect dose level.
3) (3 RR, an estimate of the recovery potential as a function of dose, derived from 
the linear-quadratic model.
Data was pooled for analysis from 3 separate experiments on each cell line.
The maximum recovery ratio at each dose level examined was calculated as the 
mean of three values on the plateau of recovery plotted against time.
According to the linear-quadratic model, split dose recovery ratio should increase 
with dose, therefore an estimation of recovery potential at a single dose level 
would not be representative of the cell line. It is assumed that full recovery from a 
split-dose treatment gives a result that is the product of the single-dose surviving 
fractions. Therefore according to the LQ model the recovery ratio is obtained by 
the relationship
loge ( RR) = 2 p d 2 
where d is the single dose level, and RR the recovery ratio.
The recovery ratio (3RR has been calculated from the linear regression slope 
obtained by plotting ( In (S2)-ln (S1) against dose 2, being the difference in 
surviving fractions obtained in split dose compared with single dose, expressed in 
natural logs.
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The recovery half-time was calculated at each dose level, assuming a simple 
rising exponential relationship. The data was fitted by the equation:
S= AR 1 - 0
where A is the intercept on the cell survival axis, R the recovery ratio, and 0 the 
time-constant for recovery (0 = loge 2/ half-time ). The equation was fitted to the 
data using the MINSER optimising method, with alogrithms kindly supplied by 
Prof.G.Steel, Radiotherapy Research Unit, Institute of Cancer Research.
5.3. Results
In all 8 lines examined, recovery of clonogenic cell survival was observed in split 
doses when compared with a single acute dose.
Results were obtained for split dose recovery capacity, described by the 
parameter p RR, the maximal recovery ratios observed at isoeffective survival 
levels, and the kinetics of recovery, expressed as the recovery half-time. These 
values for each of the 5 human glioma tumour cell lines, and 3 radiosensitive 
human tumour lines, IMR 32, A2780, and SUSA, are summarised in Tables 5.2 
to 5.4.
5.3.1.Extent of cellular recovery observed in split dose irradiations.
The dose levels used in the split dose protocol are shown in table 5.2. The 
recovery ratio at any given dose level was defined as the ratio:
surviving fraction in split dose irradiation 
survivng fraction in single dose irradiation
The maximal recovery ratio measured at each of the 3 different total dose levels 
studied per cell line is shown as a mean value, and standard error, from 3 
independent experiments per line. The choice of dose levels was determined by 
the acute radiosensitivity of each cell line, and chosen to study recovery 
proficiency over a similar survival range , ie survivng fraction 0.005 to 0.2.
5.3.2.Kinetics of cellular recovery in split dose irradiations.
A similar pattern of recovery was noted in all lines, namely, an increase in 
surviving fraction with increasing time intervals from 15 minutes, reaching a
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plateau of recovery between 60 and 180 minutes in 7 of the 8 lines. The glioma 
UVW exhibited more protracted recovery kinetics.
In pilot experiments on each cell line studied, protraction of the split dose interval 
beyond 6 hours produced a reduction in surviving fraction , attributed to cell cycle 
progression, as cultures were maintained at 37° C between fractions. In all 
subsequent experiments split dose intervals were therefore limited to a maximum 
of 6 to 8 hours.
The kinetics of the recovery process have been calculated for each cell line by 
pooling the split dose survival data obtained at each of the 3 dose levels 
examined. It is expressed in hours as 11/2 in table 5.2. The range of values 
observed in the 5 glioma lines was 0.53 to 2.6 hours, with a mean of 1.2 (SE 
0.39). This value was influenced by the prolonged recovery in UVW; the median 
value for the 5 lines was 0.9 hours.
The recovery half-times calculated for the 3 radiosensitive tumour lines, A2780, 
SUSA, and IMR32 ranged from 0.64 to 1.25 hours, with a mean of 1 hour 
(SE 0.19). There appeared therefore to be no significant differences in the 
kinetics of split dose recovery in the radioresistant gliomas, and radiosensitive 
lines.
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Table 5.2. Maximal Recovery ratio at three dose levels per cell line
Cell line
2Gy
Maximum
3Gy
recovery
4Gy
ratio at 
5Gy
radiation
6Gy
dose:
8Gy
Gliomas
UVW - - 1.18(0.12) - 1.79(0.18) 2.17(0.26)
CCM - - 1.17(0.13) - 1.22 (0.21) 1.52 (0.1)
UK - - 1.23 (0.08) - 1.55 (0.12) 1.89 (0.12)
U251 - - 1.23 (0.12) - 1.58 (0.21) 2.28 (0.31)
SB 18 - - 1.25 (0.07) - 1.37 (0.13) 1.9 (0.12)
Others:
IMR32 1.13(0.08) 1.3 (0.29) - 2.39 (0.19) - -
SUSA 1.14(0.15) 1.48 (0.19) 2.45 (0.38) - - -
A2780 1.19(0.15) 1.42 (0.28) - - 1.9 (0.26) -
Radiation dose represents total dose given in 2  fractions ie. 2Gy= 1+1 Gy; 4Gy= 2+2 Gy etc 
Values are mean of 3 separate experiments on each cell line, with standard error.
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Table 5.3.Split dose recovery ratio and recovery kinetics for 8 human tumour 
lines
Cell line (3 RR (Gy “2) 11/2 (hours) P (G y1)
Gliomas:
UVW 0.024 (0.007) 2.6 (0.79) 0.042 (0.004)
CCM 0.015(0.005) 0.57 (0.11) 0.048 (0.005)
UK 0.019(0.004) 0.9 (0.14) 0.024 (0.003)
U251 0.024 (0.008) 0.53 (0.17) 0.051 (0.006)
SB18 0.017 (0.005) 1.56 (0.9) 0.026 (0.002)
mean 0.0198 1.2 0.038
IMR 32 0.071 (0.019) 1.15 (0.39) 0.032 (0.018)
SUSA 0.094 (0.032) 1.25 (0.30) 0.051 (0.014)
A2780 0.037 (0.017) 0.64 (0.29) 0.047 (0.01)
mean 0.067 1.01 0.043
Values cited for pRR, ti/2 t and p are are means with standard error 
PRR is recovery ratio measured in split dose studies.
P is p parameter calculated from LQ fits, acute radiation.
1 1/2 = mean recovery half time calculated from 3 radiation dose levels
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5.3.3. Extent of cellular recovery at isoeffective radiation dose levels.
Recovery proficiency has been compared for the 5 radioresistant glioma lines, 
and the 3 radiosensitive lines at a dose level producing approximately the same 
degree of cell kill, ie. that reducing the surviving fraction to 0.1. These values are 
shown in table 5.4.
This dose level varied between cell lines, depending on acute radiosensitivity.
The difference between mean recovery ratio at this isoeffect level has been 
compared for the 5 glioma lines, and the 3 radiosensitive lines, using Students t 
test. The differences are significant at the p 0.05 level, suggesting that the 
radioresistant lines exhibit higher recovery from radiation damage than the 3 
radiosensitive tumour lines, when compared at doses producing equivalent cell 
kill.
The relationship between potential to recover from radiation damage, and acute 
radiationsensitivity is displayed in figure 5.1. Recovery ratio measured at the 0.1 
isoeffect dose level has been compared with the parameter of acute 
radiosensitivity for each cell line, namely, the surviving fraction at an acute dose of 
2Gy. A positive correlation is noted, although the glioma cell line CCM exhibits a 
recovery ratio comparable with the most radiosensitive lines.
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Table 5.4.Comparison of recovery achieved at isoeffective radiation dose 
levels in 8 human tumour lines
Cell line Dose to achieve Maximal Recovery
SF 0.1 ratio observed
UVW 6Gy (3+3) 1.79 (0.18)
CCM 6Gy (3+3) 1.22 (0.21)
UK 8Gy (4+4) 1.89 (0.12)
U251 6Gy (3+3) 1.58 (0.21)
SB18 8Gy (4+4) 1.9 (0.12)
mean 1.67 (0.13)
IMR32 3Gy(1.5+1.5) 1.3 (0.29)
SUSA 2Gy(1+1) 1.14(0.15)
A2780 3Gy(1.5+1.5) 1.42 (0.28)
mean 1.28 (0.08)
Values represent means of 3 independent experiments on each cell line. 
Standard error in brackets.
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Figure 5.1. Relationship between acute radiation sensitivity and cellular 
recovery capacity measured at isoeffective radiation doses.
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Values are mean recovery ratio observed for each cell line at the total, single dose of radiation 
required to achieve 90% cell kill,ie surviving fraction of 0.1, plotted against the acute radiation 
sensitivity of the line, given by the surviving fraction at a dose of 2Gy.(SF2Gy)
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5.3.4. The parameter of cellular recovery capacity, PRR
Based on the assumptions underlying the linear-quadratic model, the parameter (3 
RR was calculated for each cell line. The average value of recovery was 
calculated for three time points on the plateau region attained at each of three 
dose levels examined. The log of the maximal recovery ratio obtained at 3 dose 
levels was plotted against 2xdose 2 Least squares regression was used to 
calculate the slope, which represents p RR as defined by the linear-quadratic 
model. Plots are given in figures 5.2-3 Values are contained in table 5.3.
Values obtained for pRR in the 5 glioma lines were lower than the radiosensitive 
lines, with mean values of 0.019 and 0.067 respectively. Considerable differences 
in p are noted when the split dose values are compared with the p parameter 
calculated in acute radiation exposures.
There was no correlation between the kinetics of recovery, and the extent of 
recovery as measured by the p RR recovery parameter. The recovery half-time 
and PRR have been plotted for each of the 8 cell lines. Figure 5. 4
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Figure 5.2. Relationship between split dose recovery achieved at 3 different
dose levels, plotted as a function of 2d2: in 5 glioma cell lines.
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Figure 5.3 Relationship between split dose recovery achieved at 3 different
dose levels, plotted as a function of 2d2: cell lines A2780, IMR 32, SUSA..
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Figure 5.4. Relationship between recovery ratio, pRR, and recovery kinetics, 
in 8 human tumour cell lines.
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5.4.Discussion
The 5 human glioma cell lines examined in these experiments all displayed the 
capacity for split dose recovery from radiation damage. The values of p RR, the 
parameter of recovery derived from the LQ model, were comparable with values 
obtained in 3 low passage, radioresistant glioma lines reported by Yang etal, 
[1990 ] and two radioresistant human bladder lines [Peacocketal, 1988 ].
This study has compared the recovery proficiency of these 5 radioresistant glioma 
lines with that of 3 radiosensitive human tumour lines, to examine the hypothesis 
that cellular recovery from radiation damage might explain the wide differences in 
cellular radiosensitivity seen in these lines. When split dose recovery proficiency 
was compared at doses of radiation producing equal levels of cell kill (10% 
surviving cells) it was found that the 5 glioma lines exhibited greater recovery than 
the 3 sensitive lines, as evidenced by higher recovery ratios. A positive correlation 
was noted between this recovery ratio value for each of the 8 lines, when plotted 
against a model-free parameter of acute radiosensitivity, the surviving fraction at
I 2Gy.(correlation coefficient 0.69) A similar relationship between split dose
recovery proficiency and SF2Gy has been reported by Kelland, using 5 human 
cerival carcinoma lines, of differing acute radiosensitivity [Kelland et al, 1989 ].
j
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The importance of making comparisons of cellular recovery between lines of 
differing intrinsic radiosensitivity at 'isoeffect' levels has been stressed by previous 
workers [Guichard et al, 1984 ]. Using this approach a trend towards higher 
recovery has been noted in cell lines derived from radioresistant human tumours. 
Summarising the published literature, Guichard observed plateau phase (PLDR) 
recovery ratio values ranging from 2.8 to 24 in 6 radioresistant human lines, by 
comparison with values of 1 to 1.6 in cell lines derived from human breast 
carcinomas, and a neuroblastoma. Although the experimental methodology in 
PLDR assays differs from this study, it corroborates the apparent association 
between cellular radiosensitivity and recovery proficiency in human tumour ce|l 
lines.
The kinetics of cellular recovery processes in mammalian and human tumours 
have been investigated by other groups. Using a very similar experimental 
protocol, and data analysis procedure, Stephens found recovery half-times of 0.16 
to 0.97 hours in 5 tumour cell lines. The shortest times were recorded in 4 murine 
tumours, with the longest value of 0.97 hours being that of a human 
neuroblastoma line, and thus very similar to the half-time found for both sensitive 
and resistant lines in this study. These authors remarked on the fact that the
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values obtained for recovery half-times were lower than previously recorded in 
split dose assays by a factor of 10 [Stephens etal, 1987]. In the same study 
recovery half-times were also measured on the same cell lines, using low dose 
rate irradiation, fitting data with the Incomplete repair model of Thames, and the 
Curtis Lethal-Potentially lethal model. The absolute half-times and ranking of 
values differed considerably for the 5 cell lines studied by the three methods.
Using a similar split dose protocol, and data analysis, Kelland reported recovery 
half-times in 5 human cervical carcinoma lines. Values ranged from 0.24 to 1.25 
hours, with a mean of 0.81 hours. These estimates are comparable with the 
values obtained in the 8 human tumour lines assessed in this study. A similar lack 
of correlation was noted between half-times, and cellular radiosensitivity. It would 
therefore appear that no systematic relationship exists between the biological 
processes underlying cellular recovery kinetics, and the cellular radiosensitivity of 
mammalian cells.
It has previously been assumed 'shoulders' or shallow initial slopes to the acute 
radiation survival curves were a reflection of an ability to accumulate and repair 
radiation damage.lt has been implied, conversely, that human cells with steep 
acute radiation survival curves, with little evidence of such a shoulder region, were 
deficient in cellular recovery capacity. The lower values of recovery proficiency 
obtained for radiosensitive cell lines in this study would tend to corroborate this 
notion.
This premise has been challenged in recent years by an alternative analysis of 
split dose recovery data. As described in the introduction to this chapter, the 
assumptions underlying the linear-quadratic model predict that cellular recovery 
should increase infinitely as a function of dose, with no appropriate value for 
recovery estimated at a single dose level. This hypothesis has been supported by 
the analysis of split dose data on 13 human tumour and fibroblast lines, which has 
shown that recovery ratio continues to rise with increasing dose, with no evidence 
of a plateau even at total doses as high as 16Gy [Peacock etal, 1988]. When an 
estimate of recovery is calculated from the regression slope of log RR against 2d2’ 
the (3 RR parameter, it appeared that radiosensitive lines were not only recovery 
proficient, but apparently showed higher recovery capacities than radioresistant 
lines. This surprising result has been discussed by Steel [Steel, 1991]. It is 
postulated that cell survival following radiation might be the result of two 
processes, with a linear component due to non-repairable lesions, and a bending 
component due to repairable lesions.lt is suggested that radiosensitive cells incur 
more of each of these classes of damage per unit dose. The steep slopes
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observed on the acute radiation survival curve of radiosensitive cells is therefore 
considered to be the result of induction of irrepairable lesions (the a component of 
the LQ model). This component dominates the response at all dose levels, and 
obscures the magnitude of repairable damage, represented by the p component. 
The extent of recovery measured in split dose studies is therefore felt to reflect the 
amount of recoverable damage that is induced, rather than the overall recovery 
from all classes of radiation damage.
The data obtained in this study, analysed in a similar fashion, would tend to 
support the observations made by Peacock: recovery appeared to increase with 
dose for all 8 cell lines, although lower total doses were employed than in the 
Peacock study; secondly, the values of pRR were consistently higher in the 3 
more radiosensitive cell lines than the radioresistant glioma lines. Nonetheless, it 
is usually considered that comparisons of radiobiological endpoints are most 
appropriately made at 'isoeffect' doses, and on this basis the 5 human glioma lines 
studied exhibited a significantly higher capacity to recover from a dose of radiation 
producing 90% cell kill, by comparison with the 3 radiosensitive cell lines.
The wide spectrum of cellular radiosensitivity observed in human tumours renders 
them potentially useful models for the study of the mechanistic basis of cellular 
radiosensitivity. However, the use of cell lines of differing lineage, differentiation, 
and probably quite different modes of malignant transformation has obvious 
difficulties, especially if the aim of such studies is the identification of genes 
involved in repair of radiation damage.
It has been suggested that the use of radiosensitive human tumour cells as 
recipients in genetic complementation studies might be inappropriate, in the light 
of failure to demonstrate absolute recovery deficiency. However, if the aim of such 
investigation is to complement a putative genetic 'defect' responsible for radiation 
hypersensitivity in its widest sense, rather than 'repair' genes , then some human 
tumour types may be very valuable models. Nonetheless, the approach might be 
more productive if a greater number of isogenic mutant systems were available 
for human tumours, differing only in cellular radiosensitivity. Conversely, the role of 
oncogenic transformation itself may well modify the cellular response to radiation. 
Many continuous human tumour lines exhibit a more pronounced cellular 
radioresistance than normal human fibroblasts, and this is true of the 5 human 
glioma lines used in this study. Systematic comparisons of cellular 
radiosensitivity, and recovery from radiation damage have not been made 
between normal and malignant human cells of the same histological type.
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Speculation on the relationship between in vitro cellular recovery phenomena 
and in vivo repair of radiation damage must obviously be cautious. However, in 
vitro cellular recovery processes can be used for both mechanistic studies, and to 
screen the effects of agents with the potential to modify the radiation response.
Improvements in the outcome for human tumours managed routinely by 
radiotherapy, such as glioma, may depend upon the identification of agents 
inhibiting cellular recovery from radiation. Inhibition of recovery from sublethal 
damage , potentially lethal damage, and low dose rate sparing have been 
observed to various degrees using quite different classes of agents.
These have included chemotherapeutic drugs, putative DNA repair inhibitors, 
halogenated pyrimidines, caffeine, differentiating agents, and chemicals modifying 
intracellular thiol levels. Those agents acting via DNA repair pathways have been 
of particular theoretical interest. These include the DNA polymerase inhibitors, 
such as aphidicolin, dideoxythymidine (ddT), p arabinofuranosyladenine (P ara-A), 
and arabinofuranosylcytosine (P ara-C), the poly (ADP-ribose) transferase 
inhibitors derived from benzamide, and novobiocin. Many of the in vitro studies 
claiming enhancement of the radiation response using these agents have focused 
primarily on rodent lines, and UV damage rather than ionising radiation. Few of 
these agents have shown sufficient enhancement ratios in vitro to merit detailed 
in vivo studies, and even fewer are suitable for clinical evaluation [Kelland and 
Steel, 1988]. However, the potential approach of using cellular recovery as an 
experimental endpoint remains valid in the investigation of newer agents.
It is relevant to consider which recovery assay provides the most realistic model 
of the in vivo situation. It is commonly held that delayed post-irradiation sub­
culture of plateau phase cells mimics some of the metabolic, kinetic and cell-cell 
contact phenomena likely to pertain in human tumours. However, whilst plateau 
phase cultures are often observed in non-malignant, transformed human cells, 
many tumour lines do not form such cultures.
A detailed review of the relative merits of particular cellular recovery protocols is 
beyond the remit of this thesis. It is clear that operationally defined recovery 
assays can produce quite different assessments of radiation recovery proficiency 
when the same biological material is studied with an alternative recovery 
experimental protocol. It would therefore appear tha t, even allowing for 
experimental error, quite different molecular processes are being studied when the
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cellular recovery phenomena are evaluated by split dose, PLD, or low dose rate 
assays.
In general, positive correlations have been observed between extent of cellular 
recovery, and acute cellular radiosensitivity in all three experimental systems. By 
contrast, no such correlation has emerged between recovery kinetics and 
radiosensitivity.
Summary.
1) The 5 human glioma cell lines examined in this study all exhibit the capacity for 
split dose recovery from radiation damage. The extent of recovery of clonogenic 
survival increased with dose level, in accordance with the predictions of the linear- 
quadratic model.
2) Maximal recovery at a dose producing approximately 90% kill in all 5 glioma 
lines ranged from 1.2 to 1.9, with a mean of 1.67.
3) Recovery proficiency was assessed in 3 radiosensitive human tumour cell 
lines derived from a neuroblastoma, a teratoma, and an ovarian carcinoma. All 
exhibited split dose recovery , but values for maximal recovery at the dose level 
producing 90% cell kill were significantly lower than observed in the glioma lines.
4)This is the first in vitro study to evaluate the recovery proficiency of human 
glioma lines in a comparative manner. Results are suggestive that a factor 
determining relative radioresistance in human glioma may be a cellular recovery 
process.
5) When recovery capacity was calculated as the parameter p RR, the slope of 
the regression of log recovery ratio against 2 d2,the most radiosensitive lines gave 
higher values than the glioma lines, suggesting significant recovery capacity. This 
suggests that radiosensitive human cells are not deficient in recovery from 
radiation damage. The validity of this method of estimating and comparing the 
recovery proficiency of a given cell line is controversial.
6) A positive correlation was found in the 8 lines examined, between maximal 
recovery ratio at dose levels producing equivalent cell kill, and a measure of 
cellular radiosensitivity, the surviving fraction at 2 Gy.
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7) Recovery half-times for the glioma lines ranged from 0.53 to 2.6 hours, with a 
mean of 1.2 hours. This did not differ significantly from recovery half-times 
obtained in the radiosensitive cell lines.
8)Several alternative systems including low dose rate sparing, and delayed 
plating procedures have demonstrated clonogenic cellular recovery following 
irradiation of human tumours. A correlation has been demonstrated between 
acute radiosensitivity and extent of 'repair' in recovery assays, with a trend for 
radiosensitive cell lines to show less recovery than resistant lines, when 
compared at doses producing equivalent cell kill.
8) Given that “recovery assays” are operationally defined, it is likely that each 
technique measures radiation-induced lesions that differ both qualitatively, and 
quantitatively. This should not preclude the use of cellular recovery as an 
experimental endpoint in the elucidation of basic mechanisms determining cellular 
radiosensitivity.
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6.1.Intrinsic radiosensitivity of primary tumour cultures.
6.1.1.Clinical applications for estimations of individual radiosensitivity.
Clinical experience clearly demonstrates that the radiation dose required to 
eradicate human tumours differs significantly between individual cases. These 
observations have given rise to the notion that the radiation response of a tumour 
might be determined at the level of an individual by genetic factors, as well as 
tumour histology [Suit etal, 1989 ].
There has been increasing interest in the development of tests that might be 
predictive of radiation response in the individual, both for tumour control, and 
normal tissue toxicity.Potential assays of relevance include tests of intrinsic 
cellular radiosensitivity, flow cytometric methods for estimation of tumour 
proliferation kinetics, and techniques to determine the proportion of hypoxic cells 
within a tumour.
Major factors influencing the predictive power of any single assay include the 
clinical relevance of the biological parameter, and the technical resolution of the 
assay. Sampling errors, reproducibility, and intratumour heterogeneity may all 
hinder the prognostic value of a test in which there is real inter-patient variation. It 
must be established that there does exist a distribution of the characteristic under 
scrutiny in the population, and that there is not significant variation between 
patients in other factors influencing response.
Tucker and Thames have mathematically modelled the interaction of several 
biological parameters currently being evaluated as predictive tests in radiotherapy, 
including tests of intrinsic tumour radiosensitivity, and tumour doubling times 
[Tucker and Thames, 1989 ]. They concluded that based on data available from in 
vitro studies to date, predictive tests based on measurement of intrinsic cellular 
radiosensitivity are most likely to be correlated with clinical outcome. They further 
suggested that the magnitude of influence of cellular radiosensitivity was so great, 
that evaluation of any other predictive test of clinical outcome after radiotherapy 
would need to be corrected for this factor.
Studies have already demonstrated that significant differences do exist in the 
distribution of cellular radiosensitivity measured in biopsies from tumours of a
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given site and histology. The magnitude of interpatient variation was greater than 
experimental error. This would therefore suggest that measurement of intrinsic 
radiosensitivity might be technically feasible, and of clinical value.
Brock et al [1990 ] have examined the variation in cellular radiosensitivity at 2 Gy 
in a cohort of 140 patients with squamous carcinoma of the head and neck. Using 
a non-clonogenic, cell growth assay ( CAM assay), they obtained an average 
SF2Gy of 0.33 (range 0.11-0.91). Intra-experimental errors, and repeat 
estimations on the same tumour (multiple biopsies) gave much smaller variations 
than interpatient values. Coefficents of variation cited were 11%, 23% ,and 44% 
respectively. This data set has been criticised for the use of a non-clonogenic 
endpoint to measure response to radiation, and failure to identify the malignant 
nature of the cells grown.
A similar degree of interpatient heterogeneity of response at 2Gy has been 
demonstrated in biopsies of human cervical carcinoma. Clonogenic cell survival 
after 2 Gy was measured in 86 biopsies. A wide range of values was found, 0.13- 
0.97, with a mean SF2 of 0.47. The interpatient coefficient of variation was again 
noted to be significantly greater than experimental error.( 38% vs 19%)
In both these studies the in vitro estimations of radiosensitivity are to be 
correlated with clinical outcome.
Only one study to date has attempted to assess the variability in radiosensitivity of 
tumour primary cultures of different histological groups. Rofstad etal [1987] have 
measured clonogenic cell survival in 36 human tumour biopsies spanning 7 
different tumour sites,including melanoma, breast, cervix, 
ovary,bladder,seminoma, and head /neck tumours. Although numbers varied 
between groups, no signicant difference in mean SF2 values was detected when 
tumours were grouped by clinical site. They concluded that there was 
considerable heterogeneity of response at 2Gy between individual tumours, but no 
correlation with histology. This result would appear to be in direct conflict with the 
original conclusions of Fertil and Malaise that histology is a major determinant of 
tumour response.
6.1.2.Rationale for studies of surviving fraction at 2 Gy in this thesis
The measurement of surviving fraction at 2Gy was attempted in this study in17 
primary human glioma cultures. The purpose of these experiments was twofold:
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1) To compare the measured SF2 values obtained in primary culture with the 
values in the 5 continuous glioma lines.
Inherent in the conclusions of Fertil et al is the concept that cellular radiosensitivity 
might be genetically determined by cell lineage or differentiation. This would 
supervene over evolution of relative radio resistance in vitro to maintain real 
differences in cellular radiosensitivity. However, it is usually the case that a 
number of significant phenotypic properties change in the establishment of a cell 
in culture eg plating efficiency, doubling times, ploidy.
It was therefore considered relevant to compare the SF2 measurements obtained 
in primary and continuous cultures of human glioma to exclude the possibility that 
the observed relative radioresistance seen at high passage level was the result 
of prolonged in vitro selection.
2) An objective of the study was to assess the feasibilty of routine estimations of 
intrinsic radiosensitivity in primary glioma cultures. If sufficient interpatient 
variation was observed, compared with experimental error this might provide 
additional prognostic information.
6.1.3.Clonogenic vs nonclonogenic assays of cellular radiosensitivity: 
rationale for the use of the clonogenic survival assay in primary glioma 
cultures.
Clonogenic cell survival remains the most widely accepted experimental endpoint 
of cellular radiosensitivity. Alternative cellular endpoints include cell growth 
assays, in which a response is measured by the change in a parameter 
proportional to total cell number eg MTT assay or staining by dye [Brock etal, 
1989;Price and McMillan, 1990 ] .The major objections to these systems are that 
they fail to select against growth of non-malignant cells, such as fibroblasts, and 
require careful calibration of control estimations to ensure linearity of 
measurement.
Promising techniques include those based on scoring chromosomal or DNA 
damage. However, extensive correlation of such endpoints with in vitro 
clonogenic cell survival or clinical outcome is awaited.
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The major impetus to develop such assays has been difficulties applying the 
clonogenic assay technique to primary culture material, and the interest in 
developing assays which might give a ranking of cellular radiosensitivity within a 
matter of days rather than weeks.
The conceptual and practical limitations of using clonogenic assays of human 
tumours to measure response to therapy have been exhaustively reviewed[Selby 
e ta l , 1983 ].
Practical problems encountered include:
1) Small amounts of biopsy material, therefore limited cell numbers for assay.
2) Low percentage of biopsies exhibiting adequate growth
3) Infection of primary cultures
4) Problems acheiving good single cell suspensions to assess true clonal growth
5) Low cloning efficiency
6) Long duration of assay-weeks
7) Technical artefacts in measuring response; cell clumps; poor linearity of cloning
Despite these problems there are good reasons to use the assay, with efforts to 
minimise these problems as far as possible.
1) Agar cloning appears to select for the growth of anchorage-independent, 
malignant cells.
In the few studies which have tried to establish clonal growth from malignant 
glioma propagation of either haemopoetic or normal gial growth was not felt to 
occur. Deliberate attempts to clone normal glia resulted in cloning efficiencies of 
less than 0.001%, and full characterisation of those clones was not 
undertaken[Rosenblum etal, 1983 ].
2) Clonal growth is a well-established cellular endpoint in radiation and tumour 
research.
The properties of neoplastic cell populations are consistent with a model in which 
cells with prolifertive potential form a spectrum, from those with the capacity to 
renew the entire population, including themselves, to apparently more 
'differentiated" cells. These self and population renewing cells, which may 
constitute only a small proportion of the total population are considered stem 
cells.The model presumes that stem cells are responsible for tumour repopulation
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after treatment, and are therefore a primary target for cancer therapy. [Steel,
1977]
The validity of the stem cell model is supported by several lines of evidence.
1) There appears to be an inverse relationship between indices of tumour 
proliferation, such as mitotic rate, and the degree of tumour differentiation[Steel, 
1977].
2) Cloning assays of human tumours are usually observed to yield low colony 
numbers, of the order of 0.001-5%[Courtney and Mills, 1978 ;Davidson etal,
1990].
3) Fractionation of suspensions of cells from human tumours has demonstrated 
that proliferative activity, clonogenic potential, and cell differentiation features are 
restricted to separate subpopulations with defined physical properties[MacKillop 
etal, 1982 ].
4) The availability of clonal markers eg the Philadelphia chromosome in CML, 
have shown that tumours may arise from a multipotent stem cell,even if the 
majority of cells are differentiated progeny [Selby etal, 1983 ].
There are therefore good reasons to believe that any system aiming to assess the 
radiosensitivity in an individual patient should be aiming to identify such stem cells, 
or in the case of normal tissue, tissue-renewing units.
In this study specific measures were undertaken to facilitate agar cloning of 
human glioma primary cultures, whilst trying to avoid some recognised pitfalls in 
the assay.
1) A semisolid agar cloning system was employed, as described by both Salmon, 
and Courtney, to select for malignant growth[Salmon and Hamburger, 1977 
;Courtney and Mills, 1978 ]. A further advantage of this approach relates to 
restricting the marked motility of malignant astrocytes in monolayer culture 
systems. Pilot studies using a monolayer cloning assay similar to that used in the 
assessment of the continuous lines achieved higher cloning efficiencies, but 
scoring of indivual colonies was complicated by poor resolution of individual 
colonies.
2) Previous studies using the agar cloning system have emphasised the problems 
of low growth rate and cloning efficiency. Attempts to use such a system to 
quanitfy response of human glioma to cytotoxic drugs was significantly hampered
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by cloning efficiencies averaging 0.06%[Rosenblum etal, 1983 ] .Three specific 
manoevres designed to enhance cloning efficiency were adopted in the Courtney- 
Mills assay: routine inclusion of autologous heavily irradiated feeder cells; a 
reduction in oxygen tension from 20 to 5% during cloning; the addition of August 
rat red blood cells as additional "feeder" cells.
In this project the effect of all 3 of these procedures was assessed, and is 
discussed.
3) Particular attention was paid to obtaining a good single cell suspension prior to 
assay. Excessive processing may contribute to the low cloning efficiencies found 
in primary cultures, but this must be balanced against the need to avoid 
multiplicity. In accordance with recommendations of other workers, the quality of 
the single cell suspension used was carefully checked by haemocytometer, and 
filtration using a sterile mesh employed to remove cell clumps. Heavily irradiated 
controls (50Gy) were examined for false positive colony formation.
4) Both monolayer and agar cloning systems require that response to radiation is 
only estimated over a cloning range where linearity can be demonstrated between 
cells plated and colony numbers. Linearity declines at low colony number, 
possibily due to inadequate paracrine stimulation, and at high colony number due 
to medium depletion. In this study control and irradiated test samples were seeded 
at a range of cell densities. As only limited glioma biopsy material was available, 
cell numbers were low. Therefore a modification of the usual protocols estimating 
radiosensitivity in immediately disaggregated biopsy was employed.
Primary cultures were established for several days prior to test irradiation to 
permit expansion of cell number, and facilitate disaggregation of cell clumps. 
Whilst this period may have allowed for a degree of in vitro selection, it could be 
argued that limited propagation of the more aggressive tumour elements might 
enable a more relevant cell population to be studied. The procedure is analogous 
to the use of xenografts to establish primary biopsy cultures used by other workers 
[Smith etal, 1976 ]. A further validation of this approach is that where primary 
tumours samples have been assayed after several passages no significant 
change has been noted in radiosensitivity [Davidson e ta l , 1990 ].
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Similarly, the use of mass culture growth assays in a predictive manner requires 
such expansion of primary cultures, and results obtained on SF2 appear to 
correlate well with clonogenic assays [Price and McMillan, 1990 ].
6.2. Specific methods.
6.2.1.Establishment of primary malignant glioma cultures.
Human glioma material for this study was provided by the Departments of 
Neurosciences in Glasgow, Edinburgh and The Institute of Psychiatry, Maudsley 
Hospital.
Human glioma tissue was collected at the time of craniotomy into complete 
medium with antibiotics.( penicillin, 200units/ml; streptomycin,200ug/ml; 
gentamycin,100ug/ml; amphotericin B, 2.5ug/ml) Tissue was usually transferred to 
the lab at 4 C within 4-6 hours. Biopsies were received by post from both 
Edinburgh and the Maudsley within 24 hours of surgery, and were usually viable.
The sample was first dissected free of obvious non-tumour or necrotic material. 
Mechanical disaggregation was performed by mincing in a petri dish, using 
crossed scalpel blades, to a size of 1-2mm. The tumour material was spun down 
at 600rpm for 2minutes, then resuspended in PBS containing antiobiotics as 
above, and this washing repeated twice. Disaggregated tumour was finally 
resuspended in medium with antibiotics, and collagenase (Sigma), to give a final 
concentration of 200 units/ ml. The material was incubated at 37 °C, usually 
overnight, with occasional pipetting of the solution under sterile conditions to aid 
disaggregation. The tissue was then spun out of collagenase, and resuspended in 
complete medium with penicillin and streptomycin, to permit adherent culture in a 
T25cm2 flask. The culture was examined daily, and turbid medium containing 
cellular debris removed, and replaced with fresh medium.
When the quantity of biopsy material permitted, the tissue was cut in half prior to 
mincing, to permit assessment of intratumor heterogeneity of radiosensitivity.
As most tissue was obtained from open craniotomy, it was usually possible to 
establish 2-4 separate T25cm2 cultures de novo.
Primary culture was also established without collagenase, allowing small pieces of 
tissue to adhere in jllI quantities of medium in a T25cm2 flask, and monitored 
regularly for explant outgrowth. Using this latter procedure, outgrowth was 
regularly observed, but never proved adequate for further passage.
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The collagenase technique provided successful short-term cultures in 80% of 
samples processed. All antibiotics were discontinued after 1 week in culture. 
Passage and radiosensitivity testing was undertaken when cultures reached 80% 
confluence, and usually a T25cm2 flask would be subcultured into a T75cm2. Less 
vigorous growth was split 50:50. Time to first passage varied from 3 days to 4 
weeks.Cultures were passaged to level 3, then frozen in liquid nitrogen.
Successful recovery following freezing was 90%.
6.2.2.Soft agar cloning technique for measurement of acute radiation 
survival in primary and low passage culture.
The growth of clonogenic tumour cells in soft agar was used to measure 
radiosensitivity in vitro, according to a modified Courtney-Mills technique 
[Courtney and Mills,1978].
Primary cultures, and cultures at passage 1-3 were trypsinised using PET 
solution, and mechanically disaggregated to yield a single cell suspension. The 
final suspension was filtered through a sterile 30p mesh to remove cell clumps. 
Cells were counted and the quality of the suspension checked , using a 
haemocytometer. Cells were irradiated at ambient room temperature as a single 
cells suspension, as per the acute radiation protocol previously described.
35mm petri dishes were precoated with 1% agar (Difco). 2% agar was sterilised by 
boiling, then maintained at 45 C in a water bath to prevent setting. Aliquots of the 
single cell suspension at varying dilutions were mixed with agar, and 5 x104 
heavily irradiated (100Gy) feeder cells , to give a variable test cell number in a 
final 2 ml. volume of 0.3% agar. Pilot experiments compared the enhancement of 
cloning forming efficiency acheived by the addition of homologous or heterologous 
feeders. Control cultures contained feeder cells only. The dishes were placed on 
ice at 4° C for 5 minutes to promote setting of the agar, then transfered to a 37° C 
incubator and gased at reduced oxygen tension, according to the Courtney-Mills 
protocol.(5% 02, 8% C02.)
Test cell numbers were chosen to try to obtain 100 to 150 colonies per dish, 
allowing for a range of possible plating efficiencies of 0.001-10%, with an 
anticipated range of surviving fractions at 2 Gy of 0.1 -0.9.
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Dishes were examined for evidence of cell clumps on day 3, and discarded if 
positive. This was noted to be a rare event after proper cell filtration. Individual 
dishes were fed 0.5ml fresh medium after 10 days. Cultures were examined for 
colony formation at 2-5 weeks. Identification of viable colonies was facilitated by 
incubation for 4 hours with the tetrazolium dye MTT (3-(4,5 - dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide. This dye is reduced to a purple coloured 
formazan product by the mitochondria of live cells.
Dishes were incubated at 37° C wrapped in aluminium foil to prevent degradation 
of MTT, following the addition of 500pl of MTT (Sigma) at a concentration of 
1 mg/ml in PBS.
Colonies of greater than 50 cells were counted by eye using an inverted phase 
microscope. Validation of the criteria used to identify colonies of appropriate size 
included preliminary screening of several dishes and scoring of mean colony 
diameter of 50 colonies using an eye piece graticule micrometer scale . Colonies 
greater than 50|j,m diameter were scored as representing colonies of more than 50 
cells. Several colonies were "picked" from the agar and mechanically 
disaggregated in another petri dish to allow approximate scoring of cell numbers.
6.3. Results.
6.3.1.Establishment of primary cultures and cloning.
The primary cultures established in this study are noted in table 3.2. Other early 
passage human glioma cell lines previously established within the lab but used in 
this study are included.
The success rate in establishing a primary monolayer culture from human 
malignant glioma biopsies was 80%. Two low grade tumours were established, 
and remained viable with no evidence of growth over a period of 6-8 weeks.
Of 17 primary cultures studied, growth adequate to estimate surviving fraction at 2 
Gy was achieved in only 9 cases (52%).
The semisolid agar cloning system was found to yield efficiencies of 0.001 -5%. 
Pilot experiments on the first 3 biopsies received evaluated the effect on cloning of
a) oxygen tension ; b) the effect of adding both homologous and heterologous ( G- 
UVW continuous glioma) heavily irradiated feeder cells; c) stimulation of cloning 
efficiency by addition of irradiated August rat red blood cells.
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The effect of a reducing oxygen tension during cloning, from 20% to 5% and the 
presence of heavily irradiated homologous cells was found to be critical to 
obtaining a cloning efficiency above 0.01%.
The effect of adding heavily irradiated August rat red blood cells, as employed in 
the original Courtney-Mills protocol, was tested in pilot experiments in 3 low 
passage cultures. No enhancement of cloning efficiency was noted, therefore this 
procedure was not routinely employed.
6.3.2.Phenotypic characteristics of primary glioma cultures.
Limited evaluation of the nature of the primary and subsequent early passage 
lines was undertaken. All of the 17 primary cultures established exhibited glial 
morphology in monolayer culture, with a range of predominant patterns. Cells 
were not allowed to acheive complete confluence, but nevertheless loss of contact 
inhibition was usually observed..
At first passage 104 cells were seeded onto sterile glass coverslips in 24 well 
plates for evaluation of GFAP staining, as evidence of glial lineage. The protocol is 
described in chapter 3. The 9 primary cultures giving positive clonal growth in agar 
were all GFAP positive at the time of first passage, with more than 70% cells 
positive. Four of these cultures were retested at passage 5 by which time less 
than 5% of all cells were positive, despite little discernible change in culture 
morphology.
The morphology of BG 488 is shown in figure 3.5.
One cell line established from a biopsy subsequently reviewed as non-malignant 
gave rise to a culture that permitted 3 passages prior to senescence. GFAP 
staining was noted to remain positive in these normal glia, in comparison with 
cultures derived from malignant tissue.
6.3.3.Surviving fraction at 2Gy.
Results are presented in graphical and tabular form for the 9 cell lines. Figure 6.1 
shows the mean surviving fractions obtained at 2GY on each glioma primary 
culture, with standard deviations.. Table 6.1 contains the tabular data.
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A range of mean SF2 was found of 0.37-0.75, with a mean of 0.56. The mean 
intra-experimental coefficient for the parameter was 21%, with a range of 9-26%.
A mean repeat experimental coefficient of variation of 15% was measured by 
repeating the SF 2Gy assay on 4 cell lines at passage 2. (BG 424; BG 535; BG 
550; BG 566) Analysis of variance showed no significant differences in either 
colony forming efficiency or SF2GY values in the repeat experiments on these 4 
cell lines. Material was insufficient to permit adequate assessment of intra-tumour 
heterogeneity by measuring SF2 GY in separate parts of the same culture.
The mean coefficient of variation in SF2 Gy across the 9 primary cultures was 
25%.
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Figure 6.1 Surviving fraction at 2 Gv in primary cultures of human maliqnani
glioma
1
BG398 BG 424 BG 488 BG 500 BG 535 BG 550 BG 551 BG 555 BG 566
Glioma primary culture
Values are means obtained for each primary culture, with 1 standard deviation
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6.3.4.Effect of variation in cloning efficiency on SF2 estimation.
The lack of correlation between cloning efficiency and mean SF2Gy is shown as a 
plot of SF2 for each cell line against its mean cloning efficiency. Figure 6.2.
Figure 6.2. Relationship between colony forming efficiency and SF 2Gy 
values
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Table 6.1 .Surviving traction at 2 Gv in primary cultures of human malignant
alioma
Cell line CFE (%) mean 1SD 1SEM SF230
SF2
BG 398 0.01 0.57 0.15 0.07 4.7 x10-10
BG 424 1.2 0.63 0.16 0.07 9x10-7
BG 488 0.02 0.40 0.07 0.03 1 x10-12
BG 500 0.1 0.44 0.08 0.03 2x10-11
BG 535 0.09 0.75 0.07 0.02 1.7X10-4
BG 550 4 0.71 0.09 0.03 3.4x10-5
BG 551 0.04 0.37 0.08 0.03 1.1x10-13
BG 555 0.08 0.67 0.13 0.05 6x10-9
BG 566 0.2 0.52 0.11 0.04 3x10-9
mean 0.6 0.56 4.7 x 10-8
i 
I
Mean intra-experimental coefficient of variation for SF2 =21% 
Mean repeat experimental coefficient of variation for S F 2=15% 
Coefficient of variation for glioma group SF2 = 25%
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6.4.Discussion.
The objective of measuring radiosensitivity at 2Gy in primary glioma cultures was 
twofold: firstly, to compare the values obtained with those measured in continuous 
glioma lines in this study; secondly, to assess the feasibility and value of routinely 
measuring SF2 Gy in human glioma biopsies as a possible additional prognostic 
factor.
It was considered that the SF2 estimations in primary and continuous cultures 
should be compared by identical endpoints. Technical problems were 
encountered in attempting to use the monolayer cloning technique as the 
experimental endpoint in primary culture, namely difficulties in distinguishing true 
clonal growth due to motility of the astrocytes on plastic. For this reason a 
semisolid agar cloning system was adopted . This obviously raises the question as 
to the direct comparibility of SF2 values using different experimental systems.
The mean SF 2 value observed in the 9 primary glioma cultures of 0.56 (SD 0.12) 
compared with a value of 0.68 ( SD0.11) for the 5 continuous lines. Ideally, a 
direct comparison of glioma cultures at different passage level would have used 
the same experimental system. An alternative approach would have been to 
assess the ranking of SF2 GY obtained in primary culture of a variety of human 
tumour cultures as well as glioma. West et al have compared the values obtained 
for their primary cervix cultures with primary colorectal and lymphocyte cultures to 
show that the mean values are significantly different for these 3 cell lineages. 
Given these limitations on this data, the values of SF2 for glioma appears to be 
higher than those observed in human cervix tumours ( mean SF2 0.47, SD 0.18), 
which is considered to be a more radiocurable tumour[Davidson e ta l, 1990 ].
A full technical evaluation of any proposed predictive test of response to radiation 
is required prior to attempts at clinical correlations. The stringency of this 
requirement is such that as yet only two laboratories have attempted to make any 
tentative correlations of in vitro radiosensitivity and clinical factors [West; Brock; 
unpublished data, Proceedings of 25th Paterson Symposium on Predictive 
Radiosensitivity testing, 1990].
These technical factors include sampling errors, reproducibility on repeat 
estimations, intra-tumour heterogeneity and interpatient variation. This study
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coincided with a trend in clinical practice towards limited biopsy of human glioma, 
thus reducing numbers of samples available and quantities of tumour. Within 
these constraints it has been possible to demonstrate that successful culture of 
primary glioma could be achieved in 80% of cases, and that viable cultures could 
usually be established in material stored in holding medium for up to 36 hours.
The cloning efficiencies (CFE) achieved in this study precluded generation of full 
radiation survival curves, with the emphasis on measurement of radiosensitivty at 
2 Gy. The CFE range of 0.01-4% are clearly much lower than continuous cultures 
but are comparable with those acheived by other groups working with primary 
tumour cloning systems. They represent a log increase on the mean values cited 
for primary glioma cultures in other labs, which may reflect the use of reduced 
oxygen tension. It is probable that the use of serum-free cloning with growth factor 
supplementation determined specifically for human glioma might significantly 
enhance cloning efficiency.
The intra-experimental variation in SF2 of 21% was considerably higher than 
observed in the continuous glioma cell lines but is comparable to that observed in 
other primary tumours. Of greater concern is that the inter- patient variation of 
25% observed in SF2 in this study would suggest that the predictive power of 
measuring SF2 in glioma is likely to be obscured by intra-experimental error using 
this system.
It is recognised that the potential for considerable selection occurs once a primary 
culture is established. Similarly, the time taken to acheive measurable clonal 
growth in these cell lines varied from 3-5 weeks. The ideal predictive 
radiosensitivity test would yield an answer enabling a ranking of relative 
radiosensitivity in an individual patient within days of biopsy, in order to guide 
choice of therapy or dose of radiation.
There is therefore increasing interest in developing assays such as MTT, using 
limited cell growth over periods such as a week [Price and McMillan, 1990 ], or 
subcellular endpoints such as DNA damage. The major objection to the use of 
growth assays has been the problem of fibroblast overgrowth in non-selective 
growth conditions. This is not considered to be a problem in primary monolayer 
cultures of glia. Combined with a more detailed evaluation of the growth 
requirements of human glioma, this approach might permit assessment of 
radiosensitivity more readily. A further theoretical attraction of this type of 'mass
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culture' system is the potential for cell-cell interaction more closely akin to a 
tumour. Whilst clonogenic growth has both practical and theoretical attractions as 
an experimental endpoint, the true relationship between tumour stem cells and 
cultured clonogenic cells is far from clear[Potten and Loeffler, 1990 ].
There is an increasing trend towards reporting human cellular radiosensitivity in 
terms of response to doses of radiation of clinical interest, namely, surviving 
fraction at 2 Gy. There are now a number studies addressing the predictive value 
of SF2 obtained in primary tumour cultures. Similarly, studies evaluating the 
population distribution of normal tissue radiosensitivity are also using the SF2 
parameter. A number of concerns have been expressed regarding the means by 
which such a measurement could be employed prospectively to individualise 
radiotherapy.
It is of concern that values of SF2 for tumours of a given histology are clearly 
dependent upon the passage level of culture studied, and the assay employed. 
This would matter less if the relative ranking of radiosensitivity was preserved 
irrespective of technique. There is evidence that this does not happen.Similarly, 
they appear to generate tumour control probability curves that are not in keeping 
with clinical experience.
It is hoped that refinement of primary culture requirements for cells of a specific 
lineage, together with development of assay systems based on subcellular 
endpoints, might permit a fuller evaluation of the true clinical value of prospective 
estimations of intrinsic radiosensitivity in individual patients.
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7.1. Establishment of an in vitro assay to assess DNA dsb rejoining in 
cell-free extracts: introduction and specific methods
There is considerable interest in the development of techniques refining the 
measurement of DNA dsb induction and repair. This is critical to the further 
evaluation of this class of lesions, and their precise relationship to the 
determination of cellular radiosensitivity.
An in vitro, cell-free assay has been established within this laboratory to 
evaluate the possibility that the molecular defect underlying the cellular 
radiosensitivity of mammalian cells expressing a radiosensitive phenotype 
might be a defect in the proficiency of DNA double strand break rejoining.
The development of this assay for the study of in vitro dsb rejoining proficiency 
in human tumour cell extracts and a comparison of the results obtained in 
extracts derived from radioresistant and radiosensitive cell lines was the final 
part of this studies undertaken for this thesis.
The detailed methodology of nuclear extract preparations, bacterial and 
plasmid DNA manipulations used in these studies is contained in Chapter 2.
7.1.1. Use of in vitro plasmid dsb rejoining to investigate mechanisms 
determining cellular radiosensitivity in the V79 irs mutants.
In vitro conditions favouring the rejoining of 2 types of cohesive termini of 
restriction digested plC20H had been established within the laboratory, using 
extracts derived from V79 and the ionising radiation sensitive mutant lines irs 1 
and 2. The work formed the Ph.D thesis of Jane Parker [Parker, 1991 ]. The 
main findings of the work were:
1) Nuclear extracts from the parental V79 line, and the mutant irs 1 were able to 
catalyse the rejoining of the dsb with equal efficiency and fidelity, as assessed 
by bacterial transformation by the plasmid DNA products of the in vitro 
rejoining reaction.
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2) Extracts of the irs 2 mutant were able to catalyse the formation of linear 
plasmid DNA to high molecular weight concatemers, as evidenced by Southern 
analysis, and examination of reaction products by electron microscopy, but 
appeared unable to mediate the formation of circular plasmid molecules.These 
irs 2 extracts did not therefore appear to be generally deficient in DNA ligation 
activity.This was confirmed by assay of the activity of DNA ligase I, and II in 
these extracts.
3) Reactions attempting to restore the irs 2 defect by mixing with extract from 
the parental V79 line gave evidence of biochemical complementation in vitro.
4) It was concluded that the ionising radiation- sensitive mutant of V79, irs 2 , 
was able to rejoin cohesive dsb in plasmid DNA, but appeared to be deficient 
in a protein activity necessary for the recircularisation and rejoining of 3' or 5' 
termini in double stranded plasmid DNA.
Pilot experiments using similar assay conditions to assess ligation activity in 
extracts of human cell lines had met with technical difficulties. The cell lines 
used were MRC5, an SV40 transformed 'normal' human fibroblast line, and 
AT5BIVA, an SV40 transformed fibroblast line derived from a homozygous 
ataxia telangectasia patient. Both plasmid Southern analysis and bacterial 
transformation suggested significant extract-mediated degradation of both 
uncut and linear plasmid substrates. It was postulated that excessive nuclease 
activity in both these cell lines might be attributed to SV 40 transformation.
Thacker ( personal communication) had encountered similar difficulties in a 
similar in vitro plasmid dsb rejoining study, using MRC5 and AT5 cell extracts. 
This had been circumvented by using an excess of linear plasmid DNA 
substrate to 'quench' excess nuclease activities in extracts, in order to assess 
plasmid rejoining fidelity in the remaining linear molecules. In adopting this 
approach, it is acknowledged that the 'effective' substrate available for rejoining 
might vary between cell extracts. However, as the primary objective was 
assessment of plasmid rejoin fidelity rather than extent, then this was 
considered to be acceptable.
7.1.2. Choice of cell fractionation for in vitro studies.
It was considered that the use of nuclear extracts rather than crude whole cell 
extracts might selectively examine the activity of proteins likely to be most 
immediately involved in DNA repair activities.
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The human tumour cell lines selected for study were:
1) Two radioresistant lines, the glioma lines SB18, and UK.
2) Two radiosensitive lines, the ovarian carcinoma A2780, and the 
neuroblastoma, SKHSH.
Given that the 4 cell lines under evaluation were non-isogenic, a system for the 
comparison of protein activities between lines was required. Nuclear proteins 
were evaluated by both biochemical estimation of total protein levels, and 
seeking evidence of preservation of a specified DNA binding function.
The synthetic oligonucleotide aP3A contains the mammalian consensus 
binding site recognition sequence, CCAAT, for the ubiquitously expressed 
mammalian CCAAT box binding protein [Plumb etal, 1989 ] Evidence of 
preservation of this specific mammalian DNA-protein binding activity was 
sought in extract preparations by use of a gel retardation assay.
; Only cell-free extracts demonstrating binding activity in this assay were used in
plasmid rejoining studies. It provided confirmatory evidence that nuclear extract 
preparations were yielding functional, non-degraded proteins. The details of 
nuclear extract preparation, and evaluation of protein activities are described 
fully in chapter 2.
I
i
7.1,3.Choice of plasmid substrates for DNA repair studies
The plasmid DNA molecule chosen for this assay was plC20H, a 2.7 kb 
recombinant DNA molecule containing 1 selectable bacterial gene, encoding 
ampicillin resistance, and the Lac Z gene [Marsh etal, 1984 ] .  A restriction 
map of the plasmid is shown in figure 7.1
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Figure 7.1. Restriction map of plasmid plC20H.
Taql
0
2.5
Bgll
0.5
plC20H
2.7kb Hae II2.0
on
Hae
Hae II
Multicbning site; 117 base pairs
AGCTTA AGCTT GAATTC
Hind illTCGCGAHind III EcoR 1
Nru 1
Restriction map of plC20H simplified from Marsh (1984)
Ori= origin of replication
Lac Z= iac Z gene with direction of transcription marked 
ApR= ampiclllin resistance gene
Selected restriction sites in mufticloning site shown, with recognition sequences
226
The polylinker region of this plasmid contains a number of single -cutting 
restriction sites enabling the production of a variety of dsb of differing structure 
eg. the restriction enzyme EcoR 1 is a 6 base cutter, generating 5' phosphoryl 
breaks with 4 overhanging bases , with the recognition sequence 5' AATT ; 
Nru 1 generates blunt termini, with the recognition sequence TCGCGA.
The plasmid contains both the regulatory sequences and coding information of 
the Lac Z gene. This encodes the production of the first 146 amino acids of 
the enzyme, p-galactosidase. The bacterial host chosen for this assay, the 
E.coli strain JM 83, possesses the carboxy terminus of p-galactosidase, and 
therefore complementation can occur by association of the two portions of the 
P-galactosidase protein. This renders the bacteria "Lac Z+”, and capable of 
hydrolysing the chromogenic substrate X-gal ( 5-bromo-4-chloro-3-indolyl-b-D- 
galactoside). If degradation or loss of sequence occurs in the plasmid portion 
of the LacZ gene as part of the ligation reaction , then no complementation can
I occur, and the bacterial colonies are white rather than blue. The integrity of the
Lac Z sequence and bacterial p-galactosidase activity forms the basis of the
I assessment of dsb 'repair fidelty' in this assay.
7.1.4. Choice of specific restriction endonuclease-induced substrates.
i
The plasmid DNA substrate for rejoining reactions was plC20H, digested by 
the restriction enzyme EcoR 1 to produce linear plasmid molecules with 
cohesive termini. This type of cohesive terminus was chosen based on the 
observation of significant mis-rejoining of this substrate by extracts of AT cells 
in Thacker's study. Similarly linear plasmid substrates with non-cohesive 
termini were produced by linearisation of the plasmid using the enzyme Nru 
1.
Both restriction enzymes have a single recognition site in the plasmid plC20H, 
situated within the multicloning site of the Lac Z gene, as indicated in figure 7.1.
Similar termini are likely to arise by the action of ionising radiation, either by 
direct action, or the interaction of two adjacent single stranded events. Such 
enzymatic DNA strand breaks might be "cleaner" biochemically than those 
resulting from ionising radiation damage, with intact 5' phosphate , and 3' 
hydroxyl groups at termini, suitable for religation without further enzymatic 
modification.
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Restriction endonuclease-induced DNA dsb are, however, capable of 
producing a similar spectrum of cell events consequent upon DNA damage, 
when used in permeabilised cells. These include chromosomal aberrations , 
and subsequent cell death, as discussed in Chapter 1.
7.1.5. Choice of plasmid DNA dsb rejoining reaction conditions.
A preliminary part of this study was to establish the ligation conditions in which 
plasmid dsb rejoining could be observed using human tumour cell extracts. 
Variables to be considered included:
1) Total linear plasmid DNA concentration per reaction.
2) Reaction total volume to favour intra-molecular plasmid rejoining activity.
3) Ligation buffer cation and energy requirements.
4) Reaction temperature.
5) Reaction time course.
The reaction protocol is depicted graphically in figure 7.2.
A major objective of the assays was to enable an assessment of the fidelity of 
rejoining of the double strand break. This was to be evaluated by the 
expression of the Lac Z gene in transformed bacteria. Reaction conditions were 
therefore required which favoured recircularisation of each linear plasmid 
molecule, rather than end to end rejoining of adjacent molecules to form high 
molecular weight concatemers, as the latter molecular forms are not efficient in 
bacterial transformation.
The total plasmid concentration used was a two-fold increase over that used in 
studies with the V79 lines, to 100ng in a final volume of 350pl. This represents 
a final concentration of DNA likely to favour intra-molecular end rejoining, 
rather than intermolecular ligation.
The equation of Dugaiczyk was used to derive these conditions, which enables 
a concentration of 'free' linear ends to be calculated which favours a 
significantly higher probability of intra-molecular recircularisation, rather than 
formation of concatemers.The ratio of cyclized to concatemeric ligation 
products depends on two parameters, /, and /. J is the effective concentration 
of one end of a DNA molecule in the neighbourhood of the other end of the 
same molecule. J is therefore inversely porportional to the length of the
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molecule, a constant for a given DNA molecule, and independent of 
concentration.
3/2
J = 2
2k lb
where I i s the length of DNA in centimeters, and b the length of a randomly 
coiled segment of DNA. b is dependent on the ionic strength of the buffer, 
determining DNA rigidity.
/ is a measure of complementary termini in the solution and is specificed by
i = 2 N0M x 10 ~3 ends/ml
where No is Avogadro’s number and M is the molar concentration of DNA.
i
When j  > i intramolecular recircularisation is favoured over linear 
concatemerisation.
i
Using this formula, a j / i  ratio was calculated for the plC20H plasmid DNA 
which determined that a DNA concentration of less than 14|ig / per 350pl 
should favour such a rejoining activity [Dugaiczyk etal, 1975 ].
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Figure 7.2. In vitro plasmid rejoining protocol
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A further measure taken to minimise end to end rejoining was the specific 
omission of polyethylene glycol (PEG) from the ligation buffer. This is used to 
promote T4 ligase reactions, especially of blunt termini, as it increases 
nonenzymic cohesion of termini by macromolecular crowding. Even at such 
low plasmid DNA concentrations it may have favoured intermolecular rejoining 
events [Zimmerman and Harrison, 1985 ].
The ionic conditions were adopted empirically from the observations using V79 
extracts in this type of assay [Parker, 1991]. In choosing buffer conditions the 
requirements of many DNA ligase systems, including T4, E.coli, and 
mammalian DNA ligase, for divalent cations such as Mg2+> and ATP were 
observed [Lindahl, 1982 ].
Unless stated otherwise, dsb rejoining reactions were carried out at 14° C, 
overnight, with the following conditions:
A reaction was set up in a final volume 350pl, containing
1) plC20H plasmid DNA ; 100ng of cut or uncut substrate
2) 70 pi of 5x ligation buffer, containing 250mM Tris-HCL, 5mM ATP , 50mM 
MgCl2, and 5mM DTT.
Varying amounts of nuclear extract were added in storage buffer, containing 
50mM NaCI, 5mM MgCI2,20% glycerol, at pH 7.9. The final reaction volume 
was taken to 350pl using storage buffer, to ensure that the final plasmid DNA 
substrate concentration was constant.
The reaction was halted by the addition of an equal volume of phenol and 
plasmid DNA was then recovered as described in Chapter 2 , section 2.5.
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The following controls reactions were included in each experiment:
Substrate Treatment
1) Uncut plC20H:
2) Uncut plC20H + tumour nuclear extract
3) Uncut plC20H + tumour nuclear extract, 
boiled for 15mins.
4) Uncut plC20H +1pl T4 ligase
5) EcoRlor Nru 1 cut plC20H
6) EcoR1 or Nru 1 cut plC20H +1pl T4 ligase
7) EcoR1 or Nru 1 cut plC20H + boiled extract
The temperature conditions selected necessitated a balance between that 
required for optimal rejoining activity, and the possibility of thermal 
destabilisation of any pre-ligation complexes formed by proteins and plasmid 
DNA in aqueous solution. Both mammalian DNA ligase I and II are active at 14° 
C, and T4 ligase reactions are frequently conducted at 14° C, therefore this 
temperature was routinely used.
A preliminary assessment of comparative plasmid rejoining activity by an 
extract of the glioma cell line, UK, was conducted at 4,14 and 37° C.
Significant rejoining over background was noted at 14° C. No activity over 
background was observed at 4°C, and a reduction in activity was noted at 37° 
C, by comparison with the 14 C samples. Further reactions were therefore 
carried out at 14° C.
The time course of plasmid rejoining activity of all 4 human tumour cell line 
extracts was examined in pilot studies, (data not presented). All exhibited a 
similar pattern of activity. Maximal rejoining activity was obtained by overnight 
ligation reactions at 14°C, though 90% of the maximal activity had been 
established by 4 hours.
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7.1.6.Use of bacterial genetics to assess plasmid DNA rejoining.
The objective of the in vitro rejoining assay was to permit an assessment of 
both the extent and accuracy of rejoining of plasmid molecules mediated by 
the nuclear extracts derived from human tumour cells. The choice of the 
plasmid plC20 H , containing 2 bacterial genes, permitted the use of bacterial 
genetics to achieve these objectives.
Following appropriate temperature and ionic manipulations, strains of E.coli can 
be made "competent' to take up plasmid DNA, with a preference for circular 
molecules rather than linear DNA forms. After an appropriate expression time, 
the plasmid encoded genes are transcribed within the bacteria, altering its 
phenotype, a process known as bacterial transformation.
Selective bacterial growth media containing ampicillin then permit only 
bacterial colony formation in those bacteria transformed by the plasmid- 
encoded ampicillin resistance gene.
In the context of this assay, the expression of plasmid -encoded ampicillin 
resistance was interpreted as a marker of bacterial transformation by a 
recircularised plasmid molecule ie. the dsb forming the termini of restriction 
digested plasmid had been rejoined. The number of such ampicillin resistant 
E.coli per unit plasmid was therefore a measure of the extent of linear plC20H 
rejoining.
The EcoR 1 and Nru I plasmid restriction digests used in this study were 
sited within the second bacterial gene, the Lac Z gene as displayed in fig.7.1 
Hence expression of the Lac Z gene within ampicillin resistant colonies , 
detected by the generation of blue colonies on X-gal media, signified 
preservation of sequence at the restriction site during rejoining. The 
appearance of blue, LacZ+, Amp+ colonies was then interpreted as evidence of 
accurate plasmid DSB rejoining. White bacterial colonies resulted from 
expression of an Amp+, LacZ- phenotype in bacteria having incorporated 
rejoined plasmid in which the Lac Z was inactivated, ie. rejoining of termini 
located within this gene had occurred with loss of sequence.
Bacterial transformation procedures, and use of selective culture techniques is 
described in Chapter 2, section 2.5.
233
7.1.7. Choice of bacterial host for transformation studies.
The bacterial host used for these studies was the E.coli strain JM 83 [Yanisch- 
Perron etal, 1985 ]. The choice of this strain was based on its possession of 
the C-terminal portion of the lacZ gene; this was necessary for 
complementation of the Lac Z gene encoded within plC20H. The Rec A 
recombination pathway has been inactivated in this strain, therefore it is also 
partially lacking in recombinational activity.
7.1.8. Experimental objectives.
The experimental objectives of this part of the study were:
1) To prepare nuclear protein extracts from 4 human tumour cell lines. Two 
radioresistant tumours were selected, the glioma lines SB18, and UK. The two 
radiosensitive lines were A2780, the ovarian carcinoma line, and the 
neuroblastoma SKNSH.
2) To assess the functional protein activity of these extracts, and decide a 
means of comparison of activity in extracts derived from non-isogenic cell 
lines.
3) To establish the conditions needed to observe ligation activity in these 
extracts, specifically the time course of rejoining activity, and temperature 
dependence of the reaction.
4)To establish and minimise the major sources of experimental error, and thus 
modify the assay to permit quantitative assessment of DNA dsb rejoining 
events.
5) To compare both the extent and fidelity of rejoining of endonuclease-induced 
plasmid dsb in nuclear extracts prepared from the 4 human tumour cell lines.
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7.2 Results
7.2.1. DNA binding activity of human tumour extracts
The DNA binding activity of ubiquitously expressed CCAAT binding protein 
was used to check that extracts had preserved protein function during 
preparation.
Specific binding by functional proteins was observed in nuclear extracts derived 
from all 4 human tumour lines examined. These included two radioresistant 
human glioma cell lines, SB18, and UK, together with two radiosensitive lines, 
A2780, and IMR 32.
A gel retard analysis of the nuclear extracts used in this study is shown in 
figure
7.-3. The protein activity of the extract produces a complex with the CCAAT 
binding sequence in the aP3A radiolabelled molecule. It is shown that these 
complexes are slowed or 'retarded' in their migration through the gel by 
comparison with uncomplexed radiolabelled aP3A. The specific nature of the 
binding is demonstrated by the ability of excess unlabelled aP3A to abolish the 
formation of these complexes.
The white arrow shows the position of migration of free radiolabelled aP3a, 
unretarded by complexing with tumour proteins.
Lanes 1 ,3, and 5 contain aP3a/tumour protein complexes, slowed in migration 
relative to free aP3a. Lanes are labelled in the figure to indicate the tumour 
origin of each extract.
Lanes 2,4, and 6 illustrate the ability of an excess of cold aP3a, present in the 
pre-electrophoresis incubation, to compete for specific protein binding activity in 
each of the tumour extracts, thus reducing or eliminating the extent of formation 
of specific complexes with aP3a. It is noted that the UK extract shown in this 
plate had high aP3a binding activity that was not completely eliminated by the 
amount of cold aP3a added, (lane 6)
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The intensity of the highest molecular weight oligonucleotide/ tumour protein 
complex formed was found to correlate well with the total protein concentration 
measured in each extract by Biorad assay.
Such activity was demonstrated in all extracts prior to use in ligation reactions; 
those not active by this criteria were discarded.
Figure 7.3 Gel retard analysis of specific binding of cell extract proteins and 
the CCAAT consensus sequence in the a P3A oligonucleotide.
GATCCAAACCAG CCAAT GAGAACTGCGCCA
1 2 3 4 5 6
■
Black arrows=position of migration of radiolabelled oligonucleotide/ tumour protein complexes 
White arrow= position of migration of free radiolabelled oligonucleotide
lane 1= a P3a+ A2780 tumour extract
lane 2=a P3a+ A2780 tumour extract+ excess “cold” a P3a
lane 3= a P3a+ IMR32 tumour extract
lane 4= a P3a+ IMR32 tumour extract+ excess “cold" a P3a
lane 5= a P3a+ UK tumour extract
lane 6=a P3a+ UK tumour extract* excess “cold” a P3a
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Evidence for the rejoining of plasmid DNA double strand breaks by 
human cell extracts.
7.2.2.. Electron microscopy of plasmid DNA ligation products.
Figure 7.4 demonstrates a transmission electron micrograph of
a) EcoR1 digested linear plC20H substrate, untreated by extract.
b) EcoR1 digested plC20H treated by T4 ligase ie a 'positive' control sample;
c) +d) EcoR1 digested plC20H, incubated with 5pg of nuclear extract, SB18.
It demonstrates that restriction digested substrate was formed predominantly of 
linear forms, and that such a substrate was a suitable molecule for rejoining of 
cohesive dsb by either purified T4 ligase activity, or the protein activity of 
nuclear extracts.
Extract-mediated formation of circular plasmid molecules as depicted in panels 
(c), and (d ), gave visual evidence of the capacity of extracts to rejoin the 
restriction-induced dsb by the conversion of linear substate to circular plasmid 
forms.
The size of the plasmid molecules was assessed by digitaliser, and confirmed 
to be compatible with a 2.7Kb molecule ie. no measurable loss of DNA 
appeared to result from treatment of linear plC20H by incubation with extract. 
This observation is in keeping with bacterial transformation data, in which less 
than 1% of most bacterial colonies failed to express the LacZ gene, ie rejoining 
of ends had occurred accurately, without loss of sequence.
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F ig u re  7.4. E lectron m ic rograph  of plC20H test and contro l l iga t io n
p ro d u c ts .
& a m
0.2pm
a) E co R I cut p lC 20H  p lasm id  DNA b) EcoR1 cut p lC 20  H trea ted  w ith  T4 ligase 
c).d) E coR I cut p lC 20H  to llow ing incubation w ith 5pg  SB 18 tum ou r p ro te ins
Table 7.1 shows a representative count of the relative numbers of linear and 
circular plasmid forms, performed on 1000 molecules in 3 independent 
preparations.
Table 7.1 Electron microscopy of plC20H ligation products
Plasmid form EcoRI cut T4 ligase +ve C ^Extract
Monomer circles 2% 98% 87.5%
Monomer linears 98% 1% 11%
Dimer circles — 0.5% 0.4%
Dimer linears — 0.5% 0.9%
Extract= SB 18 ligation products
Percentages are based on counts of 1000 molecules per reaction, on three 
independent samples.
7.2.3. Bacterial transformation by plC20H plasmid, post incubatipn with 
nuclear extracts.
7.2.3.1 .Control rejoining reactions
Prior to experimental ligation reactions, two specific procedures were carried 
out. Firstly, the ability of the substrate to be religated by phage T4 (gjase was 
examined. Secondly, the 'background' level of non-linearised plC20H molecules 
following restriction digests was assessed. 100ng aliquots of cohesive and 
blunt plC20H digests were incubated with 1pl of phage T4 ligase for 11 hour at 
37° C, in a final volume of 350|il, using the ligation buffer without PECS . Aliquots 
of this ligation reaction were then used to transform competent JM83 lE.coli as 
described in section 2.2.6.2.
Control,uncut plC20H transformations yielded ampicillin-resistant, X-gjal 
positive bacterial colonies on agar plates containing both ampicillin anid X-gal.
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This provided an estimate of the efficiency of bacterial transformation per unit 
uncut plasmid DNA, as a result of incorporation of intact, circular plasmid DNA 
by bacteria. This was compared with the ’background" number of such colonies 
resulting from a residual, undigested population of plasmid molecules in the 
EcoRI and Nru I substrates.
Table 7.2. Evaluation of background transformation by "cut "plC20H 
substrates, and suitability for religation.
Substrate Treatment X exonuclease Ampicillin resistant
digestion bacterial colonies per
ng DNA
Uncut plC20H 1157+ /-228  (4)
Uncut plC20H + 1|iil X exonuclease 1297+ /-323  (4)
EcoRI digested 2+/- 1.46 (4)
plC20H
EcoRI digested + 1|llI X exonuclease 0.4 +/- 0.3 ( 4)
plC20H
EcoRI
v«
+ 1^ .1 T4 ligase 115 +/- 18(4)
EcoRI + 1^ 1 T4 ligase + 1|xl A, exonuclease 109 + /-12  (4)
Nru 1 9 .6 + /-4 .2  (3)
Nru 1 + 1(4.1 A. exonuclease 0.8 +/- 0.3 (3)
Nru 1 + 1|j.l T4 ligase 61 + /-18  (3)
Nru 1 + 1n.l T4 ligase + 1|il A, exonuclease 77+ /-21  (3)
The bacterial transformation arising from the EcoRI plC20H substrate could 
represent either a proportion of uncut molecules following restriction digestion, 
or alternatively, the rejoining activity of the JM 83 E.coli.
To test this hypothesis aliquots of uncut,EcoRI cut, and Nru 1 cut plC20H 
were incubated with 1pl of lambda exonuclease with appropriate buffer, prior to
241
bacterial transformation. This enzyme digests linear plasmid DNA therefore 
removes all linear molecules, but does not cut circular plasmid DNA.
It is shown that both EcoRI and Nru 1 substrates have a reduced bacterial 
transformation frequency following X exonuclease treatment, but there was no 
reduction in the transformation by uncut or T4 ligated products. It was therefore 
likely that the a finite level of recircularisation of the cut plasmid substrate was 
achieved by the bacterial host. However, it was decided that this activity would 
be unlikely to obscure significant rejoining activity in cell extracts. Lamda 
exonuclease treatment of test ligation products was not therefore routinely 
undertaken, to minimise plasmid DNA handling after ligation reactions.
In conclusion it was observed that:
1) Both Ecorl and Nru 1 digests of plC20H were suitable substrates for ligation 
to circular forms capable of transforming JM83 bacteria, with expression of the 
Lac Z gene.
2) A background level of uncut molecules in both substrates or bacterial 
rejoining activity would not preclude their use for test ligation assays.
7.2.3.2.Extent of rejoining of endonuclease induced DSB by human 
tumour extracts.
Quantitative evidence of rejoining of endonuclease induced dsb was assessed 
by the ability of rejoined plC20H to transform competent JM83 E.coli, thus 
producing an ampicillin resistant phenotype in the bacteria, due to incorporation 
and expression of the plasmid encoded ampicillin resistance gene. The extent 
of rejoining was expressed as the number of ampicillin resistant colonies 
growing on agar containing ampicillin. per ng of initial cut plasmid. The ability of 
plasmid DNA to transform bacterial phenotype was interpreted as evidence of 
ligation of cut plasmid molecules to regenerate circular forms.
Data has been pooled from ligation experiments using 3 independent tumour 
extracts on each of the 4 human tumours studied, to obtain values for maximal 
rejoining activity. Results were normalised within and between each 
experiment for variations in plasmid DNA recovery, bacterial viability and 
competence. This was achieved by correcting the number of ampicillin 
resistant colonies in each test plate for the number of kanamycin resistant 
colonies produced by the internal control pHSG 272 co-transformation.
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Table 7.3 Maximal bacterial transformation per 40na plC20H substrate
Substrate Treatment Bacterial colonies/ 
40ng plasmid DNA
plC20H uncut 53,260+/-11,680 (12)a
plC20H EcoRI cut 13 + /-9 .8  (12)
plC20H EcoRI cut + T4 ligase 4720+ /-760  (12)
plC20H EcoRI cut +SB 18 extract (3)^ 781 +/- 341
plC20H EcoRI cut +IJK extract (3) 1760+ /-695
plC20H EcoRI cut + IMR32 extract (3) 1002+ /-760
plC20H EcoRI cut +A2780 extract (3) 804 +/- 427
plC20H Nru 1 cut 247 +/- 53
plC20H Nru 1 cut + T4 ligase 2659 +/- 606
plC20H Nru 1 cut + UK extract (1) 2 1 7 + /-4 2
PIC20H Nru 1 cut + IMR 32 extract (1) 254 + /-51
Bacterial colonies are expressed as the number of ampicillin resistant bacterial colonies per 40 
ng plasmid DNA:; this aliquot of the inital 100ng plasmid DNA used in the rejoining reaction 
was routinely used for bacterial transformations.
Values for EcoRI cut plasmid are means of the maximal activity observed in 3 independent 
extract preparations on each cell line, with standard error of means.
Values for Nru 1cut plasmid are mean and SEM for 3 independent ligations using 1 extract 
preparation of each cell line.
a)= number of independent ligations
b) =number of independent nuclear extract preparations
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Nuclear extracts prepared from the four human tumours examined were able to 
catalyse the conversion of EcoRI cut plasmid to molecules capable of 
transforming JM 83 to an ampicillin resistant phenotype. Significant activity 
over background (ie. EcoRI cut plasmid) was obtained in extracts from all 4 cell 
lines. The maximal number of ampicillin resistant colonies obtained following 
all nuclear extract treatments was substantially reduced when compared with 
the results of simple ligation by T4 ligase. Boiling nuclear extracts abolished the 
formation of plasmid molecules capable of bacterial transformation, with no 
significant increase in bacterial colonies compared with that obtained by EcoRI 
cut plasmid alone.
Maximal bacterial colony numbers were corrected for variation in bacterial 
competence between experiments. Substantial variation in maximal 
transforming activity was observed between replicate extract preparations on 
the same cell line. Efficiency of maximal rejoining achieved by replicate extracts 
on each of the 4 cell lines was compared by analysis of variance. No 
significant difference was observed in maximal bacterial transformation by the 
products of EcoRI cut plasmid ligations obtained in extracts of the 4 tumour 
lines.
By contrast, no significant bacterial transformation over background was 
detected when the ligation reaction products of Nru 1 cut plasmid (blunt termini) 
treated by an extract of either the radioresistant glioma, UK, or the 
radiosensitive neuroblastoma, IMR32 were used to transform JM83 E.coli. The 
extracts used had significant activity as evidenced by the production of 
transformed bacteria after incubation with EcoRI cut plasmid. The lack of 
bacterial transformation by the reaction products of Nru 1 cut plasmid and both 
UK and IMR32 extracts was suggestive of reduced ability of these extracts to 
rejoin blunt termini to yield a circular plasmid form capable of bacterial 
transformation.
7.2.3.3.Protein concentration dependence of bacterial transformation.
The ability of nuclear protein extracts of each of the 4 human tumours to rejoin 
EcoRI cut plC20H in a concentration dependent manner was examined, by 
varying the total extract protein added to a ligation reaction. The activity of
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each extract was examined over the range of 0.1-200 jigs, ie approximately 3 
logs of variation in total protein concentration. When plasmid DNA recovered 
from ligation reactions was used to transform competent JM 83 E.coli, a 'dose- 
response' was observed, as evidenced by increasing numbers of transformed , 
ampicillin-resistant bacteria per 40ng plasmid.
Data obtained on 3 independent extracts from each of the 4 human tumour 
lines is shown in figures 7- 6-9.
Values represent the mean and standard deviation of the number of ampicillin 
resistant bacteria obtained per 40 ng plasmid substrate DNA. Values were 
corrected within an experiment on each extract for relative numbers of 
kanamycin resistant bacteria per replicate.
In all 4 human tumour extracts the number of ampicillin resistant colonies 
obtained increased over background with the amount of protein extract added, 
finally reaching a plateau. In the case of SB18 extract 2, and IMR32 extract 2, 
an initial increase in bacterial transformation with increasing extract protein 
was followed by a subsequent decrease in transformation, rather than a 
plateau.
Replicate extract preparations on the same cell line displayed activity over 
differing total protein ranges.
245
Fig
ur
e 
7.5
. 
M
ax
im
al
 
ba
ct
er
ia
l 
tra
ns
fo
rm
at
io
n 
fo
r 
pl
C2
0 
H 
su
bs
tr
at
es
SCUM* l nJN
>lf!n ruN
ese&i ^1+ i niN
ino i. njfsi HOSOld
08Z2V+l-dOO3
3edWI+iy«>3
>in+i.yoo3
8t9S+m003
ese6j| t±+ lyoog
lyooa HOSOld
jnoun H03Old
VNQ P!Luse|d 6uoWS9!u° l° °  |e|je*oeq
ba
ct
er
ia
l 
co
lo
nl
es
/4
0n
g 
pl
as
m
id
 
DN
A 
ba
ct
er
ia
l 
co
lo
nl
es
/4
0n
g 
pl
as
m
id
 
DN
A 
ba
ct
er
ia
l 
co
lo
nl
es
/4
0n
g 
pl
as
m
id
 
D
N
A
Figure 7.6 Dose dependent increase in bacterial transformation: SB 18
extracts
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Figure 7.7 Dose dependent increase in bacterial transformation: UK extracts
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Figure 7.8 Dose dependent increase in bacterial transformation:IMR
32extracts
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Figure 7.9 Dose dependent increase in bacterial transformation: A2780
extracts
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7.2.3.4.Fidelity of rejoining of EcoR1 cut plC20H substrate.
The fidelity of the plasmid rejoining process was assessed by the ability of 
transformed bacteria to express the Lac Z gene, as evidenced by p- 
galactosidase activity. This was detected by the production of blue bacterial 
colonies on agar plates containing X-gal. Only those EcoR1 cut plasmid 
molecules rejoined accurately would be capable of expressing the Lac Z gene. 
Hence the proportion of total ampicillin resistant bacterial colonies that were 
blue was a measure of the fidelity of the rejoining of the endonuclease-induced 
double strand break. Those endonuclease dsb rejoined with loss of information 
would result in in activation of the Lac Z gene, and the production of white 
colonies.
The fidelity of plasmid rejoining was high in tumour extracts of all 4 cell lines, 
with the proportion of white colonies varying between 0.75-0.94% of the total 
bacterial colony number. The results obtained for rejoining of the EcoR1 cut 
plasmid are shown in table 7.4, and figure 7.10. A Students t-test was then 
used to test the hypothesis that fidelity of rejoining did not differ significantly 
between radiosensitive (IMR 32, A2780), and radioresistant (SB18,IJK) cell 
lines. Differences between means for the 2 groups of cell lines did not reach 
statistical significance (p=0.5).
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Table 7.4. EcoR1-cut plasmid misrejoining following treatment with 
human tumour nuclear extracts.
Cell line Extract Total white Total blue % misrejoined
colonies colonies
A2780 1 43 6246 0.7
2 29 2367 1.2
3 27 7647 0.35
mean+SE 0.75 (0.24)
IMR32 1 58 9030 0.63
2 81 9323 0.86
3 93 10349 0.89
mean+SE 0.79 (0.08)
SB 18 1 107 12685 0.83
2 22 4682 0.47
3 48 3351 1.4
mean+SE 0.9 (0.27)
UK 1 63 3534 1.7
2 34 4964 0.68
3 181 39905 0.45
mean+SE 0.94 (0.38)
Number of colonies for each independent extract represent crude numbers 
pooled from multiple experiments, uncorrected for inter-experimental 
variations in bacterial competence.
251
Figure 7.10 Misrepair events in rejoining of EcoR1 cut plC20H by human 
cell extracts
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Results are depicted for 3 independent extract preparations on each of the 4 human tumour 
lines studied.
Total = number of ampicillin resistant bacterial colonies obtained in multiple experiments on 
given extract preparation
white = number of ampicillin resistant, Lac Z- bacterial colonies obtained for given extract 
preparation
I  total 
□  white
1 2 3 6 7 8 11 12 13 16 17 18
SB 18 IJK IMR 32 A2780
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7.2.4 Visualisation of plC20H ligation products by Southern analysis.
The plasmid products of control and test ligation reactions were separated by 
gel electrophoresis, and blotted to nitrocellulose filters, prior to probing with 
radiolabelled plC20H, as described in section 2.2.5.1.
7.2.4.1 .Effect on tumour nuclear extracts on uncut plasmid.
Figure 7.11 shows a Southern blot containing the reaction products of 
incubating 100ng uncut plC20H with extracts derived from the glioma 
line,SB18, and the neuroblastoma line,IMR32.
Lane M contains the 1 Kb ladder markers. Lanes 2-7 were loaded with 10ng of 
plasmid DNA.
Lane 1 shows the positions of migration of the 3 predominant forms contained 
within uncut plC20H. The fastest form is labelled SCM, and represents the 
position of migration of monomeric supercoiled, closed circular plasmid. The 
second major form is labelled 'rc+lin'; this position marked the migration of both 
relaxed circular plasmid, and linear plasmid following digestion. The third band 
is marked 'dsc' and contains dimeric supercoiled circular forms. Further 
multimeric circular forms are seen as high molecular weight bands.
Lanes 2 and 3 illustrates the action of an extract derived from SB 18 ; extract 
was added to a 100ng uncut plasmid incubation at 2 protein levels, 10pg and 
20|ig total protein in lane 2 and 3 respectively. The major findings were that 
new bands appeared, labelled with small arrows, thought to represent 
topoisomerase-like activity in the tumour extract, causing unwinding of 
supercoiled monomer and dimer circles. No obvious degradation of plasmid 
DNA had occurred in overnight incubations with extract.
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Figure 7.11. Southern blot of plC20H DNA; effect of tumour 
extracts on uncut plasmid
M 1 2 3 4 5 6 7
DSC ► 
RC+lin
scm -►
4
Filter has been probed with nick-translated, 32P labelled plC20H plasmid DNA.
M = 1 Kb ladder
SCM = position of m igration of m onom eric ,superco iled , c ircu la r p lC 2 0 H  D N A
RC +LIN  = position of m igration of linear and relaxed c ircu la r p lC 2 0 H  
DSC = dimeric circular plC20H
4  = positions of migration of partia lly  unw ound su pe rco iled  p la sm id
Lanes 1-7 w ere each loaded w ith 10ng of p lC20H plasm id, fo llow ing  in cuba tion  of p lasm id  w ith  
extracts
1= 10ng o funcut p lC20H alone
2= " "+ 10 pg SB18 extract prote in
3= " ”+ 20pg SB 18 "
4= " "+ 10 pg IMR 32
5= " ''+20 pg IMR32 "
6 = " "+10pg boiled SB 18 "
7= " "+10pg boiled IMR32
254
Lanes 4 and 5 demonstrate the effect of 10 and 20pg protein extract from 
IMR32 on uncut plasmid. In this extract the topoisomerase-like action was 
sufficient to cause disappearance of the dimeric supercoiled form, and a 
significant reduction in the monomer supercoiled molecules. Again, no 
smearing of DNA was detected, suggesting little degradation of the plasmid 
molecule by extract.
Lane 6 and 7 illustrate that boiling of both SB18 and IMR32 extracts prior to 
incubation with uncut plasmid abolished the unwinding activity on supercoiled 
forms, suggesting that the activity was an active protein function.
Control incubations of uncut plasmid with extracts derived from all 4 cell lines, 
SB18, UK, IMR32, and A2780 were all noted to produce similar results, 
namely, no evidence of plasmid degradation, and variable topoisomerase-like 
unwinding of supercoiled plasmid. Lack of plasmid degradation by these 
extracts enabled the use of relatively low plasmid concentrations in 
experimental ligations.
Effect of tumour nuclear extracts on EcoR1 cut plC20H.
Tumour extracts prepared from all 4 human cell lines studied were able to 
catalyse the rejoining of linear plC20H molecules, as evidenced by the 
appearance of bands migrating in the same position as supercoiled circular 
control DNA.
Figure 7.12 shows the position of migration of
1) Uncut plC20H
2) Linear, EcoR1 cut plC20H substrate
3) Positive ligation control; T4 ligase treated linear plC20H
4) EcoR1 cut plC20H, incubated with 20|ig of SB18 nuclear proteins 
5,6,7) Replicates of EcoR1 cut plC20H, incubated with 20|ig of V79 hamster 
nuclear proteins
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Figure 7.12 Southern blot of plC20H DNA; linear plasmid, T4 positive 
control, and products of human glioma SB18 , and hamster V79 reaction 
products.
1 2 3 4 5 6 7
W
HC
DSC-*-
RC+LIN
SCM'
Filter has been probed with nick-translated. 32P labelled plC20H plasmid DNA
w position ot wells
SCM = supercoiled monomenc circular plasmid
RC+LIN = relaxed circular, and linear plasmid
DSC = dimer supercoiled circular plasmid
HC high molecular weight concatemers
1 10ng of uncut plC20H
2 10ng ot linear, EcoR1 cut plC20H substrate
3 lOng of positive ligation control. T4 ligase treated linear plC20H
4 10ngof EcoR1 cut plC20H, incubated with 20pg of SB 18 nuclear
proteins
5.6,7 = 10ng replicates of EcoR1 cut plC20H, incubated with 20pg of V79
hamster nuclear proteins
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This figure demonstrates that the EcoR1 digested substrate appeared to 
contain no residual supercoiled, circular molecules (lane 2), and therefore the 
reappearance of a plasmid DNA form migrating at this position must represent 
the effect of tumour extract mediated rejoining activity.
Lane 3 illustrates the effect of T4 ligase on EcoR1 cut plasmid, namely, the 
conversion of linear molecules to supercoiled circular forms. This finding is in 
keeping with electron microscopy and bacterial transformation data.
Lanes 4 by comparison with 5,6, and 7 illustrate the quite dissimilar effects on 
linear plC20H, of extracts derived from human and V79 hamster lines. Lane 4 
contains a 10ng aliquot of the plasmid products of an overnight incubation of 
100ng of EcoR1 cut plC20H, with 20jig of SB18 (human glioma) extract. Lanes 
5. 6, and 7 each contain a similar quantity of the ligation products of incubating 
100ng EcoR1 digested plasmid with 20pg of V79 extract. The human tumour 
extract mediated the formation of a plasmid form migrating at the position of 
supercoiled circular DNA, suggestive of rejoining of the linear plasmid to a 
circular form. By contrast, the V79 hamster extract has converted the linear 
substrate to high molecular weight forms, with very little evidence of 
hybridisation at the position of supercoiled circular DNA. None of the 4 different 
human tumour extracts examined in ligation reactions showed any evidence of 
formation of high molecular weight forms.
As the relaxed circular form of plC20H migrates at a similar position to its linear 
form, it was not possible to monitor the formation of this type of product by 
Southern analysis. Running gels with ethidium bromide did not aid separation 
of these forms.
A dose-response relationship was sought for each tumour extract investigated 
by examining the effect of adding variable amounts of extract protein to a fixed 
amount of linear plC20H substrate(1 OOng). Total extract protein concentrations 
were varied over the range 100ng to 200jig per 350ml reaction volume, ie a 
range in excess of 3 logs. At the maximum protein concentrations examined, in 
which a plateau of bacterial transformation had been reached , some residual 
DNA was always observed migrating in the same position of linear/ relaxed 
circular plasmid. It is probable that residual plasmid DNA migrating in this 
position represented a combination of successfully ligated, relaxed circular 
DNA, as well as some linear molecules which had been degraded by extract 
activity , and were not suitable for ligation.
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Figure 7.13 illustrates the effect of incubating varying amounts of nuclear 
protein derived from the glioma SB18, with a fixed amount (100ng) of EcoR1 
cut plC20H linear substrate.Lanes 5 to 10 contain the plasmid products of 
reactions between ECoR1 cut plasmid and added nuclear protein levels 
varying from 100ng to 100|ig This blot demonstrates the ability of active 
extract proteins to catalyse the formation of a fast migrating plasmid form. This 
is compatible with rejoining of linear plasmid to reconstitute a supercoiled, 
circular molecule. The effect of boiling extracts prior to addition to the ligation 
reaction can be seen to produce no fast forms.(lanes2-4).
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7.13. Southern blot of plC20H DNA; protein concentration dependent 
increase in formation of rejoined plasmid by tumour extract SB18.
LIN^>
SQM-*-
M 1 ? 3 4 5 6 7 8 9  10
M = size m arkers
SCM = position of m igration of monom eric, supercoiled p lC 2 0 H
LIN = position of m igration of linear plC20H (and relaxed c ircu la r DNA)
lanes 1-10 were loaded w ith 10 ng of p lC 20H , follow ing incubation w ith  extracts
1= EcoR1 cut p lC 20H  alone
2= EcoR1 cut p lC 20H  + 500ng boiled SB 18 protein
3= EcoR1 cut p lC 20H  + 1pg boiled SB18 protein
4= EcoR1 cut p lC 20H  + 10pg boiled SB 18 protein
5= EcoR1 cut p lC20H + 100ng SB18 protein
6= EcoRI cut p lC 20H  + 200ng SB 18 protein
7= EcoR1 cut p lC20H + 500ngS B 18  protein
8= EcoR1 cut p lC20H + Ip g  SB18 protein
9= EcoRI cut p lC20H + lOpg SB 18 protein
10= EcoRI cut p lC 20H  + 100pg SB 18 protein
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Figure 7.14. Southern blot of plC20H reaction products; effect of incubation 
with tumour extract IMR32
1 2 3 4 5 6
DSC
RC+lin
SCM
Filter has been probed with nick-translated, 32P labelled plC20H plasmid DNA.
Each lane is loaded with 10ng plC20H plasmid ligation reaction products
sc= position of migration of supercoiled, circular plC20H DNA
Lln+rc= position of migration of both residual linear, and relaxed circular plC20H
dsc= dimer supercoiled plasmid
Lane 1= 10ng uncut plC20H
Lane 2= EcoRI cut plC20H
Lane 3= " +1ml T4 ligase (pos.control)
Lane 4= " +500ng IMR protein extract
Lane 5= " +1pg IMR protein extract
Lane 6= " +10pg IMR protein extract
2 6 0
Figure 7.14. illustrates the ability of nuclear proteins from the human 
neuroblastoma line, IMR32, to mediate the production of fast migrating plasmid 
molecules from linear EcoRI cut substrates.
Lane 1 contains the uncut plasmid alone.
Lane 2 shows positive control ,ie EcoRI cut DNA after incubation with 1|il T4 
ligase. It shows the reappearance of the fast migrating plasmid form (SC), by 
comparison with the linear control in lane 1.
Lane 3 shows the single band of EcoRI digested plC20H.
Lanes 4,5,and 6 show the reappearance of a fast-migrating plasmid form (SC), 
following incubation of cut plasmid with 500ng, 1 jug, and 10pg of IMR extract 
proteins respectively.
Plasmid Southern blots of ligation products were not directly comparable 
between hybridisations, due to variation in activity in the nick translated probes, 
and small variations in plasmid DNA loading. They were used to corroborate 
bacterial transformation data, namely, that the 4 human tumour extracts were 
capable of catalysing the production of plasmid forms that migrated in the 
same position as supercoiled circular plasmid DNA.
A consistent relationship was found between the ability of ligation reaction 
plasmid DNA to transform bacteria to ampicillin resistant, Lac Z+ phenotypes , 
and the appearance of supercoiled plC20H forms on Southern analysis.
A further observation made by Southern analysis was the apparent lack of 
activity catalysing the formation of high molecular weight concatemers in the 
extracts of the 4 human tumour lines examined. By contrast, this type of 
rejoining activity was the preferential mode of rejoining of linear plasmid 
molecules mediated by extracts from the hamster V79 and irs mutants.
The formation of high molecular weight ligation products was not observed to 
be an activity in any of 3 independent extract preparations on 4 human tumour 
extracts examined, namely, SB18 (glioma), UK (glioma), IMR32 
(neuroblastoma), and A2780 (ovarian carcinoma).
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7.3.Discussion
7.3.1.In vitro DNA dsb rejoining activity of human tumour extracts.
These results demonstrate that cell-free extracts can be successfully prepared 
from human tumour cells, retaining in vitro some of the nuclear protein activities 
that may be involved in the processing of DNA strand breaks in vivo.
The principal objective in pursuing the in vitro studies of DNA dsb rejoining was 
to evaluate the possibility that human cell lines of differing intrinsic 
radiosensitivity might exhibit differences in their ability to rejoin DNA dsb.
These results have shown no significant quantitative differences in the cohesive 
dsb rejoining activity of the nuclear extracts of the 4 human cell lines 
examined, both in terms of maximal rejoining observed, or the fidelity of the 
process. A more limited study using extracts from 2 cell lines, the 
radioresistant glioma UK , and the radiosensitive neuroblastoma IMR 32, 
showed an inability to rejoin non-cohesive dsb in vitro.
7.3.2 Processing of plasmid substrates by human extracts
It is pertinent to consider the activities demonstrated by the human cell extracts 
examined in these studies, both in terms of the relevance of this in vitro model 
to cellular DNA repair processes, and to postulate methods by which the 
system might be developed further.
A schematic representation of the protein activities proposed for these studies 
is presented in figure 7.15.
Nuclear protein fractions were used in this study, in an attempt to enrich for the 
protein activities likely to be involved in the processing of genomic DNA 
damage. However, no further fractionation of extracts was undertaken. Extracts 
obtained could therefore contain a multiplicity of enzymes acting on DNA, 
including ligases, polymerases, phosphatases, nucleases, and kinases.
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Figure 7.15 Proposed schema for processing of plC20H plasmid 
molecules by human extracts, and relationship to bacterial 
transformation events.
EcoRI digest 
amp
 \ m
cohesive termini
LacZ
accurate rejoining 
in LacZ gene
nucleases.phosphatases
kinases.polymerases
DNA ligases DNA ligases
\(5)
LacZ
inaccurate rejoining 
in LacZ gene
Ampicillin-resistant, Ampicillin-resistant,
Lac Z+ colonies of E.coli Lac Z- colonies of E.coli
For explanation of figure see section 7.3.2.
Nru 1 digest 
amp
non-cohesive termini 
'if
amp
\
\^
1
amp
Islsls!
No rejoining
V
No bacterial colonies
263
Thacker has shown that the comparative efficiency of rejoining in 7 different 
restriction-induced termini ranks very differently when mediated by human cell 
nuclear protein fractions, compared to purified T4 ligase activity. This is 
suggestive that these in vitro assays are evaluating several competing protein 
activities. [North, 1990 ]
The activities of DNA ligases are presumed in the rejoining of the plasmid dsb 
modelled in this system. Three forms of ligase activity have been identified in 
mammalian cells. They catalyse phosphodiester bond formation at single 
strand nicks with adjacent 3'OH and 5' P04 termini in double stranded DNA. 
Theoretically, no other enzymic activity would be required to rejoin 
endonuclease-induced dsb. This scenario is depicted in pathway (1). Human 
DNA ligase activities within the extracts are proposed to be capable of rejoining 
the EcoR 1 cohesive termini, leading to recircularisation of the plasmid 
substrate, and accurate restitution of Lac Z gene function. The circular plasmid 
form is taken up by JM 83 E.coli, leading to an ampicillin-resistant phenotype, 
expressed as clonal growth on ampicillin-containing agar plates. The Lac Z 
gene product,the enzyme (3-galactosidase, confers blue coloration on the 
colonies.
However, degradation of termini by nucleases or phosphatases present in the 
extracts could have rendered the plasmid substrate unsuitable for ligase activity 
without further modification. (2) Such modification might have included kinase­
like restitution of phosphate groups, or polymerisation to produce "fill-in" of base 
loss using the undamaged strand as a template. (3)
It is proposed that loss of information within the coding region of the Lac Z gene 
leads to "misrepair" in this model. The plasmid molecule is eventually 
recircularised by ligation, after possibly incomplete modification of the degraded 
termini (4) by kinase or polymerase activities. Within the context of this model, 
misrepair results in the formation of a plasmid molecule capable of bacterial 
transfomation to the ampicillin-resistant phenotype, but with a non-transcribing 
Lac Z gene. This produces clonal growth with no blue coloration.
The extent to which such enzymic modification of degraded termini could have 
been expected in these reactions is uncertain. The finding of significant 
amounts of residual linear substrate molecules on Southern analysis, (see fig. 
7.11 -14) and the observation of a "plateau"or fall in bacterial transformation 
with increasing protein concentrations (figs.7.6-9) is suggestive of degree of
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degradation of plasmid substrate. However, a residual level of linear plasmid 
form is also observed following treatment of cut plasmid with purified T4 ligase. 
This later observation would suggest that endonuclease digestion by EcoR 1 
produced a proportion of substrate molecules unsuitable for religation.
It is envisaged that a proportion of the EcoR“\ digested molecules are 
unsuitable for ligation de novo, but that a further fraction of the available 
substrate is degraded by enzymic activity within the extracts prior to successful 
ligation. (5) This molecule is incapable of bacterial transformation.
It is probable that the technique used in this study to produce nuclear protein 
fractions would have preserved significant DNA ligase II. This 70 kDa enzyme 
is tightly associated with chromatin, therefore retained in nuclear preparations.
It represents 80% of the ligase activity of non-dividing cells. By comparison, 
DNA ligase I, the major enzymic form present in rapidly dividing cells, readily 
leaks from the nucleus even under isotonic preparations. There is emerging 
evidence that DNA ligase II might be DNA damage inducible.
7.3.3 Fidelity of dsb rejoining in human extracts
Several explanations can be proposed for the low level of 'misrepair' observed 
in this system. It is possible that the extracts did not preserve significant levels 
of DNA polymerases or kinases to render degraded termini suitable for ligation. 
Alternatively, the reaction conditions may have been biased to the observation 
of a finite level of ligase activity, but suboptimal for other enzyme activities. 
However, the use of a similar in vitro system by Thacker has proven capable of 
showing mis-rejoining of such linear plasmid substrates by extracts from human 
AT cells. Extracts from AT5BIVA mis-rejoined up to 13.8 % of EcoRI cohesive 
termini, by comparison with a maximum rate of 0.5% in extracts from the 
human fibroblast line, MRC 5. Hence the cohesive, 5' 4-base overhang 
substrate generated by EcoR^ has proven capable of revealing a defect in the 
fidelity of AT cell extracts, and therefore was an appropriate substrate for these 
studies.
The major technical difference in his protocol was the use of a forty-fold 
increase in final plasmid DNA concentration. This was adopted to circumvent 
substrate degradation initially observed in SV40 transformed cell lines. It is 
possible that such a relative "excess" of plasmid substrate served to quench 
excessive nuclease or phosphatase activities in extracts, leaving a proportion of 
termini suitable for ligation after minor modification only.
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All white bacterial colonies were judged to have arisen as the result of loss of 
sequence at the termini created by scission through the Lac Z gene. However, 
it is conceivable that inactivation of the gene could have resulted from a 
variable extent of degradation by extracts , with a range of deletion sizes. 
Thacker et al evaluated the range of deletion sizes leading to LacZ gene 
inactivation in the plasmid pUC18, following treatment by MRC5 and AT5 
extracts. Plasmid DNA minipreps from 150 individual white colonies showed a 
range of deletion sizes from 20-500 base pairs. However, approximately 60 % 
of these mis-rejoining events were the result of the loss of 50 base pairs or 
less. Perhaps more importantly, there appeared to be no difference in the 
distribution of deletion sizes when mis-rejoining was mediated by extracts of 
MRC5 or AT5 cells.
Such an analysis of the distribution of deletion events arising from mis-rejoining 
events was not undertaken in this study.
7.3.4. Effect of class of dsb termini on rejoining proficiency
The products of the incubation of non-cohesive, Nru I digested plasmid 
substrate with extracts from 2 cell lines, UK and IMR32, failed to show any 
increase in bacterial transformation over background. This observation was 
made in extracts known to be active in rejoining activity of the cohesive EcoR 1 
substrate. A similar lack of rejoining of non-cohesive termini was noted for Hinc 
II digests by Thacker et al.
North et al observed that the extent of overall rejoining mediated by human 
cell extracts was closely related to both the structure and chemistry of the 
breaks. A 5-fold difference was observed in rejoin efficiency for Sal I (5* 
TCGA overhang, 10 hydrogen bonds) compared to EcoR 1 (5' AATT overhang, 
8 hydrogen bonds). This was associated with a 98-fold increase in misrejoining 
of the less efficiently rejoined EcoR 1 break [North etal, 1990].
Similarly, the Acc I substrate (5 ' CG, 2 base overhang) showed a significantly 
lower rejoin rate, with reduced fidelity. Thus it was suggested that those termini 
rejoined least efficiently were more likely to suffer loss of fidelity. However, no 
systematic relationship existed between the size of base overhang, and 
likelihood of rejoining. It is possible that specific base chemistry is as important 
as the extent of base overhang at the site of strand breaks.
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The results obtained in this study, suggesting accurate rejoining of EcoRI type 
strand breaks in 4 human cell lines, are comparable with the results obtained 
for MRC5 extracts by Thacker. It is also in keeping with the suggestion that 
EcoRI-induced termini are efficiently rejoined, when the kinetics of dsb are 
observed in permeabilised cell systems.
Similarly, the observed inability of these human cell extracts to rejoin non- 
cohesive substrates in vitro is of interest. The rejoining of non-cohesive ends is 
usually mediated by DNA ligase I. It is possible that the method of cell 
fractionation and nuclear protein extraction used in these studies preserves 
little of this activity, known to be readily leaked from the nucleus even under 
isotonic conditions.
Studies with permeabilised rodent cells have shown that restriction enzymes 
generating blunt termini (eg Pvu I I ) are effective in generating chromosomal 
aberrations, by comparison with enzymes introducing cohesive breaks 
[Bryant, 1988 ]. One interpretation of such observations is that blunt dsb might 
comprise a subset of lesions less effectively rejoined after DNA damaging 
events, leading to subsequent cell death.
An extension of these studies would include a more comprehensive evaluation 
of both a range of cohesive and non-cohesive termini, in extracts from several 
radioresistant and radiosensitive lines.
7.3.5 Relevance of in vitro model to cellular DNA repair processes
A number of methodological compromises were accepted in the design of this 
in vitro assay. A naked plasmid DNA molecule in aqueous solution can provide 
only a limited approximation to the complexity of genomic DNA.
A further consideration was the use of the non-physiological temperature of 
14° C to study protein activities. These conditions were chosen in the 
knowledge of the activity of mammalian ligases, and were thought likely to 
minimise thermal destabilisation of ligation complexes, and excess nuclease 
activity.
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In pilot studies examining the effect of running the reaction at 37 °C, overnight, 
substantial degradation of plasmid was found, with a fall in bacterial 
transformations.(data not presented) A possible modification of the system 
might include the use of physiological temperatures, in conjunction with a 
significant increase in the plasmid DNA concentration. This would tend to 
favour the formation of linear concatemers and other high molecular weight 
forms of ligation products. The former appear not to be transforming molecules, 
therefore could not contribute to an evaluation of extent or fidelity of rejoining 
using bacterial genetics. The formation of circular multimers could introduce 
multiplicity problems in transformations.
The relevance of the endonuclease-induced DNA double strand break to those 
induced by ionising radiation lesions has been discussed in section 7.1. It is 
likely that enzymes such as phosphatases and nucleases, present within the 
extracts, may themselves modify the 'clean' restriction-induced termini. 
Rejoining activity detected therefore might represent a competition between 
end degradation and rejoining. Evidence in support of this notion lies in the 
noted difference between maximal bacterial transformation mediated by pure 
T4 ligase activity, and all extracts examined.
Considerable variability was observed in the dsb rejoining activity of replicate 
extracts on individual cell lines, despite standardisation of both the preparation 
of extracts, and ligation reactions.
7.3.6. Further protein activites participating in dsb rejoining.
Several classes of proteins not conventionally considered to be frank DNA 
repair enzymes might participate in the rejoining of DNA dsb. These include 
proteins initiating strand exchange, or altering DNA conformation eg 
topoisomerases. Other classes of activity include the alignment of strand 
breaks prior to the formation of ligation complexes, or the protection of termini 
prior to rejoining [Malynn etal, 1988 ; de Vries etal, 1989 ]
By inference, deficiencies or enhanced induction of some of these activites 
might help determine the proficiency of DNA repair pathways.
In Southern analyses of uncut plasmid DNA incubated with human extracts the 
production of plasmid forms intermediate in migratory position between closed
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and relaxed circular DNA was noted. It is postulated that this represents a 
topoisomerase-like activity within extracts, altering the degree of supercoiling of 
plasmid DNA.
It was noted that V79 hamster extracts , prepared under identical conditions to 
extracts of the 4 human cell lines studied, catalysed the formation of high 
molecular weight concatemers in ligation conditions specifically designed to 
favour only intra-molecular rejoining. This activity was not observed in the 4 
human extracts examined. This could not be attributed to any systematic 
difference in the overall protein levels yielded by extract preparation, as 
measured by Biorad assay.
One interpretation of this data is that the V79 cell extracts might possess a 
protein activity that participates in the alignment of termini prior to rejoining of 
termini, analogous to the end-alignment activity detected in fertilised Xenopus 
eggs [Pfeiffer and Veilmetter, 1988 ].
It suggests that caution should also be exercised in extrapolating from rodent 
models of DNA repair events, to human systems.
7.3.7.Conclusions
1) Cell-free extracts prepared from 4 human tumour extracts have 
demonstrated the capacity to rejoin cohesive endonuclease digests of the 
plasmid molecule plC20H in vitro.
2) This activity was evidenced by recircularisation of the substrate plasmid 
molecules on electron microscopy, the detection of a form migrating in the 
same position as closed circular DNA on Southern analysis, and the ability of 
plasmid to transform the phenotype of JM 83 E.coli.
3) Significant rejoining activity over background was detected for the cohesive 
substrate produced by EcoRI digestion in extracts from all 4 cell lines.
4) By contrast, no rejoining activity in excess of background was observed for 
the non-cohesive substrate generated by Nru1 digestion in extracts from the 2 
cell lines studied.
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5) It is proposed that this dsb rejoining predominantly represents activity of 
human DNA ligases.
6) No difference in proficiency of rejoining of cohesive dsb was detected in 
extracts prepared from 2 radioresistant human tumour lines, by comparison 
with 2 radiosensitive human tumour lines.
7) The fidelity of rejoining of cohesive dsb was high in extracts from all 4 cell 
lines. The incidence of "misrepair", as evidenced by the proportion of ampicillin- 
resistant, Lac Z- bacterial colonies was 0.75-0.94% of total bacterial 
colonies.Rejoin fidelity of the EcoRI cut plasmid substrate studied did not differ 
significantly between extracts derived from radiosensitive or resistant cell 
lines.
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CHAPTER 8
Conclusions
Summary of conclusions.
1) Human malignant glioma appears to lie at an extreme of clinical 
radioresistance, defined relative to the radiocurability of other human tumours 
commonly managed by radiotherapy given with curative intent.
Empirical attempts to circumvent such resistance, based on theoretical 
assumptions regarding the mechanistic basis of radioresistance have met with 
little therapeutic gain.
2)Human glioma continuous cell lines provide useful models for the study of the 
in vitro behaviour of human malignant glioma. The five cell lines evaluated in 
this thesis exhibited phenotypic heterogeneity, whilst preserving evidence of 
both astrocytic lineage, and the transformed, malignant phenotype.
3) All five human glioma lines exhibited monolayer colony formation, thus 
permitting the use of clonogenic cell survival as an endpoint for studies of 
intrinsic cellular radiosensitivity. Each line also exhibited the capacity for 
anchorage -independent growth, readily forming multicellular spheroid 
aggregates, which could be used for further fundamental or applied studies.
4) The establishment of further human glioma cell lines, ideally of near-diploid 
status, with persistent markers of astrocytic differentiation, but unequivocal 
malignancy, would aid further studies on the biological behaviour of human 
glioma. This might be facilitated by a more rigorous evaluation of the specific 
growth requirements of primary cultures of human malignant glioma.
5) The intrinsic radiosensitivity of the five human glioma cell lines was 
measured by clonogenic cell survival after high dose-rate, acute radiation and 
compared with eight other human tumour cell lines; these comprised five 
carcinoma-derived lines, and three embryonal tumour lines. Considerable 
variability was found in the intrinsic cellular radiosensitivity of these thirteen cell 
lines, despite high passage level.
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6) The intrinsic cellular radiosensitivity of these five human glioma lines lies at 
the extreme of values published for human tumour cell lines. Considerable 
overlap of cellular radiosensitivity was noted between the glioma lines, and 
carcinoma-derived lines. Intrinsic cellular radiosensitivity might contribute to the 
marked clinical radioresistance observed in high grade human glioma.
7) It has been postulated that the radiocurability of human tumours might be 
determined by the relative capacity of tumour clonogens to ‘recover’ from 
ionising radiation-induced damage. The 5 human glioma cell lines examined in 
this study all exhibited the capacity for cellular recovery, as operationally 
defined in a split-dose irradiation protocol. Recovery was assessed at three 
radiation dose levels, and was found to increase with dose, in accordance with 
the predictions of the linear-quadratic model of radiation action.
8) Cellular recovery was similarly evaluated in 3 radiosensitive human tumour 
cell lines, derived from a neuroblastoma, IMR32, a teratoma, SuSa, and an 
ovarian carcinoma, A2780. These lines also exhibited clonogenic cellular 
recovery.
9) The linear-quadratic model predicts that cellular recovery should increase 
with radiation dose, hence recovery extent cannot be adequately defined at a 
single radiation dose level. pRR , calculated as the slope of the regression of 
the recovery ratio obtained at different radiation dose levels, expressed in logs, 
against 2d2 where d was the radiation dose given, has been suggested as a 
method of quantifying cellular recovery potential. Using this parameter, the 3 
radiosensitive cell lines studied exhibited greater recovery potential than the 5 
human glioma lines. However, a more conventional comparison of extent of 
recovery at an ‘iso-effective’ radiation dose level producing 90% cell kill gave 
higher values in the human glioma lines, than in the radiosensitive lines.
The evaluation of split dose cellular recovery data remains one of the most 
controversial areas of human cellular radiobiology. However, these results 
suggest that there is no systematic deficiency in cellular recovery from radiation 
damage in radiosensitive human tumour cell lines.
10) The intrinsic cellular radiosensitivity of human glioma primary cultures was 
evaluated in a semi-solid agar cloning system. Of 17 biopsies established,
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growth adequate to evaluate clonogenic cell survival was only obtained in 9 
cultures (52%). A mean SF2Gy value of 0.56 (SD 0.12) was observed in this 
group of tumours. Whilst this value was lower than observed in the continuous 
glioma lines (0.68), it remains within the range of SF2Gy values considered to 
define ‘relative’ radioresistance in human tumours.
Both the number of evaluable cultures, and the cloning efficiency might be 
improved by the optimisation of culture conditions for human glial cells.
11) The molecular determinants of cellular radiosensitivity remain poorly 
understood. DNA double strand breaks(dsb) are a class of radiation-induced 
lesions whose fate correlates with post-irradiation cell death in a number of 
systems. It has been proposed that differences in proficiency of DNA dsb 
rejoining might underlie variability in intrinsic cellular radiosensitivity.
Studies in this thesis included the establishment of conditions for the 
observation of DNA dsb rejoining by human cell extracts in an in vitro system. 
The ability of nuclear protein extracts derived from 4 human tumour cell lines of 
differing intrinsic cellular radiosensitivity was assessed, using restriction- 
induced dsb within plasmid DNA. Evidence of dsb rejoining was sought by 
monitoring changes in physical plasmid conformation ( Southern blotting; 
electron microscopy), and bacterial phenotypic transformation by plasmid- 
encoded “reporter” genes.
12) Nuclear protein extracts from 2 radioresistant glioma cell lines, and 2 
radiosensitive human tumour lines demonstrated the ability to rejoin cohesive 
dsb under defined in vitro conditions.The process was observed to be energy- 
dependent, and could be abolished by pretreatment of proteins by boiling or 
proteinase K. A protein concentration-dependent increase in cohesive dsb 
rejoining was observed in extracts of all 4 cell lines, with no systematic 
differences in proficiency of rejoining between extracts of radioresistant or 
radiosensitive cell lines.
13) Extracts proficient in rejoining the cohesive termini were unable to ligate 
blunt termini generated by Nru 1 digestion. Further investigation of this 
phenomena is warranted.
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14) Fidelity of dsb rejoining was monitored by the expression of the ampicillin- 
resistant, LacZ+ phenotype in bacteria transformed by successfully rejoined 
plasmid molecules. “Misrepair” events were operationally defined in this 
system as the percentage of ampicillin-resistant bacterial colonies failing to 
express the Lac Z gene product. Such events were observed in 0.75-0.94% of 
transformations, with no statistical differences in rejoin fidelity between extracts 
derived from radioresistant or radiosensitive cell lines for the cohesive EcoR1 
cut plasmid substrate.
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